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ABSTRACT 
 
 
The past century has witnessed tremendous advancements in both organic methodology 
and total synthesis.  With the synthetic conquest of molecular giants such as amphotericin and 
brevetoxin A, it becomes increasingly apparent that the complexity of the target defines the time 
and resources needed, rather than the likelihood of success in reaching the target compound. This 
has, in part, nourished a general desire to develop new reactions that increase the efficiency in 
which molecules are made through two major strategies.  First, the development of reactions that 
initiate powerful bond formations can reduce synthetic steps, by skipping intermediates and 
accessing the correct functional group(s) directly from C−H bonds.  Secondly, highly selective 
reactions (stereo-, regio-, site-) have allowed these methods to be applied to complex molecules 
(having many functional groups) at late stages in a synthesis, thus eliminating traditional 
protecting group manipulations.  Nature has already recognized the power of these strategies and 
routinely oxidizes C−H bonds directly for the purpose of biosynthesis or metabolism by using 
various tailoring enzymes. In an attempt to mimic nature, synthetic chemists have tried to change 
the way that molecules are made in the laboratory by establishing the C−H bond as a functional 
group in its own right. This work describes the development of novel C−H oxidation and 
amination reactions as new strategies for simplifying and diversifying synthetic sequences.  
First, harnessing the abundance of α-olefins as starting materials, palladium (II) catalysis 
is used to effect a divergent intramolecular allylic C−H activation reaction to generate two 
different products from a common starting material. By taking advantage of the inherent 
reactivity of a urea nucleophile, two medicinally important moieties are formed and further 
elaborated to furnish nonproteinogenic amino acids. The divergent nature of this reactivity stems 
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from a change in mechanism as a result of switching from a Pd(II)/bis-sufloxide catalyst to a 
Pd(OAc)2 catalyst.  
Our group has previously shown that the terminal oxidant in our Pd(II)/bis-sulfoxide 
catalyzed systems, benzoquinone (BQ), also serves as a ligand to Pd in order to promote 
functionalization from a monomeric Pd-π-allyl intermediate. From this, we hypothesized that 
stoichiometric amounts of BQ may serve to deactivate the Pd(II)/bis-sulfoxide, requiring the use 
of higher catalyst loadings. In an effort to improve on the overall efficiency of the allylic C−H 
amination systems reported by our group, we have developed reaction conditions where the 
terminal oxidant, BQ, is formed in situ, in a catalytic fashion rather than being used in super 
stoichiometric amounts. This was accomplished via an oxidation potential relay consisting of a 
metal co-catalyst and catalytic amounts of dihydrobenzoquinone (DHBQ) under 1 atm of oxygen. 
The use of molecular O2 as the new terminal oxidant under these reaction conditions offers a low 
cost and non-toxic alternative to BQ. As a consequence, this new system allows for reduced 
palladium catalyst loadings (2.5-5 mol%) and no stoichiometric byproducts (therefore a more 
facile product purification), while maintaining high levels of reactivity and selectivity for the 
linear allylic amination reaction. 
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CHAPTER 1: CATALYST-CONTROLLED C−O VERSUS C−N ALLYLIC 
FUNCTIONALIZATION OF TERMINAL OLEFINS 
 
1.1  Introduction 
 
 
 
 
 
 
 
 
 
Despite the fact that C−H bonds are the least reactive in organic chemistry, in nature, 
enzymes have evolved not only to oxidize them, but also discriminate between the different 
types of C−H bonds (such as secondary or tertiary) in complex molecule settings. For 
example, the taxadiene core is oxidized with high regio- and stereospecificity by a variety of 
tailoring P450 enzymes in order to construct a biologically active molecule that is currently 
used in cancer therapy, namely taxol (Figure 1.1, A).1 While C−H oxidations prevail in 
nature, direct C−H aminations are rare and even nature has to go through oxygenated 
intermediates to arrive at nitrogen functionality. In the biosynthesis of amino acids, for 
example glutamate, the amino moiety is installed via a carbonyl group from α-ketoglutarate 
(Figure 1.1, B). 
Taxol !
H
H
taxa-4(5),11(12)diene
H
AcO O OH
O
AcO
BzO
HO
XO
X = N-benzoyl-"-phenylisoserine
C—H
oxidation/
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HOOC COOH
O
#-ketoglutarate
NADPH, NH3
enzyme
HOOC COOH
NH2
L-glutamate
H
Figure 1.1 C-H Functionalizations in Nature
A. Oxidation
B. Amination
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While nature can do direct allylic and aliphatic C−H bond functionalizations, chemists have not 
yet mastered these types of transformations in the laboratory. Allylic alcohols and amines are 
traditionally synthesized in many steps while exposing the substrates to various oxidative and 
reductive conditions (Figure 1.2, A).2,3 Several transition metal catalyzed methods have been 
developed in order to make these transformations more efficient, however, especially for allylic 
functionalizations, preoxidized materials such as allylic acetates, carbonates etc are still required 
(Figure 1.2, C).4,5 Cross-metathesis approaches also deserve mention because they give rise to the 
same linear allylic amine products from terminal olefins (Figure 1.2, B).6 Boc-protected allyl 
amine can be coupled with methyl but-3-enoate in 31% yield and >10:1 E:Z selectivity using the 
Grubbs catalyst.7 Although this method appears to be superior to previous Witting routes used to 
form the same product, the use of excess amine coupling partner and the low yields are clear 
disadvantages. Yields and substrate scope could be improved by the addition of catalytic Lewis 
acidic alkyl or aryl boranes.8  
 
R OH
R
or oxidation
R O
activation/
displacement
R NR2
R
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NR2+ R NR2
R O
olefination OR' reduction
R OHHNR2
R
X
R'
Pd(0)
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Figure 1.2 Traditional Allylic Oxidations and Aminations
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An attractive alternative to these existing methods would be to directly and selectively 
transform a C−H bond to the desired functional group (Figure 1.3); this approach has already 
proven to be very appealing due to the ubiquitous nature of C−H bonds, the fact that they are 
inert to most reagents that alter other functional groups and because little to no synthetic 
overhead is needed in terms of the starting materials that are utilized. There are also challenges 
associated with treating the C−H bond as a functional group (i.e. reactivity, selectivity), and our 
group has been very successful at overcoming these challenges by developing a Pd(II)/bis-
sulfoxide catalyst 1 that selectively reacts with allylic C−H  bonds from terminal olefins to yield 
a valuable Pd-π-allyl electrophile. This strategy has now been applied to a variety of C−H 
activation reactions including oxidations,9-15 aminations,16-20 alkylations21-23 and 
dehydrogenations.24,25 Significant advances have also been made in the C−H functionalization of  
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R
AcOH 
or   
NHR2
C-H Oxidation 
or         
Amination R OH
R NR2
or
Hydrolysis
Figure 1.3 Streamlined synthesis of allylic alcohols and allylic amines
Figure 1.4 Selected Examples of C-H Functionalizations
Allylic Amination Allylic Oxidation
H
BQ (2 equiv.) 
MeOCONHTs (2 equiv.) 
TBME, 45°C
S S Ph
O
Ph
O
Pd(OAc)2
.
1 (10 mol%)
DIPEA (6 mol%)
N
Ts
COOMe TBSO
H
AcOH (4 equiv.) 
Dioxane, 45°C
S S Ph
O
Ph
O
Pd(OAc)2
.
1 (10 mol%)
BQ (2 equiv.)
TBSO
OAc
84%
72%
Aryl Oxidation Aliphatic Oxidation
MeO
H
NMeO
AcOH,  100°C
Pd(OAc)2 (5 mol%)
Oxone (1.1 equiv.)
69%
MeO
OAc
NMeO OPiv
H
Fe(PDP) (5 mol%)
AcOH (0.5 equiv.)
H2O2 (1.2 equiv.)
50%
x3
MeCN
OPiv
HO
	  	   4	  
compounds,26-29 and perhaps even more impacting, that of strong, aliphatic C−H bonds30,31 
(Figure 1.4).  
These examples and many others indisputably show that C−H activation is starting to 
emerge as a very powerful strategy for streamlining and diversifying synthetic sequences. I 
envisioned that these goals could further be achieved by the development of a selective method 
that takes one C−H bond in a common starting material and transforms that into different 
functional groups based on the reaction conditions (Figure 1.5). Tethered urea starting materials 
proved to be ideal for such a process due to the nucleophilicity of both the oxygen and the 
nitrogen atoms which, under our oxidative reaction conditions, could potentially give rise to 
different products after attack on the electrophilic Pd-π-allyl intermediate. As seen in Figure 1.5, 
both heterocyclic compounds formed in this system are precursors to important amino acid 
motifs and further elaboration easily reveals non-proteinogenic α-hydroxy-β-aminoacids and 
α,β-diaminoacids.   
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C H C FGC FG Conditions 2 Conditions 1
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R
O
NHR N O
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O
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1.2 Results and Discussion 
1.2.1 Reaction Design and Optimization 
With the goal of increasing diversity, we wanted to take advantage of the ambident nature 
of the urea nucleophile and tune its reactivity such that both the oxygen and the nitrogen atom 
act as nucleophiles, separately, and give rise to different products from a common urea starting 
material. The two heterocyclic products that are formed (2-aminooxazoline from C−O bond 
formation and imidazolidinone from C−N bond formation), as well as their corresponding amino 
acids are prevalent motifs in a variety of natural products and medicinally important molecules,32-
37 therefore developing a streamlined synthesis to these compounds stood to have a significant 
impact.  
 
 
 
 
 
 
 
 
 
 
 
 
R
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Figure 1.6 Proposed Mechanism for Pd(II)/BisSO catalyzed C-H Activation Reactions
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 Figure 1.6 depicts the general proposed mechanism for our Pd(OAc)2/bis-sulfoxide 
catalyzed reactions (shown for a tethered urea substrate), which we have termed serial ligand 
catalysis.9 The Pd(II)/bis-sulfoxide catalyst first binds to the terminal olefin and effects a C−H 
cleavage event to arrive at an electrophilic Pd-π-allyl intermediate. The C−H cleavage likely 
proceeds via an intramolecular concerted metallation/deprotonation mechanism that releases 
acetic acid and forms the Pd-π-allyl species. This hypothesis has been supported by 
computations,38 as well as the catalytic incompetence of palladium bearing chloride ligands in 
place of acetates. Nucleophilicity becomes very important in the next step. We have shown in 
our previous publications that typically, pronucleophiles have been very successful in these types 
of reactions; therefore, the more nucleophilic the urea tether or the more electrophilic the Pd-π-
allyl intermediate, the higher the chances for a successful functionalization step to form the five-
membered ring heterocycle. In order to promote this functionalization step, we typically employ 
two different strategies: (a) activation of the electrophilic Pd-π-allyl intermediate towards 
nucleophilic attack by the use of π-acidic ligands (BQ) acting with a Lewis acid co-catalyst (eg. 
Cr(salen)Cl) and (b) activation of the nucleophile by addition of exogenous base that is able to 
increase the concentration of deprotonated nitrogen nucleophile in solution. Functionalization is 
also enhanced by a potential ligand exchange with BQ, promoting ring closure and release of a 
Pd(0) species. BQ then reoxidizes Pd(0) back to Pd(II) which reenters the catalytic cycle.  
As mentioned above, palladium(II)/bis-sulfoxide catalysis has proven itself to be a general 
platform for allylic C—H to C—O and C—N reactions of terminal olefins under mildly acidic, 
oxidative conditions. For example, 1,2- and 1,3-aminoalcohol precursors are readily accessible 
from homoallylic and bis-homoallylic carbamates (Figure 1.7). Under similar conditions, 
homoallylic ureas could furnish either valuable 1,2-diamine (C—N) precursors or 1,2- 
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aminoalcohol (C—O) precursors. Under aminopalladation conditions or under the reductive, 
basic conditions of Pd(0)-catalyzed allylic substitutions, ambident urea nucleophiles have 
provided exclusively C—N products in the form of imidazolidinones.39-51  This is thought to be 
due to both a kinetic (base promoted deprotonation at nitrogen) and thermodynamic preference 
for C—N alkylation [Pd(0)-catalyzed equilibration]. Given that Pd(II)/bis-sulfoxide catalysis 
proceeds under acidic, oxidative conditions that do not favor nitrogen deprotonation or promote 
reversible functionalization, O-alkylation may compete with N-functionalization using urea 
terminal olefin substrates. Additionally, O-alkylation may be further promoted by the addition of 
an azaphilic Lewis acid additive that binds to the nitrogen and retards nucleophilic attack. 
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Significantly, the 1,2-aminoalcohol products furnished by this method would have the opposite 
regiochemistry to those previously obtained from carbamate nucleophiles.  
With this in mind, optimization of the proposed divergent C−H functionalization reaction 
began with tethered urea starting material 3 being subjected to our standard Pd(II)/bis-sulfoxide 
reaction conditions (Table 1.1). Using no additive, I was pleased to observe some reactivity, 
however, the system presented no selectivity for formation of either heterocycle (Table 1.1, entry 
1). As expected, a basic additive (DIPEA – diisopropylethylamine) completely shut down C−O  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1 Reaction Optimization and Control Experiments
iPr
HN
S SO OPh Ph
Pd(OAc)2
BQ or MeBQ
45°C
iPr
L.A.
co-catalyst
(8 - 10 mol%)
Yield of 4 
(%)c,d
Yield of 5 
(%)c,d
none
DIPEA
B(C6F5)3
AgOTf
Cr(salen)Cl
AgOTf
TfOH
TfOH
AgOTf
AgOTf
AgOTf
B(C6F5)3
none
B(C6F5)3
19%
0%
50%
76%
8%
56%
64%
0%
0%
0%
0%
0%
0%
0%
28%
38% 
7% 
9% 
8%
trace
28%
0% 
0%
46% 
59% 
62% 
32% 
0%
NHNs
O
ON
NHNs
Pd
catalyst
(10 mol%)
cat. 1
1
1
1
1
1
1
1
none
none
2
2
2
2
none
anti - 4
iPr
NNsHN
O
anti - 5
a All reactions were run using THF (1.0M) as solvent, MeBQ (methyl-p-benzoquinone, 1.5 
equiv.) as terminal oxidant and 8 mol% L.A. co-catalyst for 6 hours unless otherwise noted. 
b Reactions with cat. 1 were run with an additional 5 mol% BisSO ligand [1,2-
bis(phenylsulfinyl)ethane]. c Average of 2 runs. d Observed diastereoselectivities in crude 
reaction mixtures: >20:1 anti:syn dr for 4 for all entries; dr for 5: entry 1, 1.3:1 dr anti:syn; 
entry 2, 4.4:1 dr; entry 4, 1:1 dr; entry 7, 2.5:1 dr; entries 3, 5, 10, 11, 12, 13 >20:1 dr; dr 
determined by 1H NMR analysis of the crude reaction mixture. e Reactions run to complete 
conversion: entry 1, 24h; entry 3, 2h; entry 10, 72h. f Reaction stopped at 18h (37% rsm); 
no improved conversion was observed at 48h or 72h. g DCM (dichloromethane, 1.0M) 
used as solvent; For entry 4, 1 equiv. of DMA was added. h Reaction stopped before 
complete conversion at 2h. Increased reaction times resulted in product decomposition. i 
>99% rsm, 0% E-internal olefin. j Reaction run using THF (1.66M) as solvent, BQ (p-
benzoquinone, 1.05 equiv.) as terminal oxidant and 10 mol% L.A. co-catalyst for 72 hours.
entrya,b
1e
2f
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Pd(OAc)2
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-
-
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-
Ns
Ns
Ns
Ns
Ns
Ts
Ns
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Ns
Ns
Ns
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functionalization and led to exclusive C−N bond formation albeit in modest yield (entry 2). 
However, we found that catalytic Lewis acids such as B(C6F5)352 and Ag(OTf)53-56 increased 
selectivity to now favor formation of the aminooxazoline product, furnishing 4 in 50% and 76% 
yield, respectively (entries 3 and 4). These types of Lewis acids have been shown before to have 
azaphilic properties, that is, to preferentially bind the nitrogen atom of an amide functional group 
over the oxygen atom. In contrast, inclusion of an oxophilic Lewis acid such as Cr(salen)Cl,16,17 
previously shown to activate intermediate π-allylPd(BQ) electrophiles towards functionalization, 
led to diminished yields and no selectivity for this reaction (entry 5). The reaction becomes even 
more selective for the aminooxazoline product when switching to a p-toluenesulfonyl protecting 
group on the urea tether, although the substrate is at this point less reactive, producing only 56% 
yield of the desired product (entry 6). Catalytic triflic acid (TfOH) additive promotes reactivity 
but with lower selectivity for anti-aminooxazoline 4 (entry 7) and this result is consistent with 
experimental observations that water, which may form triflic acid in situ, erodes C—O:C—N 
ratios. In key control experiments, I have also shown that the palladium catalyst 1 is absolutely 
necessary for reactivity (entries 8 and 9). With these results, I have demonstrated for the first 
time that an ambident O/N nucleophile can be tuned to favor C—O bond formation under 
palladium catalysis. Intrigued by these results that the π-allylPd intermediate produced from 
catalayst 1 was able to favor formation of the aminooxazoline product, we next wondered what 
the role of the bis-sulfoxide ligand was and whether this was necessary for the observed 
selectivity. By simply removing the bis-sulfoxide ligand and using Pd(OAc)2 (2) as the catalyst, 
we made the unexpected observation that C—N bond formation was now exclusive, forming 
imidazolidinone 5 in 46% yield (entry 10). Optimization of this result led to synthetically useful 
yield and excellent diastereoselectivities as well as C—N:C—O ratios when using either 
	  	   10	  
Ag(OTf) (entry 11, 59%) or B(C6F5)3 Lewis acids (entry 12, 62%). A control experiment with no 
Lewis acid showed a diminished yield of the desired imidazolidinone product (entry 13, 32%) 
due to an oxidative amination pathway (aminopalladation/β-hydride elimination) of the terminal 
olefin that led to 30% of the corresponding aminopalladated product. As expected, omission of 
the Pd(OAc)2 catalyst led to no reactivity (entry 14). 
Together, the two optimized systems represent the first example of successfully tuning the 
reactivity of an ambident nucleophile under palladium catalysis to selectively form different 
products from a common starting material. 
 
1.2.2 Reaction Scope 
 
 
 
 
 
 
 
 
 
 
 
ON
tBu
NHNs
(±)-6
79% yield
17:1 C-O:C-N
ON
NHNs
OTBS
(+)-9
79% yieldd
>20:1 C-O:C-N
ON
NHNs
OTBS
(-)-10
60% yieldd   
14:1 C-O:C-N
R
HN NHNs
O
AgOTf (8 mol%)
MeBQ (1.5 equiv.)
DCM (1.0M), 45°C, 6h
a C-O:C-N = anti:2-aminooxazoline : anti-imidazolidinone; All yields are reported for the major 
diastereomer. b 7: 5.6:1 dr anti:syn 2-aminooxazoline; 12: 4:1 dr. c Reaction run at 45°C with a 0.12:1 
DMA:DCM solvent mixture. d Reaction run at 40°C with a 0.12:1 DMA:DCM solvent mixture. e Unable 
to determine crude selectivity due to peak overlap; isolated selectivity reported.
ON
R
NHNs
ON
NHNs
OBnBnO
(-)-11
65% yieldd,e
19:1 C-O:C-N
ON
Me
NHNs
iPr
(±)-7
82% yieldb
>20:1 C-O:C-N
ON
NHNs
Me
F
(-)-13
67% yieldd
13:1 C-O:C-N
1
72% avg. isolated yield
10:1 to 20:1 C-O:C-Na
Table 1.2 PdII/bis-sulfoxide/Ag catalyzed allylic C-O bond formation
H
Pd(OAc)2
(10 mol%)
ON
Me
NHNs
tBu
ON
Me
NHNs
(±)-8
79% yieldc
19:1 C-O:C-N
(±)-12
61% yieldb,c
10:1 C-O:C-N
H H
H
S S
OO
Ph Ph
MeO
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With the two sets of optimized reaction conditions in hand, I next turned to explore the substrate 
scope and functional group tolerance for each system. In terms of sterics, moderate to high levels  
of steric bulk adjacent to the urea tether (R = ethyl, isopropyl, t-Bu) are well tolerated, furnishing 
the corresponding products in high yields and selectivities with both systems (4, 5, 6, 14, 15).  
anti-2-Aminooxazolines (7, 8 and 12) and anti-imidazolidinones (16 and 17), derived from 
common tertiary amines, can also be accessed in excellent yields and selectivities. These 
represent a class of sterically challenging vicinal diamine and amino-alcohol precursors that are 
difficult to access otherwise in optically enriched form. With this method however, in each case, 
a single starting material was converted selectively into either C—O or C—N functionalized 
products simply by using the appropriate palladium catalyst. 
  
 
 
 
 
 
 
 
 
 
 
 
 
R
HN NHNs
O
B(C6F5)3 (8 mol%)
BQ (1.05 equiv.)
THF (1.66M) 
45°C, 72h
NNsHN
R
O
NNsHN
O
OBnBnO
(-)-18
51% Yield
NNsHN
tBu
O
(±)-15
63% Yield
NNsHN
O
(±)-21
49% Yieldb
Pd(OAc)2 2 (10 mol%)
62% avg. isolated yielda
10:1 to 20:1 C-N:C-O
Table 1.3 PdII/B catalyzed allylic C-N bond formation
NNsHN
Me
O
iPr
(±)-16
76% Yieldc
MeO
NNsHN
O
OBnBnO
(-)-19
42% Yield
NNsHN
iBu
O
(±)-17
94% Yieldc
NNsHN
Me
O
tBu
NNsHN
Et
O
(±)-14
55% Yieldb
(±)-20
63% Yieldb
a Diastereoselectivities and C-N:C-O ratios were measured by 1H NMR of the crude reaction 
mixtures; >20:1 dr and >20:1 C-N:C-O unless otherwise noted. b 14: 9.8:1 dr; 20: 7:1 dr; 21: 12:1 
dr. c 16: 10:1 C-N:C-O; 17: 10:1 C-N:C-O
HH
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Lewis basic starting materials such as substrates containing proximal benzylated diols capable of 
catalyst deactivation via metal chelation are also tolerated under both reaction manifolds with 
exceptional selectivities [(-)-11, (-)-18, (-)-19]. Aryl moieties were evaluated and the products 
generated displayed excellent selectivities for either the C—O or the C—N functionalized 
products [(-)-12, (-)-13, 21]. The diastereoselectivity for both processes appears to be very high; 
in most cases examined, only the anti-aminooxazolines and anti-imidazolidinones are observed 
by 1H-NMR of the crude reaction mixtures. I have also shown that the diastereoselectivity for 
these reactions is predictable and is unaffected by other stereocenters present in the molecule. 
For example, in substrates such as (+)-9, (-)-10, (-)-11, (-)-13, (-)-18 and (-)-19, the anti 
diastereomers if formed predominantly and the diastereoselectivity is controlled entirely by the 
stereocenter containing the urea tether. It is significant to note that alternative methods to 
generate these products require de novo syntheses of separate starting materials. Reactions such 
as these that take a common intermediate and obtain divergent outcomes based on catalyst 
control have the potential to significantly advance synthetic efficiency and flexibility. 
 
1.2.3 Diversification to biologically relevant motifs 
 The terminal olefin functionality is an excellent handle for further manipulations and 
diversification of a molecule. One can imagine transforming a terminal olefin into a variety of 
different functionalities such as shown in Figure 1.8. Given that the heterocycles formed in this 
divergent system are considered precursors to valuable 1,2-aminoalcohols and 1,2-diamines, I 
was interested in exploring further the oxidative cleavage pathway from the terminal olefin; this  
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could give rise to important nonproteinogenic amino acids that are found in numerous 
biologically active compounds and synthetic peptides57,58 and are also difficult to form otherwise 
in optically enriched form. 
Figure 1.9 summarizes the steps that were optimized for the aforementioned 
transformations. Beginning with readily accessible homoallylic N-nosyl urea precursors (4 steps 
from commercial starting materials, see the Experimental Data section), application of Pd(II)/bis-
sulfoxide /LA-catalyzed oxidation or Pd(II)/LA catalyzed amination methods furnished either the 
corresponding aminooxazoline (±)-8 or imidazolidinone (±)-20 in excellent yields and 
selectivities (Tables 1.2, 1.3). Elaboration of the vinyl moiety of aminooxazoline (±)-8 via 
ruthenium trichloride-catalyzed oxidative cleavage affords carboxylic acid (±)-22 in 86% yield. 
N-nosyl-2-aminooxazoline (±)-22 was then subjected to hydrolysis under acidic conditions to 
afford the α-hydroxy-β-amino acid (±)-23 in 80% yield. Imidazolidinone (±)-20 could also be 
readily elaborated to α,β-diamino acid (±)-25 via a three-step sequence. 
 
N O
NHR
R
HN NR
O
R
N O
NHR
R COOH
HN NR
O
R COOH
R
NH2
OH
COOH
R
NH2
NH2
COOH
R
R
O
R
OH
OH
Epoxidation
Dihydroxylation
Metathesis
R
R'
Oxidative cleavage
R
O
H(OH)
H2
R
Figure 1.8 Terminal Olefin Diversifications
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Ruthenium catalyzed oxidative cleavage of the olefin afforded carboxylic acid (±)-24 in 
78% yield. Mild PhSH/K2CO3 removal of the N-nosyl group, followed by acidic hydrolysis gave 
rise to the corresponding α,β-diamino acid in 90% over the last two steps. These methods enable 
the selective and efficient generation of heterocyclic and acyclic polyoxidized pharmacophores 
and may expedite discovery of new medicinal agents. 
 
1.2.4 Mechanistic Experiments  
One of the most important and intriguing aspects of the newly discovered reactivity is the 
switch in selectivity from C—O to C—N bond formation with the ambident urea nucleophile. 
Optimization data (Table 1.1) suggests that this switch is dictated by the choice of palladium (II) 
ON
Me
NHNs
tBu H
(±)-8
79% yield
19:1 C-O:C-N
ON
Me COOH
NHNs
tBu H
(±)-22
2. H2SO4
(±)-23
NNsHN
iBu
O
(±)-20
63% yield
>20:1 C-O:C-N
1. RuCl3.xH2O, 
    H5IO6
NNsHN
iBu COOH
O
(±)-24
3. 2M HCl
COOH
NH2
iBu
NH2
(±)-25
C-O Reaction:  (1) RuCl3.xH2O (0.04 equiv.), NaIO4 (6 equiv.), MeCN:CCl4:H2O (1:1:1.5), rt 
(86%); (2) H2SO4:D2O (1:1), 130°C (80%)
C-N Reaction: (1) RuCl3.xH2O (0.04 equiv.), H5IO6 (6 equiv.), MeCN:CCl4:H2O (1:1:1.5), 0°C -> 
rt (78%); (2) PhSH (1.8 equiv.), K2CO3 (2.5 equiv.), DMF, 0°C -> 45°C (99%); (3) 2M HCl, 100°C 
(90%)
A.
B.
2. PhSH   
     K2CO3
1. RuCl3.xH2O,        
    NaIO4
86% 80%
syn-amino
alcohol
78%
syn-diamine
tBu COOH
NH2
OH
Me
90%              
(over 2 steps)
Figure 1.9 Elaboration to aminoacid derivatives
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catalyst. In order to confirm that it is a switch in palladium catalyst alone that is causing the 
selectivity for C—O vs C—N bond formation in these two reactions, I subjected a common 
starting material 26 to either 10 mol% Pd(II)/bis-sulfoxide catalyst 1 or  Pd(OAc)2  2 under 
otherwise identical reaction conditions of azaphilic Lewis acid co-catalyst, solvent, oxidant, and 
temperature (Figure 1.10).  
 
 
 
 
 
 
 
  
Remarkably, both Lewis acid co-catalysts B(C6F5)3 and Ag(OTf) delivered imidazolidinone 
product anti-15 and 2-aminooxazoline product anti-6 in comparable yields with excellent C—O 
vs. C—N selectivities of >20:1. Most importantly, these selectivities are dependent solely on the 
nature of the palladium catalyst. This study raised another important question that is related to 
the mechanism by which a simple switch in palladium catalyst leads to divergent outcomes from 
a common starting material. I hypothesized that the observed difference in the reactivity of the 
urea nucleophile when switching from Pd(II)/bis-sulfoxide 1 to Pd(OAc)2 2 arises from a change 
in mechanism from allylic C—H oxidation that furnishes anti-2-aminooxazoline products to 
olefin isomerization/oxidative olefin amination that generates anti-imidazolidinones. It has been 
established in our previous publications that Pd(II)/bis-sulfoxide 1 effects a C—H cleavage event  
Figure 1.10 Ligand Effect on Selectivity
>20:1 C-O:C-N>20:1 C-N:C-O
HN
O
NHNsHN
O
NNs N
NHNs
O
(±)-26 (±)-6(±)-15
Pd(OAc)2
S S
O
PhPh
O
.
Pd(OAc)2  
(10 mol%)
LA (10 mol%)
BQ (1.05 equiv) 
THF (1.66M)
45°C, 72h
same
(10 mol%)
LA (10 mol%)
a Isolated yield, average of 2 runs at 0.3 mmol; b The ratios were determined by 
1H NMR analysis of crude reaction mixture.
B(C6F5)3:  6, 61%; 15 , 64%
Ag(OTf):  6, 60%; 15 , 61%
Lewis acids (LA)a,b
2 1
tBu tBu tBu
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leading to the formation of a Pd-π-allyl intermediate (See Figure 1.6 for a general mechanistic 
scheme). This electrophilic species is known to react with a wide range of nucleophiles (oxygen, 
nitrogen, carbon) under varying reaction conditions. Consistent with C—O alkylation proceeding 
via such a mechanism (Figure 1.11, A), stoichiometric π-allyl  
 
 
 
 
 
 
 
 
intermediate 28 was formed in situ and was shown to afford anti-aminooxazoline 29 as the major 
product in the presence of AgOTf (Figure 1.11, B). 
B.
iPr
HN
O
NHTs
Pd(TFA)2
S S
O
PhPh
O
.
d8-THF (0.66M) 
45°C, 2h
(1 eq.)
iPr
HN
O
NHTs
LnPd
AgOTf    
(1 eq.)
MeBQ           
(1 eq.), 3h
N
NHTs
O
iPr
42% yield(±)-27
(±)-29
(±)-28
+ (±)-30
12 % (C—N
product)
Figure 1.11 Proposal and Evidence for C-O Bond Formation Mechanism
HN
R
O
NHR
 C-H cleavage
S S Ph
O
Ph
O
Pd(OAc)2
.
R
HN
NHR
O
LnPd
N O
NHR
RFunctionalization
A.
HN
R
O
NHR Pd(OAc)2 HN
R
O
NHR
Oxidative Amination
HN NR
O
R
Isomerization
HN NHNs
O
NNsHN
O
HN NHNs
O
59% yield
>20:1 dr
59% yield
>20:1 dr
BQ (1.05 eq.)
THF (1.66 M)
45°C, 72h
Pd(OAc)2 (10 mol%)
B(C6F5)3 (10 mol%) same
conditions
Figure 1.12 Proposal and Evidence for C!N Bond Formation Mechanism
A.
B.
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It has also been reported in the literature that the sulfoxide ligand is known to retard 
olefin isomerization, therefore I envisioned that its exclusion allows Pd(OAc)2/B(C6F5)3 to effect 
an isomerization of the terminal olefin starting material to the internal E-olefin, which would 
then be capable of undergoing an oxidative amination pathway (aminopalladation/β-hydride 
elimination) to give rise to the desired imidazolidinone product (Figure 1.12A). Isomerizations of 
terminal olefins catalyzed by Pd(II)-salts are well documented in the literature59 and the addition  
 
 
 
 
 
 
 
of Lewis acid additives60  has been shown to promote these processes. To test this hypothesis, I 
independently synthesized the corresponding internal olefin (Figure 1.13) and subjected it to the 
same reaction conditions as the terminal alkene (Figure 1.12B). I was delighted to observe a 
comparable yield and selectivity for the final product as obtained from the terminal olefin. This 
experiment therefore supports the hypothesis that the internal olefin is an intermediate in this 
reaction pathway. 
I next evaluated the rate of functionalization over time for terminal olefin substrate 3 and 
the corresponding E-internal olefin substrate 33, which would lead to the observed anti-
stereochemistry via an aminopalladation mechanism. Consistent with our hypothesis, both 
O
H
StBu
O
NH2
Ti(OEt)4, THF
r.t., 3-4h
N
H
S O
tBu
DCM, 0°C, 40 min.
MgBr
HN
S O
tBu
tBuOH, Et2O, -78°C
NH3, Na0
HN
S O
tBu
HCl, MeOHNH2 . HCl
67% (over 2 steps) 93%
90%
HN
O
NHNs
Figure 1.13 Synthesis of the E-internal olefin isomer
rt, 50 min
69%
Et3N, THF r.t., 20h
NsNCO
A
D
B C
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substrates formed the anti-imidazolidinone product with comparable overall kinetic profiles, 
yields and selectivities as seen in Figure 1.14. 
 
 
 
 
 
 
 
 	   An interesting aspect of this reactivity is that inclusion of a Lewis acid results in O-
functionalization from a π-allylPd intermediate and in exclusive N-functionalization via the 
aminopalladation pathway. This outcome may be explained by considering that π-allylPd N-
functionalization proceeds via external attack that requires an anionic, nucleophilic nitrogen. In 
accord with this, I have observed that Pd(0)-catalyzed allylic substitution of an analogous allylic 
acetate substrate, known to proceed via a π-allylPd intermediate, does not proceed without 
inclusion of stoichiometric base (Figure 1.15).  
 
 
 
 
Figure 1.14 Comparison of Kinetic Profiles
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Figure 1.15 C-N Bond Formation  under p-allylPd conditions
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The Lewis-acid co-catalysts used in this study may coordinate to the urea nosyl nitrogen and 
block its attack on the Pd/π-allyl complex and/or generate highly electrophilic π-allylPd 
intermediates that are preferentially attacked by the hard oxygen urea nucleophile (Figure 1.16). 
In contrast, aminopalladation is a process that has been noted to proceed under both acidic and 
basic reaction conditions.61 Figure 1.16 summarizes the proposed mechanisms for the C—O and  
 
 
 
 
 
 
 
C—N bond forming reactions, supported by evidence from experiments described above. With 
Pd(II)/bis-sulfoxide catalyst 1, the terminal olefin undergoes a C—H cleavage event leading to 
the formation of a π-allylPd intermediate. As mentioned before, I hypothesized the Lewis acid 
could now have a dual role; it could either bind the nitrogen atom, blocking its attack on the π-
ally intermediate or it could make the π-allylPd more electrophilic and therefore more 
susceptible to attack by the hard oxygen nucleophile. In the presence of Pd(OAc)2 and the 
B(C6F5)3 Lewis acid, the terminal olefin undergoes isomerization to the internal position. 
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Figure 1.16 Proposed Mechanisms
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Through oxidative amination, this internal alkene can now give rise to the desired 
imidazolidinone product. 
 
1.3 Conclusions 
This work represents a novel process that uses palladium catalysis in combination with 
Lewis acid co-catalysis for the formation of either anti-2-aminooxazolines or anti-
imidazolidinone products from common ambident urea precursors. The inclusion of Lewis acid 
promotes O-alkylation in reactions proceeding with ambident O/N nucleophiles via π-allylPd 
intermediates, thereby offering a strategy for expanding the scope of nucleophiles subject to 
palladium catalysis. Moreover, the discovery of facile isomerization/olefin palladation under 
LA/Pd(II) conditions may broaden the scope of allylic functionalization reactions available from 
terminal olefins. These methods enable the selective and efficient generation of heterocyclic and 
acyclic polyoxidized pharmacophores and may expedite discovery of new medicinal agents. 
 
1.4 Experimental Data 
General Information: All commercially obtained reagents for the allylic oxidation and 
amination reactions were used as received; Pd(OAc)2 (Johnson-Matthey Chemicals), Pd[1,2-
bis(phenylsulfinyl)ethane](OAc)2 “Catalyst 1” (Strem Chemicals and Sigma-Aldrich), (R,R)-
N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediaminochromium(III) chloride 
“Cr(salen)Cl” (Sigma-Aldrich) and Tris(pentafluorophenyl)borane “B(C6F5)3” (Strem 
Chemicals) were stored in a glove box under an argon atmosphere at -20°C and weighed out in 
the glove box prior to use. Catalyst 1 was also prepared according to the published procedure22 
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and used interchangeably with commercial catalyst. Methyl-p-benzoquinone (Sigma-Aldrich) 
and p-benzoquinone (Sigma-Aldrich) were sublimed and stored in the glove box up to two weeks 
prior to use. Silver trifluoromethanesulfonate “AgOTf” (Strem Chemicals) was recrystallized 
immediately prior to use following the outlined procedure below. p-Nitrobenzenesulfonyl 
isocyanate was prepared as described below. Solvents tetrahydrofuran and dichloromethane were 
purified prior to use by passage through a bed of activated alumina (Glass Contour, Laguna 
Beach, California). All allylic amination reactions were run under argon gas. The following 
precautions were taken in order to exclude moisture while the reactions were set up: the vials 
were flame dried prior to use, all of the solid reagents were combined in a glove box and the 
liquid components of the reaction mixture were added outside of the glove box under a flow of 
argon. All other reactions were run over a stream of N2 gas unless otherwise stated. Thin-layer 
chromatography (TLC) was conducted with E. Merck silica gel 60 F254 precoated plates (0.25 
mm) and visualized with UV and potassium permanganate stain. Flash chromatography was 
performed as described by Still using ZEOprep 60 ECO 43-60 micron silica gel (American 
International Chemical, Inc.). 1H NMR spectra were recorded on a Varian Unity-400 (400 MHz), 
Varian Inova-500 (500 MHz), or Varian Unity-500 (500 MHz) spectrometer and are reported in 
ppm using solvent as an internal standard (CDCl3 at 7.26 ppm). Data reported as: s = singlet, d = 
doublet, t = triplet, q = quartet, p = pentet, sext. = sextet, sept. = septet, m = multiplet, b = broad, 
ap = apparent; coupling constant(s) in Hz; integration. Proton-decoupled 13C NMR spectra were 
recorded on a Varian Unity-400 (100 MHz) and Varian Unity-500 (125 MHz) spectrometer and 
are reported in ppm using solvent as an internal standard (CDCl3 at 77.16 ppm). 
Diastereoselectivity of the allylic amination reaction was determined by 1H NMR analysis of the 
crude reaction mixture unless otherwise noted. IR spectra were recorded as thin films on NaCl 
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plates on a Perkin-Elmer Spectrum BX and are reported in frequency of absorption (cm-1). HPLC 
analysis was performed on an Agilent Technologies 1100 HPLC system with a model 1100 
Quaternary Pump, Diode Array Detector, Thermostat, and Autosampler using a Chiral 
Technologies Inc. Chiralcel OJ-H column (0.46 cm x 25 cm). High-resolution mass spectra were 
obtained at the University of Illinois Mass Spectrometry Laboratory. Optical rotations were 
obtained using a JASCO DIP-360 digital polarimeter and a 3.5 x 50 mm cell and are reported as 
follows: [a]λToC (c = g/100 mL, solvent). 
 
Synthesis of p-Nitrobenzenesulfonyl Isocyanate (NsNCO) 
 
 
 
 
 
 
All glassware must be dried in the oven overnight. A three-necked round bottom flask is 
equipped with a cold finger, a glass stopper and a stopcock joint, which is kept closed until 
otherwise noted. The entire system is then dried with a heating gun and upon cooling to room 
temperature, the cold finger is cooled to -78°C for the remainder of the reaction time. p-
Nitrobenzenesulfonamide (1 equiv.), butyl isocyanate (0.4 equiv.) and 1,2-dichlorobenzene 
(0.64M) are added in the specified order. The heterogeneous mixture is brought to reflux in a 
sand bath until the mixture becomes clear brown (15-30 minutes). A separate round bottom flask 
is flame dried and charged with triphosgene (0.67 equiv.) and phenanthridine (0.0067 equiv.) 
This flask is then connected to the stopcock on the three-necked flask through a black rubber 
tube and placed on top of a 100°C oil bath, slightly touching the oil such that the 
triphosgene/phenanthridine mixture sublimes very slowly. ATTENTION: At this point, the 
O2N
S
O
O
NH2
Triphosgene
BuNCO
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1,2-dichlorobenzene
reflux O2N
S
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O
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stopcock is opened in order for the in situ formed phosgene to enter the reaction mixture. 
IMPORTANT NOTE: Fast heating of the triphosgene/phenanthridine mixture will result in 
rapid gas evolution and increased pressures in the reaction vessel! Melting and bubbling of the 
triphosgene/phenanthridine mixture indicates phosgene formation. Phosgene will then condense 
into the three-necked flask, forming small smoke clouds as it drips into the reaction mixture. The 
slow condensation continues until all triphosgene/phenanthridine has melted; at this point, the 
reaction is stirred at reflux for another 1.5 hours. The three-necked flask is removed from the 
sand bath and slowly cooled to room temperature while the system is purged with nitrogen to 
remove any excess phosgene (the hood should be kept closed in order to avoid phosgene 
escape!). Purging with nitrogen is continued for 2 hours. The flask previously charged with 
triphosgene and phenanthridine is quenched in an ethanol bath. A phosgene strip should be used 
after 2 hours to check for any remaining gas. If the strip does not change color, it is safe to 
continue with the isolation. The 1,2-dichlorobenzene is removed by short path distillation and the 
remaining dark brown oil is transferred into a smaller round bottom flask, using a minimum 
amount of 1,2-dichlorobenzene for rinsing. p-Nitrobenzeneisocyanate is isolated by Kugelrohr 
distillation of the dark brown oil (1 torr, 175°C) as a crystalline, pale yellow solid (80% - 95% 
yield). The solid is quickly transferred into a different container and stored under Argon gas at -
20°C. 
Characterization of Diastereomers (syn and anti 2-aminooxazoline; syn and anti 
imidazolidinone) 
Each of the four diastereomers was synthesized and the corresponding spectral data is 
presented below. The main difference between the 13C NMR spectra of the 2-aminooxazoline 
and the imidazolidinone lies in the chemical shift of the allylic carbon atom. For the syn- and 
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anti-2-aminooxazolines, the allylic carbon has a chemical shift between 81.0 ppm and 86.7 ppm, 
consistent with a carbon atom bonded to oxygen. For the syn- and anti-imidazolidinones, the 
chemical shift of the allylic carbon lies between 62.6 ppm and 68.2 ppm, consistent with a 
carbon atom bonded to nitrogen. 
anti-Imidazolidinones: The internal vinylic proton has a range of 5.65 – 5.80 ppm and appears 
as a ddd (typical coupling constants: J = 17.0, 10.0, 8.5 Hz). The allylic proton has a range of 
4.50 – 4.90 ppm and appears as a dd (typical coupling constants: J = 8.0, 2.0 Hz). 
anti-2-Aminooxazolines: The internal vinylic proton has a range of 5.77 – 5.90 ppm and appears 
as a ddd (typical coupling constants: J = 17.0, 10.5, 7.0 Hz), shifted downfield compared to the 
anti-imidazolidinone internal vinylic proton by 0.05 - 0.1 ppm. The allylic proton has a range of 
4.80 – 5.10 ppm and appears as an apparent triplet (typical coupling constants: J = 6.5 Hz), 
shifted downfield compared to the anti-imidazolidinone allylic proton by ~0.2 ppm. 
syn-Imidazolidinone: The internal vinylic proton has a chemical shift of 5.6 ppm, shifted 
upfield compared to the anti-imidazolidinone internal vinylic proton by ~0.1 ppm. The allylic 
proton has a chemical shift of 4.85 ppm, shifted downfield compared to the anti-imidazolidinone 
allylic proton by ~0.2 ppm. The peak appears as a dd with a typical coupling constant of J = xx 
Hz. 
syn-2-Aminooxazoline: The internal vinylic proton has a chemical shift of 5.92 ppm, shifted 
downfield compared to the anti-2-aminooxazoline internal vinylic proton by ~0.02 ppm. Typical 
coupling constants are J = 17.0, 10.0, 7.5 Hz, very similar to the ones found for the anti-2-
aminooxazoline internal vinylic proton. The allylic proton has a chemical shift of 5.15 ppm, 
shifted downfield compared to the anti-2-aminooxazoline allylic proton by ~0.2 - 0.3 ppm. A 
typical coupling constant for this peak is J = 7.8 Hz. 
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 (±)-N-((4R,5R)-4-isopropyl-5-vinyl-4,5-dihydrooxazol-2-yl)-4-nitrobenzenesulfonamide:      
1H NMR (500MHz, CDCl3) δ 8.32 (d, J = 9.0 Hz, 2H), 8.11 (d, J = 8.5 Hz, 2H), 
7.66 (bs, 1H), 5.86 (ddd, J = 17.3, 10.5, 6.8 Hz, 1H), 5.45 (d, J = 17.0 Hz, 1H), 
5.39 (d, J = 10.5 Hz, 1H), 4.83 (t, J = 6.3 Hz, 1H), 3.58 (t, J = 6.0 Hz, 1H), 1.89 
(sext., J = 6.7, 1H), 0.99 (d, J = 6.5 Hz, 3H), 0.96 (d, J = 6.5 Hz, 3H);  13C NMR (125 MHz, 
CDCl3) δ 161.1, 149.9, 148.0, 133.3, 127.8, 124.2, 120.6, 82.8, 66.1, 32.0, 18.0, 17.8; IR (film, 
cm-1): 3217 (br), 3114, 2966, 2935, 2875, 1631, 1531; HRMS (ESI) m/z calc’d for C14H18N3O5S 
[M+H]+: 340.0967, found 340.0966.  
(±)-N-((4S,5R)-4-isopropyl-5-vinyl-4,5-dihydrooxazol-2-yl)-4-nitrobenzenesulfonamide:  
1H NMR (500MHz, CDCl3) δ 8.33 (d, J = 9.0 Hz, 2H), 8.12 (d, J = 8.5 Hz, 2H), 
7.55 (bs, 1H), 5.92 (m, 1H), 5.53 (d, J = 19.0 Hz, 1H), 5.50 (d, J = 10.5 Hz, 1H), 
5.15 (t, J = 7.8 Hz, 1H), 3.83 (t, J = 7.5 Hz, 1H), 1.91 (m, 1H), 0.99 (d, J = 6.5 Hz, 
3H), 0.96 (d, J = 6.5 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 161.5, 149.8, 147.8, 128.5, 127.7, 
124.0, 122.6, 82.8, 64.1, 28.1, 19.6, 18.4; IR (film, cm-1): 3380, 3107, 2968, 1628, 1529, 1425, 
1350; HRMS (ESI) m/z calc’d for C14H18N3O5S [M+H]+: 340.0967, found 340.0963. 
General Synthesis for N-((4S,5S)-4-isopropyl-5-vinyl-4,5-dihydrooxazol-2-yl)-4-
nitrobenzenesulfonamide and N-((4S,5R)-4-isopropyl-5-vinyl-4,5-dihydrooxazol-2-yl)-4-
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nitrobenzenesulfonamide: 
 
(±)-(4R,5R)-  4-isopropyl-1-((4-nitrophenyl)sulfonyl)-5-vinylimidazolidin-2-one: 
1H NMR (500 MHz, CDCl3) δ 8.35 (d, J = 9.0 Hz, 2H), 8.24 (d, J = 9.0 Hz, 2H), 
5.76 (ddd, J = 17.0, 10.0, 8.3 Hz, 1H), 5.43 (d, J = 17.0 Hz, 1H), 5.31 (d, J = 10.0 
Hz, 1H), 5.16 (m, 1H); 4.63 (dd, J  = 8.3, 2.3 Hz, 1H); 3.11 (dd, J = 5.5, 2.3 Hz, 
1H); 1.79 (m, 1H); 0.94 (ap t, J = 6.8 Hz, 6H);  13C NMR (125 MHz, CDCl3) δ 154.2, 150.6, 
145.0, 135.1, 129.9, 124.1, 119.5, 62.6, 61.8, 32.7, 17.8, 17.2; IR (film, cm-1): 3253 (br), 3109, 
2964, 1734, 1531; HRMS (ESI) m/z calc'd for C14H18N3O5S [M+H]+ : 340.0967, found 340.0965.      
(±)-(4R,5S)-4-isopropyl-1-((4-nitrophenyl)sulfonyl)-5-vinylimidazolidin-2-one: 
1H NMR (500 MHz, CDCl3) δ 8.33 (d, J = 9.0 Hz, 2H), 8.24 (d, J = 9.0 Hz, 2H), 
5.63 (m, 1H), 5.52 (d, J = 16.0 Hz, 1H), 5.40 (d, J = 10.0 Hz, 1H), 5.03 (bs, 1H); 
4.84 (dd, J  = 9.0, 7.0 Hz, 1H); 3.50 (dd, J = 10.5, 6.5 Hz, 1H); 1.67 (m, 1H); 0.94 
(d, J = 6.5 Hz, 3H), 0.86 (d, J = 6.5 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 154.8, 150.6, 144.9, 
130.2, 129.5, 123.9, 122.8, 64.1, 61.6, 27.6, 19.9, 18.2; IR (film, cm-1): 3253 (br), 2931, 1738, 
1529; HRMS (ESI) m/z calc'd for C14H18N3O5S [M+H]+ : 340.0967, found 340.0968. 
Crystal Structure of an anti-2-aminooxazoline 
 
NNsHN
O
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Table 1.  Crystal data and structure refinement for bm49uas. 
Identification code  bm49uas 
Empirical formula  C15 H19 N3 O5 S 
Formula weight  353.39 
Temperature  178(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2  
Unit cell dimensions a = 14.985(4) Å a= 90°. 
 b = 15.638(4) Å b= 90°. 
 c = 7.3222(18) Å g = 90°. 
Volume 1715.8(7) Å3 
Z 4 
Density (calculated) 1.368 Mg/m3 
Absorption coefficient 0.219 mm-1 
F(000) 744 
Crystal size 0.301 x 0.26 x 0.128 mm3 
Theta range for data collection 1.88 to 25.40°. 
Index ranges -18<=h<=18, -18<=k<=18, -8<=l<=8 
Reflections collected 18847 
Independent reflections 3152 [R(int) = 0.0357] 
Completeness to theta = 25.40° 99.9 %  
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Absorption correction Integration 
Max. and min. transmission 0.9797 and 0.9517 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3152 / 44 / 243 
Goodness-of-fit on F2 1.056 
Final R indices [I>2sigma(I)] R1 = 0.0289, wR2 = 0.0739 
R indices (all data) R1 = 0.0319, wR2 = 0.0759 
Absolute structure parameter -0.04(7) 
Extinction coefficient 0.0036(10) 
Largest diff. peak and hole 0.394 and -0.270 e.Å-3 
Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 
103) for bm49uas.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
 
 
Crystal Structure of an anti-imidazolidinone 
 
Table 1.  Crystal data and structure refinement for bc65uas. 
Identification code  bc65uas 
Empirical formula  C13 H15 N3 O5 S 
	  	   29	  
Formula weight  325.34 
Temperature  183(2) K 
Wavelength  1.54178 Å 
Crystal system  Triclinic 
Space group  P-1    
Unit cell dimensions a = 7.4903(3) Å a= 62.217(3)°. 
 b = 10.3952(5) Å b= 82.840(4)°. 
 c = 11.0256(5) Å g = 85.266(4)°. 
Volume 753.31(6) Å3 
Z 2 
Density (calculated) 1.434 Mg/m3 
Absorption coefficient 2.174 mm-1 
F(000) 340 
Crystal size 0.329 x 0.156 x 0.13 mm3 
Theta range for data collection 4.55 to 67.47°. 
Index ranges -8<=h<=8, -12<=k<=12, -13<=l<=13 
Reflections collected 9048 
Independent reflections 2581 [R(int) = 0.0367] 
Completeness to theta = 67.47° 95.3 %  
Absorption correction Integration 
Max. and min. transmission 0.8359 and 0.6757 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2581 / 574 / 372 
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Goodness-of-fit on F2 1.047 
Final R indices [I>2sigma(I)] R1 = 0.0393, wR2 = 0.1028 
R indices (all data) R1 = 0.0507, wR2 = 0.1112 
Largest diff. peak and hole 0.142 and -0.205 e.Å-3 
 
Table 2.  Atomic coordinates  ( x 104) and equivalent isotropic displacement parameters (Å2x 
103) for bc65uas.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
 
Synthesis of Homoallylic N-nosyl Ureas 
 
 
General Procedure: The homoallylic amine salt C was synthesized according to the 
procedure described by Ellman and coworkers.62 The crystalline amine salt was dissolved in THF 
(0.35M) in a flame dried N2 filled round-bottom flask. Et3N (2 equiv.) was added next via 
syringe and the reaction mixture was stirred at room temperature for 5 minutes. Nosyl isocyanate 
(1 equiv.) was then added in one portion. The reaction was stirred at room temperature until 
completed by TLC analysis. A solution of 1M HCl was added dropwise until the solution 
became acidic (pH<2). The aqueous layer was extracted with EtOAc (3 times) and the combined 
organic layers were dried over MgSO4, filtered and concentrated in vacuo. Purification by flash 
chromatography (EtOAc/hexanes/1% AcOH) provided the pure homoallylic N-nosyl urea D as a 
R
HN NHNs
O
R
NH2 . HCl
R
HN
S
O
tBu
R
N
R'
S
O
tBu
R
O
R'
tBu
S
O
NH2
Ti(OEt)4
DCM, rt
DCM, 0°C
MgBr
THF, rt
R' R' R'
>99%
65 - >90% 70 - 99%
HCl 
MeOH
rt
60 - >90%
NsNCO, Et3N
no column
no column
A B C D
	  	   31	  
white solid, which was further recrystallized from hexanes using minimal EtOAC (the 
recrystallization ensures higher reactivity). Final yields for the starting materials range from 
60%-95% yield based on the homoallylic amine precursor. 
(±)-N-((2-methylhex-5-en-3-yl)carbamoyl)-4-nitrobenzenesulfonamide: Product obtained as a 
white solid. 1H NMR (500 MHz, CDCl3) δ 8.36 (d, J = 9.0 Hz, 2H), 8.10 (d, J = 
9.0 Hz, 2H), 6.43 (d, J = 9.0 Hz, 1H), 5.68 (m, 1H), 5.07 - 5.02 (m, 2H), 3.73 (m, 
1H), 2.30 (m, 1H), 2.16 (m, 1H), 1.80 (m, 1H), 0.88 (ap t, J = 6.0 Hz, 6H); 13C 
NMR (125 MHz, CDCl3) δ 151.5, 150.9, 145.6, 134.3, 128.5, 124.6, 118.0, 55.7, 36.7, 31.6, 19.3, 
17.9; IR (film, cm-1): 3340, 3072 (br), 2964, 2881, 1670, 1527; HRMS (ESI) m/z calc'd for 
C14H20N3O5S [M+H]+: 342.1124, found 342.1123. 
 
(±)-4-methyl-N-((2-methylhex-5-en-3-yl)carbamoyl)benzenesulfonamide: Product obtained 
as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.77 (d, J = 8.5 Hz, 2H), 7.32 (d, 
J = 8.0 Hz, 2H), 6.44 (d, J = 9.0 Hz, 1H), 5.67 (m, 1H), 5.06 – 5.00 (m, 2H), 
3.71 (m, 1H), 2.44 (s, 3H), 2.29 – 2.11 (m, 2H), 1.77 (m, 1H), 0.86 (d, J = 2.5 
Hz, 3H), 0.85 (d, J = 2.5 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 151.9, 150.9, 144.5, 136.9, 
134.3, 129.7, 126.9, 117.6, 54.9, 36.6, 31.2, 21.6, 19.1, 17.5; IR (film, cm-1): 3342, 3078 (br), 
2962, 2881, 1662, 1545; HRMS (ESI) m/z calc'd for C15H23N2O3S [M+H]+: 311.1429, found 
311.1423. 
 
 (±)-N-(hex-5-en-3-ylcarbamoyl)-4-nitrobenzenesulfonamide: Product obtained as a white 
solid. 1H NMR (500 MHz, CDCl3) δ 8.38 (d, J = 9.0 Hz, 2H), 8.10 (d, J = 9.0 
Hz, 2H), 6.32 (d, J = 8.0 Hz, 1H), 5.71 (m, 1H), 5.1 - 5.07 (m, 2H), 3.78 (m, 
HN NHTs
O
HN NHNs
O
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1H), 2.34 – 2.17 (m, 2H), 1.62 – 1.43 (m, 2H), 0.88 (t, J = 7.5 Hz, 6H); 13C NMR (125 MHz, 
CDCl3) δ 150.9, 150.6, 145.1, 133.6, 128.3, 124.5, 118.4, 51.7, 38.4, 27.2, 10.2; IR (film, cm-1): 
3373, 3099 (br), 2968, 1666, 1533; HRMS (ESI) m/z calc'd for C13H18N3O5S [M+H]+: 328.0967, 
found 328.0961. 
 
(±)-N-((6-methylhept-1-en-4-yl)carbamoyl)-4-nitrobenzenesulfonamide: Product obtained as 
a white solid. 1H NMR (500 MHz, CDCl3) δ 9.62 (bs, 1H), 8.36 (m, 2H), 8.09 
(m, 2H), 6.37 (d, J = 9.0 Hz, 1H), 5.69 (m, 1H), 5.04 (m, 2H), 3.94 (m, 1H), 
2.29 (m, 1H), 2.17 (m, 1H), 1.49 (m, 1H), 1.34 (m, 2H), 0.90 (d, J = 6.5 Hz, 3H), 0.88 (d, J = 7.0 
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 151.3, 150.8, 145.4, 133.7, 128.5, 124.6, 118.6, 48.7, 
43.8, 39.7, 25.1, 23.1, 22.2; IR (film, cm-1): 3348, 3130 (br), 3105, 2958, 2904, 1664, 1533; 
HRMS (ESI) m/z calc'd for C15H22N3O5S [M+H]+: 356.1280, found 356.1281. 
 
(±)-N-((2,2-dimethylhex-5-en-3-yl)carbamoyl)-4-nitrobenzenesulfonamide: 
Product obtained as a white solid. 1H NMR (500 MHz, CDCl3) δ 9.74 (bs, 1H), 
8.34 (d, J = 9.0 Hz, 2H), 8.09 (d, J = 8.5 Hz, 2H), 6.46 (d, J = 10.0 Hz, 1H), 5.63 (m, 1H), 4.99 
(d, J = 17.0 Hz, 1H), 4.91 (d, J = 10.0 Hz, 1H), 3.70 (m, 1H), 2.47 (m, 1H), 1.95 (m, 2H), 0.89 (s, 
9H); 13C NMR (125 MHz, CDCl3) δ 151.8, 150.8, 145.6, 135.4, 128.4, 124.6, 117.4, 58.7, 35.0, 
34.9, 26.5; IR (film, cm-1): 3348 (br), 3111, 2962, 2873, 1662, 1533; HRMS (ESI) m/z calc'd for 
C15H22N3O5S [M+H]+: 356.1280, found 356.1277. 
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(±)-N-((2,3-dimethylhex-5-en-3-yl)carbamoyl)-4-nitrobenzenesulfonamide: Product obtained 
as a white solid. 1H NMR (500 MHz, CDCl3) δ 9.07 (bs, 1H), 8.37 (d, J = 9.0 Hz, 
2H), 8.09 (d, J = 9.0 Hz, 2H), 6.41 (bs, 1H), 5.61 (ddd, J = 24.5, 10.0, 7.5 Hz, 
1H), 5.05 (d, J = 17.5 Hz, 1H), 5.01 (d, J = 10.0 Hz, 1H), 2.53 (dd, J = 14.0, 7.5 
Hz, 1H), 2.37 (dd, J = 14.0, 7.0 Hz, 1H), 2.21 (sept, J = 6.8 Hz, 1H), 1.20 (s, 3H), 0.88 (d, J = 
3.0 Hz, 3H), 0.87 (d, J = 3.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 150.7, 150.1, 145.4, 133.2, 
128.5, 124.6, 119.2, 60.1, 40.1, 34.0, 20.1, 17.2, 17.2; IR (film, cm-1): 3356, 3205 (br), 3089, 
2970, 1666, 1533; HRMS (ESI) m/z calc'd for C15H22N3O5S [M+H]+: 356.1280, found 356.1282. 
 
(±)-4-nitro-N-((2,2,3-trimethylhex-5-en-3-yl)carbamoyl)benzenesulfonamide: Product 
obtained as a white solid. 1H NMR (500 MHz, CDCl3) δ 8.38 (d, J = 9.0 Hz, 
2H), 8.10 (d, J = 9.0 Hz, 2H), 6.38 (s, 1H), 5.59 (m, 1H), 5.03 (d, J = 16.8 Hz, 
1H), 4.95 (d, J = 10.3 Hz, 1H), 2.73 (dd, J = 14.5, 6.8 Hz, 1H), 2.24 (dd, J = 
14.5, 7.3 Hz, 1H), 1.31 (s, 3H), 0.96 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 150.6, 150.2, 145.5, 
134.4, 128.2, 124.5, 118.4, 62.7, 39.3, 39.3, 25.9, 20.5; IR (film, cm-1): 3365, 2974, 1697, 1535, 
1352, 1161; HRMS (ESI) m/z calc'd for C16H24N3O5S [M+H]+: 370.1437, found 370.1436. 
 
 (±)-N-((1-(4-methoxyphenyl)-2-methylpent-4-en-2-yl)carbamoyl)-4-
nitrobenzenesulfonamide: Product obtained as a light yellow solid. 
1H NMR (500 MHz, CDCl3) δ 8.27 (d, J = 9.0 Hz, 2H), 7.86 (d, J = 
9.0 Hz, 2H), 7.00 (d, J = 8.5 Hz, 2H), 6.73 (d, J = 8.5 Hz, 2H), 6.24 (s, 1H), 5.75 (m, 1H), 5.14 – 
5.11 (m, 2H), 3.78 (s, 3H), 3.02 (d, J = 13.2 Hz, 1H), 2.83 (d, J = 14.0 Hz, 1H), 2.57 (dd, J = 
14.0, 8.0 Hz, 1H), 2.36 (dd, J = 14.0, 7.0 Hz, 1H), 1.28 (s, 3H); 13C NMR (125 MHz, CDCl3) 
HN NHNs
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O
MeO
	  	   34	  
δ 158.4, 150.5, 149.7, 144.9, 132.7, 131.4, 128.4, 128.3, 124.4, 119.7, 113.5, 57.2, 55.2, 43.2, 
43.1, 24.2; IR (film, cm-1): 3356, 3246, 3078, 2914, 1670, 1533, 1512, 1454, 1350; HRMS (ESI) 
m/z calc'd for C20H24N3O6S [M+H]+: 434.1386, found 434.1383. 
 
Synthesis of the E-internal olefin 
 
 
 
 
 
 
Procedure: Isobutyraldehyde (1.1 equiv.) was added to a solution of Ti(OEt)4 (2 equiv.) in THF 
(0.26M) in a flame dried round-bottom flask. After stirring at rt for 10 min, the tert-
butanesulfinamide (1 equiv.) was added in one portion and the reaction was stirred at rt until 
complete by TLC. Upon completion, saturated NaCl was added and the mixture was vigorously 
stirred for ~1.5-2h. The reaction mixture was then filtered through Celite using ethyl acetate. The 
layers were separated and the aqueous layer was extracted with EtOAc (3x). The combined 
organic layers were dried with MgSO4, filtered and concentrated to give A as a light yellow oil 
that was carried forward without any further purification. 
 Aldimine A (1 equiv.) was dissolved in DCM in a flame dried round-bottom flask and the 
solution was cooled to 0°C in an ice bath. 1-propynylmagnesium bromide (1.5 equiv.) was then 
added dropwise and the reaction mixture was let stir at 0°C until complete by TLC (30-40 
minutes). Upon completion, saturated NH4Cl was added at 0°C to quench the reaction. The two 
O
H
StBu
O
NH2
Ti(OEt)4, THF
r.t., 3-4h
N
H
S O
tBu
DCM, 0°C, 40 min.
MgBr
HN
S O
tBu
tBuOH, Et2O, -78°C
NH3, Na0
HN
S O
tBu
HCl, MeOHNH2 . HCl
67% (over 2 steps) 93%
90%
HN
O
NHNs
rt, 50 min
69%
Et3N, THF r.t., 20h
NsNCO
A
D
B C
	  	   35	  
layers were separated and the aqueous layer was extracted with DCM (3x). The combined 
organic layers were dried with MgSO4, filtered and concentrated to give B as a light yellow oil. 
The two diastereomers were further purified by flash column chromatography using a 
EtOAc/Hexanes gradient. 
 A three-neck round-bottom flask was flame dried and topped with a cold finger. Metallic 
Na (10 equiv.) was added to the flask and the system was purged with nitrogen. The cold finger 
and the flask were cooled to -78°C and ammonia gas (0.03 M with respect to the sulfinyl amine) 
was condensed over the sodium metal directly from an ammonia tank to produce a deep blue 
solution (NOTE: if the deep blue color start to disappear, add more Na metal). Next, a solution 
of amine B in tert-butanol (1.85 M) and diethyl ether (0.27 M) was rapidly added to the flask via 
syringe. The reaction mixture was stirred -78°C until complete by 1H NMR (a small aliquot can 
be removed, quenched with NH4Cl(sat), and the organic layer diluted with CDCl3). The reaction 
was quenched by addition of solid NH4Cl portion wise until the deep blue color disappeared. The 
solution was diluted with DCM and slowly warmed to rt; ammonia gas evolution was observed. 
When ammonia gas ceased to evolve (check with pH paper), the contents of the flask were 
transferred to a separatory funnel using DCM and water and the aqueous layer was extracted 
with DCM (3x). The combined organic layers were dried with MgSO4, filtered and concentrated 
to give C as a light yellow oil, which was used in the next step without further purification. 
 Internal olefin C (1 equiv.) was dissolved in MeOH (1M) in a flame dried flask. After 5 
minutes, a 1M solution of HCl in diethyl ether (2 equiv.) was added dropwise and the reaction 
mixture was stirred at rt until complete by TLC (40-50 minutes). At this time, the solvent was 
removed in vacuo followed by addition of small portions of diethyl ether that crashed out the 
	  	   36	  
HCl salt of the deprotected amine product D. The white solid was isolated by filtration and 
carried forward without purification. 
(±)-(E)-N-((2-methylhex-4-en-3-yl)carbamoyl)-4-nitrobenzenesulfonamide: Product obtained 
as a white solid according to the general procedure. 1H NMR (500 MHz, CDCl3) 
δ 8.38 (m, 2H), 8.11 (d, J = 9.0 Hz, 2H), 6.51 (m, 1H), 5.55 (dq, J = 15.0, 6.5 Hz, 
1H), 5.33 (m, 1H), 4.06 (m, 1H), 1.77 (m, 1H), 1.70 (d, J = 6.5 Hz, 3H), 0.87 (d, 
J = 6.5 Hz, 3H), 0.85 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 151.3, 150.7, 145.3, 
128.7, 128.5, 128.1, 124.6, 57.9, 32.4, 18.7, 18.3, 17.9; IR (film, cm-1): 3348, 3150 (br), 3109, 
2964, 2875, 1662, 1535; HRMS (ESI) m/z calc'd for C14H20N3O5S [M+H]+: 342.1124, found 
342.1114. 
Synthesis of Aryl Substituted Homoallylic N-nosyl Ureas 
 
General Procedure for the synthesis of Acid A:63,64 Lithium diisopropylamide was prepared in 
a flame dried N2 filled round-bottom flask by the dropwise addition of nBuLi (2.2 equiv.) to a 
solution of diisopropylamine (2.65 equiv.) in THF (0.5M) at -78 °C. Once the addition was 
complete, the flask was warmed to 0 °C and stirred for 15-20 minutes. After cooling the reaction 
mixture to -78 °C, 4-pentenoic acid (1 equiv.) was added dropwise followed by the addition of 
DMPU (2 equiv.) in one portion. The mixture was warmed to room temperature and stirred for 
approximately 30 minutes. After cooling to 0 °C, 4-fluorobenzyl bromide (1.1 equiv.) was added 
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dropwise causing the reaction mixture to change color from cloudy yellow to purple and 
eventually to clear yellow upon complete addition of the electrophile. The reaction mixture was 
warmed to room temperature and stirred until completed by TLC analysis. The reaction was 
quenched at 0 °C with 10% HCl. The aqueous layer was extracted three times with EtOAc. The 
combined organic layers were washed twice with 10% HCl, dried over MgSO4, filtered and 
concentrated in vacuo to yield the pure acid as a yellow oil. 
General Procedure for the synthesis of protected amine B:65 A flame dried N2 filled round-
bottom flask was charged with THF (0.125M). NaN3 (7 equiv.), Bu4NBr (0.15 equiv.), ZnCl2 
(0.033 equiv.), di-tert-butyl dicarbonate (1.1 equiv.) and acid A (1 equiv.) were sequentially 
added. The flask was fitted with a condenser under N2 atmosphere and the reaction mixture was 
heated to 65-70 °C on a heating mantle. After the reaction was complete as shown by TLC 
analysis, it was cooled to room temperature, quenched with 10% NaNO2 (same volume as THF) 
and stirred for approximately 30 minutes. The aqueous layer was extracted three times with 
EtOAc. The combined organic layers were washed once with saturated ammonium chloride, 
sodium bicarbonate and brine, then dried over MgSO4, filtered and concentrated in vacuo. 
Purification by flash chromatography (10% EtOAc/hexanes) provided the protected amine B as a 
white solid. 
General Procedure for the synthesis of free amine C: A flame dried N2 filled round-bottom 
flask was charged with B and DCM (1.0M) and the mixture was stirred at room temperature to 
ensure homogeneity. Trifluoroacetic acid (1.0M) was then added dropwise and the reaction 
mixture was stirred at room temperature until completed by TLC analysis. The solvent and the 
trifluoroacetic acid were removed in vacuo to yield the pure free amine as an orange oil.  
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The N-nosyl urea D was synthesized according to the general procedure described for the 
synthesis of homoallylic N-nosyl ureas. 
 
(±)-N-((1-(4-methoxyphenyl)pent-4-en-2-yl)carbamoyl)-4-nitrobenzenesulfonamide: Product 
obtained as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 8.92 (bs, 1H), 
8.23 (d, J = 8.5 Hz, 2H), 7.79 (d, J = 8.5 Hz, 2H), 7.08 (d, J = 8.5 Hz, 
2H), 6.82 (d, J = 8.5 Hz, 2H), 6.48 (d, J = 8.0 Hz, 1H), 5.76 (m, 1H), 5.11 (m, 2H), 4.08 (m, 1H), 
3.80 (s, 3H), 2.85 (dd, J = 14.3, 5.8 Hz, 1H), 2.67 (dd, J = 14.5, 8.8 Hz, 1H), 2.35 (m, 1H), 2.26 
(m, 1H); 13C NMR (125 MHz, CDCl3) δ 158.6, 151.0, 150.6, 145.2, 133.7, 130.2, 129.4, 128.2, 
124.5, 118.9, 114.2, 55.4, 51.7, 39.2, 38.6; IR (film, cm-1): 3356, 3200 (br), 3106, 2927, 1668, 
1533; HRMS (ESI) m/z calc'd for C19H22N3O6S [M+H]+: 420.1229, found 420.1231. 
 
(±)-(E)-5-methyl-4-(3-((4-nitrophenyl)sulfonyl)ureido)hex-2-en-1-yl acetate: 
1H NMR (500 MHz, CDCl3) δ 8.40 (d, J = 8.5 Hz, 2H), 8.11 (d, J = 9.0 Hz, 
2H), 6.60 (d, J = 8.0 Hz, 1H), 5.69 – 5.60 (m, 2H), 4.55 (d, J = 4.5 Hz, 2H), 
4.17 (m, 1H), 2.09 (s, 3H), 1.83 (m, 1H), 0.88 (d, J = 6.5 Hz, 6H); 13C NMR 
(125 MHz, CDCl3) δ 170.9, 151.0, 150.7, 145.1, 132.2, 128.4, 126.2, 124.6, 64.1, 57.0, 32.2, 
20.9, 18.6, 17.9; IR (film, cm-1): 3361, 3103, 2962, 1738, 1675, 1533, 1350; HRMS (ESI) m/z 
calc'd for C16H22N3O7S [M+H]+: 400.1178, found 400.1181. 
 
General Synthesis for (-)-N-(((2S,3S)-2-((tert-butyldimethylsilyl)oxy)hex-5-en-3-
yl)carbamoyl)-4-nitrobenzenesulfonamide and (-)-N-(((2S,3R)-2-((tert-
butyldimethylsilyl)oxy)hex-5-en-3-yl)carbamoyl)-4-nitrobenzenesulfonamide:66   
 
NHNs
O
HN
OAc
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(-)-(S)-2-((tert-butyldimethylsilyl)oxy)propanal: The spectral data are in agreement with the 
data reported in the literature. Ref.  1H NMR (500 MHz, CDCl3) δ 9.62 (s, 1H), 4.10 (q, 
J = 6.7 Hz, 1H), 1.28 (d, J = 7.0 Hz, 3H), 0.92 (s, 9H), 0.01 (s, 3H), 0.09 (s, 3H); 
[α]D23.9 = -11.4 (c = 1.90, CHCl3) [Lit.: [α]D24.7 = -12.1 (c = 1.96, CHCl3)]. 
 
(+)-(S,E)-N-((S)-2-((tert-butyldimethylsilyl)oxy)propylidene)-2-methylpropane-
2-sulfinamide:  The spectral data are in agreement with the data reported in the 
literature.  Ref. 1H NMR (500 MHz, CDCl3) δ 7.96 (d, J = 4.0 Hz, 1H), 4.57 (m, 1H), 
1.36 (d, J = 6.5 Hz, 3H), 1.20 (s, 9H), 0.89 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H);  [α]D24.4 = +165.8 (c 
= 2.13, CH2Cl2) [Lit.: [α]D21 = +25.38 (c = 2.13, CH2Cl2)]. 
 
(S)-N-((2S,3S)-2-((tert-butyldimethylsilyl)oxy)hex-5-en-3-yl)-2-methylpropane-2-
sulfinamide: Product obtained as a clear oil.  1H NMR (500 MHz, CDCl3) 
δ 5.77 (m, 1H), 5.06 (m, 2H), 3.91 (d, J = 6.5 Hz, 1H), 3.89 (qd, J = 6.5, 3.0 Hz, 
1H), 3.12 (ddd, J = 13.0, 6.8, 3.0 Hz, 1H), 2.37 (ddd, J = 14.5, 7.0, 6.0 Hz, 1H), 
OTBS
O
O
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2.21 (m, 1H), 1.23 (d, J = 6.5 Hz, 3H), 1.21 (s, 9H), 0.89 (s, 9H), 0.07 (s, 3H), 0.07 (s, 3H); 13C 
NMR (125 MHz, CDCl3) δ 135.2, 117.4, 69.4, 61.3, 56.0, 38.3, 25.9, 23.0, 20.9, 18.1, -3.9, -4.7; 
IR (film, cm-1): 3207 (br), 2954, 2929, 2858, 1471, 1387; HRMS (ESI) m/z calc'd for 
C16H36NO2SiS [M+H]+: 334.2236, found 334.2246; [α]D22.2 = +32.8 (c = 1.0, CHCl3). 
 
 (-)-(4S,5S)-4-allyl-5-methyloxazolidin-2-one: The spectral data are in agreement with the data 
reported in the literature.  Ref. 1H NMR (500 MHz, CDCl3) δ 5.72 (m, 1H), 5.49 
(bs, 1H), 5.18 (m, 1H), 4.34 (p, J = 6.1 Hz, 1H), 3.46 (dd, J = 12.5, 5.5 Hz, 1H), 
2.25-2.37 (m, 2H), 1.42 (d, J = 3H); [α]D24.0 = -34.2 (c = 0.65, CHCl3) [Lit. for (+)-
(4R,5R)-4-allyl-5-methyloxazolidin-2-one: [α]D = +36.5  (c = 0.40, CHCl3)]. 
 
(-)-N-(((2S,3S)-2-((tert-butyldimethylsilyl)oxy)hex-5-en-3-yl)carbamoyl)-4-
nitrobenzenesulfonamide: Product obtained as a white solid.  1H NMR (500 
MHz, CDCl3) δ 8.34 (m, 2H), 8.11 (d, J = 9.0 Hz, 2H), 6.99 (d, J = 9.0 Hz, 1H), 
5.67 (m, 1H), 5.01 (m, 2H), 3.92 (ap. q, J = 6.2 Hz, 1H), 3.71 (ap. q, J = 7.7 Hz, 
1H), 2.25 (m, 2H), 1.04 (d, J = 6.0 Hz, 3H), 0.97 (s, 9H), 0.13 (s, 3H), 0.11 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ 151.8 150.7, 145.6, 134.4, 128.5, 124.6, 117.9, 68.4, 55.7, 37.7, 25.9, 21.5, 
18.1, -3.9, -4.8; IR (film, cm-1): 3383, 3105, 2954, 2929, 2889 (br), 2858, 1691, 1531; [α]D24.8 = -
12.7 (c = 0.45, CHCl3). 
 
(+)-(S)-N-((2S,3R)-2-((tert-butyldimethylsilyl)oxy)hex-5-en-3-yl)-2-methylpropane-2-
sulfinamide: Product obtained as a clear oil.  1H NMR (500 MHz, CDCl3) δ 5.85 
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(m, 1H), 5.14 (m, 2H), 3.79 (qd, J = 6.2, 4.9 Hz, 1H), 3.36 (ap. d, J = 6.5 Hz, 1H), 3.19 (m, 1H), 
2.40 (m, 2H), 1.19 (s, 9H), 1.13 (d, J = 6.5 Hz, 3H), 0.87 (s, 9H), 0.04 (s, 3H), 0.04 (s, 3H); 13C 
NMR (125 MHz, CDCl3) δ 134.8, 118.8, 70.8, 61.3, 56.1, 36.1, 25.9, 22.9, 19.9, 18.1, -3.9, -4.7; 
IR (film, cm-1): 3230 (br), 2956, 2929, 2858, 1473; HRMS (ESI) m/z calc'd for C16H36NO2SiS 
[M+H]+: 334.2236, found 334.2246; [α]D24.7 = +35.6 (c = 1.10, CHCl3). 
 
(-)-N-(((2S,3R)-2-((tert-butyldimethylsilyl)oxy)hex-5-en-3-yl)carbamoyl)-4-
nitrobenzenesulfonamide: Product obtained as a white solid. 1H NMR (500 
MHz, CDCl3) δ 9.49 (bs, 1H), 8.34 (d, J = 8.5 Hz, 2H), 8.10 (d, J = 8.5 Hz, 2H), 
6.65 (d, J = 9.0 Hz, 1H), 5.66 (m, 1H), 5.01 (d, J = 17.0 Hz, 1H), 4.96 (d, J = 
10.0 Hz, 1H), 3.93 (m, 1H), 3.78 (m, 1H), 2.35 (m, 1H), 2.21 (m, 1H), 1.14 (d, J = 6.5 Hz, 3H), 
0.89 (s, 9H), 0.07 (s, 3H), 0.05 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 151.3, 150.7, 145.4, 134.9, 
128.5, 124.5, 117.7, 69.7, 55.6, 33.2, 25.9, 20.2, 18.1, -3.9, -4.6; IR (film, cm-1): 3354, 3150 (br), 
3109, 3080, 2956, 2931, 2858, 1668, 1535; HRMS (ESI) m/z calc'd for C19H32N3O6SSi [M+H]+: 
458.1781, found 458.1788. [α]D26.3 = -23.7o (c = 1.0, CHCl3). 
 
General Synthesis for (-)-N-(((2S,3S)-1,2-bis(benzyloxy)hex-5-en-3-yl)carbamoyl)-4-
nitrobenzenesulfonamide and (-)-N-(((2S,3R)-1,2-bis(benzyloxy)hex-5-en-3-yl)carbamoyl)-
4-nitrobenzenesulfonamide:66,67 
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(+)-(R)-2,3-bis(benzyloxy)propanal: The spectral data are in agreement with the data reported 
in the literature. Ref. 1H NMR (500 MHz, CDCl3) δ 9.73 (d, J = 1 Hz, 1H), 7.37-
7.26 (m, 10H), 4.75 (d, J = 12 Hz, 1H), 4.70 (d, J = 12 Hz, 1H), 4.57 (d, J = 12 
Hz, 1H), 4.54 (d, J = 12 Hz, 1H), 3.99 (m, 1H), 3.82-3.76 (m, 2H). [α]D25.3 = +33.2o (c = 1.1, 
CHCl3). [Lit. for (S)-2,3-bis(benzyloxy)propanal: [α]D25 = -37.6o (c = 1.1, CHCl3)]. 
 
(+)-(S)-N-((2S,3S)-1,2-bis(benzyloxy)hex-5-en-3-yl)-2-methylpropane-2-sulfinamide: 1H 
NMR (500 MHz, CDCl3) δ 7.36-7.27 (m, 10H), 5.76 (m, 1H), 5.04-5.01 (m, 
2H), 4.67 (dd, J = 29.5, 11.5 Hz, 2H), 4.53 (dd, J = 20.5, 12 Hz, 2H), 3.95 (m, 
1H), 3.9 (d, J = 8 Hz, 1H), 3.66 (dd, J = 10, 5.5 Hz, 1H), 3.60-3.54 (m, 2H), 
2.35-2.22 (m, 2H), 1.18 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 138.4, 137.9, 135.2, 128.4, 128.3, 
127.9, 127.7, 127.6,117.2, 79.9, 73.3, 72.8, 69.9, 57.7, 56.2, 34.9, 22.7; IR (film, cm-1): 3298, 
3066, 3032, 2916 (br), 1720, 1641, 1454, 1363; HRMS (ESI) m/z calc'd for C24H34NO3S [M+H]+: 
416.2259, found 416.2252. [α]D24.9 = +15.8o (c = 1.04, CHCl3). 
 
(-)-N-(((2S,3S)-1,2-bis(benzyloxy)hex-5-en-3-yl)carbamoyl)-4-nitrobenzenesulfonamide: 
Product obtained as a white solid. 1H NMR (500 MHz, CDCl3) δ 9.07 (bs, 
1H), 8.07 (d, J = 9.0 Hz, 2H), 7.93 (d, J = 8.5 Hz, 2H), 7.64 (d, J = 9.5 Hz, 
1H), 7.32-7.38 (m, 5H), 7.18-7.24 (m, 5H), 5.68 (m, 1H), 4.96 (m, 2H), 
4.66 (d, J = 12.0 Hz, 1H), 4.52 (d, J = 12.5 Hz, 1H), 4.46 (m, 2H), 4.34 (m, 1H), 3.69 (m, 2H), 
3.55 (m, 1H), 2.24 (m, 1H), 2.12 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 151.6, 150.3, 145.2, 
137.7, 137.2, 134.1, 128.7, 128.7, 128.6, 128.5, 128.3, 128.0, 127.9, 124.3, 118.0, 77.2, 73.6, 
71.8, 68.8, 50.8, 35.8; IR (film, cm-1): 3352, 3102 (br), 3066, 3033, 2868, 1682, 1531; HRMS 
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(ESI) m/z calc'd for C27H30N3O7S [M+H]+: 540.1804, found 540.1803. [α]D27 = -25.5o (c = 0.29, 
CHCl3). 
 
(-)-N-(((2S,3R)-1,2-bis(benzyloxy)hex-5-en-3-yl)carbamoyl)-4-nitrobenzenesulfonamide: 
Product obtained as an orange thick oil. 1H NMR (500 MHz, CDCl3) δ 8.56 
(bs, 1H), 8.10 (d, J = 9.0 Hz, 2H), 7.96 (d, J = 8.5 Hz, 2 H), 7.25-7.39 (m, 
10H), 6.86 (d, J = 9.0 Hz, 1H), 5.66 (m, 1H), 4.98 (m, 2H), 4.74 (d, J = 11.5 
Hz, 1H), 4.59 (d, J = 11.5 Hz, 1H), 4.43 (dd, J = 22.5, 12.0 Hz, 2H), 4.09 (ap q, J = 7.5 Hz, 1H), 
3.68 (m, 1H), 3.45 (dd, J = 9.5, 5.5 Hz, 1H), 3.30 (dd, J = 9.5, 6.5 Hz, 1H), 2.23-2.34 (m, 2H); 
13C NMR (125 MHz, CDCl3) δ 151.4, 150.5, 145.0, 138.0, 137.7, 134.1, 128.7, 128.7, 128.6, 
128.2, 127.9 (br), 127.7, 124.3, 118.2, 77.2, 73.6, 73.1, 69.8, 51.1, 37.0; IR (film, cm-1): 3367, 
3120 (br), 3104, 3068, 2900, 2872, 1680, 1531; HRMS (ESI) m/z calc'd for C27H30N3O7S 
[M+H]+: 540.1804, found 540.1796. [α]D25.8 = -6.7o (c = 0.39, CHCl3). 
 
General Synthesis for N-(((2S,3S)-1-(2-fluorophenyl)-2-methylhex-5-en-3-yl)carbamoyl)-4-
nitrobenzenesulfonamide:68,69   
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 (-)-(S)-3-(2-fluorophenyl)-N,2-dimethyl-N-((2R,3R)-3-phenylbutan-2-yl)propanamide: 
Product obtained as a white solid. 1H NMR (3.2:1 rotamer ratio, 
asterisk denotes minor rotamer peaks, 500 MHz, CDCl3) δ 6.98-7.37 
(m, 10H), 4.56 (d, J = 6.8 Hz, 1H), 4.46* (ap. d, J = 9.0 Hz, 1H), 4.39 (bs, 1H), 4.21* (bs, 1H), 
4.09* (p, J = 7.8 Hz, 1H), 3.29* (q, J = 6.8 Hz, 1H), 3.15* (dd, J = 14.0, 6.8 Hz, 1H), 3.02 (h, J 
= 6.9 Hz, 1H), 2.86-2.91 (m, 2H), 2.81* (dd, J = 13.5, 8.0 Hz, 1H), 2.68-2.74 (m, 4H), 1.77* (ap. 
d, J = 3.0 Hz, 1H), 1.13 (d, J = 7.0 Hz, 3H), 1.11*(d, J = 6.5 Hz, 3H), 0.98 (m, 3H); 13C NMR 
(3.2:1 rotamer ratio, all chemical shifts included, 125 MHz, 
CDCl3) δ 178.3, 160.5, 142.6, 132.1, 132.1, 128.9, 128.6, 128.5, 128.3, 128.3, 127.8, 127.1, 126.
5, 124.1, 124.1, 115.3, 115.2, 76.7, 37.2, 34.0, 17.4, 14.5; IR (film, cm-1): 3354 (br), 2981, 2933, 
1620 (br);  
 
(-)-(S)-3-(2-fluorophenyl)-2-methylpropan-1-ol: The spectral data are in agreement with the 
data reported in the literature.  Ref. 1H NMR (500 MHz, CDCl3) δ 7.18 (m, 2H), 
7.06 (t, J = 7.5 Hz, 1H), 7.01 (t, J = 8.8 Hz, 1H), 3.51 (m, 2H), 2.78 (dd, J = 13.0, 
6.3 Hz, 1H), 2.50 (dd, J = 14.0, 7.8 Hz, 1H), 1.98 (h, J = 6.7 Hz, 1H), 1.35 (t, J = 5.5 Hz, 1H), 
0.94 (d, J = 6.5 Hz, 3H); [α]D23.9 = -9.1o (c = 0.75, CHCl3). 
 
 (+)-N-(((2S,3R)-1-(2-fluorophenyl)-2-methylhex-5-en-3-yl)carbamoyl)-4-
nitrobenzenesulfonamide:  Product obtained as a white solid. 1H NMR 
(500 MHz, CDCl3) δ 9.28 (bs, 1H), 8.32 (d, J = 9.0 Hz, 2H), 8.10 (d, J = 
8.5 Hz, 2H), 7.01-7.22 (m, 4H), 6.60 (d, J = 9.0 Hz, 1H), 5.71 (m, 1H), 
5.11 (m, 2H), 3.84 (m, 1H), 2.76 (dd, J = 13.5, 4.0 Hz, 1H), 2.43 (m, 1H), 2.20-2.31 (m, 2H), 
NHNs
O
HNF
N
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1.99 (m, 1H), 0.83 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 161.3 (d, J = 242.8 Hz), 
151.6, 150.7, 145.4, 134.0, 131.4 (d, J = 4.5 Hz), 128.4, 128.3 (d, 8.3 Hz), 126.9 (d, J = 15.5 Hz), 
124.7, 124.3, 118.6, 115.5 (d, J = 22.0 Hz), 54.7, 37.7, 35.9, 32.3, 15.6; IR (film, cm-1): 3344, 
3182 (br), 3105, 3074, 2978, 2906, 1666, 1533; HRMS (ESI) m/z calc’d for C20H23N3O5SF 
[M+H]+: 436.1342, found 436.1346; [α]D24.5 = +41.8o (c = 0.7, CHCl3). 
 
Optimization of the C−O and C−N Bond Forming Reactions 
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Entry 1: In a glove box, the following solids were all first weighed onto wax paper then 
sequentially added to a ½ dram borosilicate vial topped with a Teflon-lined cap and containing a 
Teflon stir bar: (±)-N-((2-methylhex-5-en-3-yl)carbamoyl)-4-nitrobenzenesulfonamide 3 (102.4 
mg, 0.3 mmol), methyl-p-benzoquinone (54.9 mg, 0.45 mmol), 1,2-bis(phenylsulfinyl)ethane 
(4.2 mg, 0.015 mmol) and White Catalyst 1 (15.1 mg, 0.03 mmol). Dry THF (300 mL, 1.0M) 
was quickly added outside of the glove box; the vial was capped, placed in a 45°C aluminum 
block and stirred for 24 hours. An aliquot of the crude reaction mixture was analyzed by 1H 
NMR to obtain the crude C−O:C−N selectivity. After analysis, this sample was added back to the 
total crude reaction mixture, which was concentrated in vacuo. Purification by flash 
chromatography (30% EtOAc/hexanes) provided anti-(±)-N-((4R,5R)-4-isopropyl-5-vinyl-4,5-
dihydrooxazol-2-yl)-4-nitrobenzenesulfonamide and anti-(±)-(4R,5R)-4-isopropyl-1-((4-
nitrophenyl)sulfonyl)-5-vinylimidazolidin-2-one. Run 1 (46.8 mg, 0.138 mmol, 46% yield [1:1.6 
C−O:C−N; 1.3:1 dr anti:syn]); Run 2 (47.8 mg, 0.141 mmol, 47% yield [1:1.5 C−O:C−N; 1.3:1 
dr anti:syn]). Average: 47% yield, 1:1.6 C−O:C−N (4:5), 1.3:1 dr anti:syn. 
 
Entry 2: The reaction was set up following the procedure described for Entry 1.  Additionally, 
DIPEA (4.2 mL, 0.024 mmol, 0.08 equiv.) was added outside of the glove box at the same time 
as the solvent addition. The reaction was placed in a 45°C aluminum block and stirred for 18 
hours upon which complete conversion was observed. Run 1 (39.7 mg, 0.117 mmol, 39% yield 
[1:>20 C−O:C−N; >20:1 dr]); Run 2 (37.7 mg, 0.111 mmol, 37% yield [1:>20 C−O:C−N; >20:1 
dr]). Average: 38% yield, 1:>20 C−O:C−N, 4.4:1 dr anti:syn. 
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Entry 3: The reaction was set up following the procedure described for Entry 1. Additionally, 
B(C6F5)3 (12.7 mg [97% via Strem], 0.024 mmol, 0.08 equiv.) was also added to the ½ dram vial 
inside of the glove box. The reaction was placed in a 45°C aluminum block and stirred for 2 
hours upon which complete conversion was observed. Run 1 (57.0 mg, 0.169 mmol, 56% yield 
[4.9:1 C−O:C−N, 4.4:1 dr]); Run 2 (58.0 mg, 0.171 mmol, 57% yield [4.9:1 C−O:C−N, 4:4:1 
dr]). Average: 57% yield, 4.9:1 C−O:C−N, >20:1 dr anti:syn. 
 
Entry 4: The reaction was set up following the procedure described for Entry 3 replacing 
B(C6F5)3 with freshly recrystallized AgOTf (6.2 mg, 0.024 mmol, 0.08 equiv.). THF was also 
replaced with DCM as the solvent for the reaction and additionally, 1 equivalent of dry DMA 
was added prior to addition of the solvent. The reaction was placed in a 45°C aluminum block 
and stirred for 6 hours upon which complete conversion was observed. Run 1 (76.3 mg, 0.225 
mmol, 84% yield [7:1 C−O:C−N, 1:1 dr]); Run 2 (78.4 mg, 0.231 mmol, 85% yield [7:1 
C−O:C−N, 1:1 dr]). Average: 85% yield, 7:1 C−O:C−N, 1:1 dr anti:syn. 
 
Entry 5: The reaction was set up following the procedure described for Entry 1. Additionally, 
Cr(salen)Cl (15.3 mg, 0.024 mmol, 0.08 equiv.) was also added to the ½ dram vial inside of the 
glove box. The reaction was placed in a 45°C aluminum block and stirred for 2 hours upon 
which maximum product formation was observed. Run 1 (15.3 mg, 0.045 mmol, 15% yield [1:1 
C−O:C−N, >20:1 dr]); Run 2 (17.7 mg, 0.052 mmol, 17% yield [1:1 C−O:C−N, >20:1 dr]). 
Average: 16% yield, 1:1 C−O:C−N, >20:1 dr anti:syn. 
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Entry 6: The reaction was set up following the procedure described for Entry 4 using (±)4-
methyl-N-((2-methylhex-5-en-3-yl)carbamoyl)benzenesulfonamide as the starting material (31.0 
mg, 0.1 mmol, 1 equiv.). Run 1 (17.3 mg, 0.056 mmol, 56% yield (>20:1 C−O:C−N); Run 2 
(17.1 mg, 0.055 mmol, 55% yield (>20:1 C−O:C−N). Average: 56% yield, >20:1 C−O:C−N. 
 
Entry 7: The reaction was set up following the procedure described for Entry 4 replacing AgOTf 
with TfOH (0.008 mmol, 0.08 equiv.). Run 1 (21.7 mg, 0.064 mmol, 64% yield [2.2:1 C−O:C−N, 
2.8:1 dr]); Run 2 (21.4 mg, 0.063 mmol, 63% yield [2.2:1 C−O:C−N, 2.2:1 dr]). Average: 64% 
yield, 2.2:1 C−O:C−N, 2.5:1 dr anti:syn. 
 
Entry 8: The reaction was set up following the procedure described for Entry 7 omitting the 
addition of the Pd catalyst 1. No conversion of the starting material and no product formation 
were observed by 1H NMR analysis of the crude reaction mixture. 
 
Entry 9: The reaction was set up following the procedure described for Entry 4 omitting the 
addition of the Pd catalyst 1. The reaction was placed in a 45°C aluminum block and stirred for 6 
hours. No conversion of the starting material and no product formation were observed by 1H 
NMR analysis of the crude reaction mixture. 
 
Entry 10: In a glove box, the following solids were all first weighed onto wax paper then 
sequentially added to a ½ dram borosilicate vial topped with a Teflon-lined cap and containing a 
Teflon stir bar: (±)-N-((2-methylhex-5-en-3-yl)carbamoyl)-4-nitrobenzenesulfonamide 3 (102.4 
mg, 0.3 mmol), methyl-p-benzoquinone (54.9 mg, 0.45 mmol), Pd(OAc)2 catalyst 2 (6.7 mg, 
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0.03 mmol) and freshly recrystallized AgOTf (6.2 mg, 0.024 mmol). THF (300 mL, 1.0M) was 
quickly added outside of the glove box, the vial was capped and placed in a 45°C aluminum 
block and stirred for 72 hours. An aliquot of the crude reaction mixture was analyzed by 1H 
NMR to obtain the crude diastereoselectivity. After analysis, this sample was added back to the 
total crude reaction mixture, which was concentrated in vacuo. Purification by flash 
chromatography (30% EtOAc/hexanes) provided anti-(±)-(4R,5R)-4-isopropyl-1-((4-
nitrophenyl)sulfonyl)-5-vinylimidazolidin-2-one. Run 1 (46.9 mg, 0.138 mmol, 46% yield 
[1:>20 C−O:C−N, >20:1 dr anti:syn]); Run 2 (45.9 mg, 0.135 mmol, 45% yield [1:>20 
C−O:C−N, >20:1 dr anti:syn]). Average: 46% yield, 1:>20 C−O:C−N, >20:1 dr anti:syn. 
 
Entry 11: The reaction was set up following the procedure described for Entry 10, replacing 
methyl-p-benzoquinone with p-benzoquinone (34.1 mg, 0.315 mmol, 1.05 equiv.). Run 1 (61.1 
mg, 0.18 mmol, 60% yield [1:>20 C−O:C−N, >20:1 dr anti:syn]); Run 2 (59.2 mg, 0.174 mmol, 
58% yield [1:>20 C−O:C−N, >20:1 dr anti:syn]). Average: 59% yield, 1:>20 C−O:C−N, >20:1 
dr anti:syn. 
 
Entry 12: The reaction was set up following the procedure described for Entry 11. B(C6F5)3 
(15.8 mg, 0.03 mmol, 0.010 equiv.) was added in place of AgOTf to the 1 dram vial inside of the 
glove box. Run 1 (61.9 mg, 0.182 mmol, 61% yield [1:>20 C−O:C−N, >20:1 dr anti:syn]); Run 
2 (62.1 mg, 0.183 mmol, 62% yield [1:>20 C−O:C−N, >20:1 dr anti:syn]). Average: 62% yield, 
1:>20 C−O:C−N, >20:1 dr anti:syn. 
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Entry 13: The reaction was set up following the procedure described for Entry 12 omitting 
B(C6F5)3 from the reaction vial. Run 1 (32.3 mg, 0.095 mmol, 32% yield [1:>20 C−O:C−N, 
>20:1 dr anti:syn]); Run 2 (32 mg, 0.094 mmol, 31% yield [1:>20 C−O:C−N, >20:1 dr anti:syn]). 
Average: 32% yield, 1:>20 C−O:C−N, >20:1 dr anti:syn. 
Entry 14: The reaction was set up following the procedure described for Entry 12 omitting the 
Pd(OAc)2 catalyst. No conversion of starting material and no product formation were observed 
by 1H NMR analysis of the crude reaction mixture. 
 
Scope of the Allylic Oxidation Reaction 
General Procedure for the Allylic Oxidation Reaction: A ½ dram borosilicate vial containing 
a Teflon stir bar was flame dried, sealed with a Teflon lined cap and taken inside a glove box. 
The homoallylic N-nosyl urea starting material (1 equiv.), freshly sublimed methyl-p-
benzoquinone (1.5 equiv.), White Catalyst (0.10 equiv.), 1,2-bis(phenylsulfinyl)ethane (0.05 
equiv.) and AgOTf (0.08 equiv.) were added to the ½ dram vial in the glove box, in the order 
specified. The vial was securely sealed with the Teflon lined cap and taken out of the glove box. 
Dichloromethane (1.0M) was quickly added to the ½ dram vial outside of the glove box, under a 
flow of Argon gas. The vial was then sealed, vortexed and placed in an aluminum block to stir at 
45 °C for exactly 6 hours. If the reaction is allowed to run longer than 6 hours an erosion of the 
C−O:C−N selectivity is observed. The solution was allowed to cool to room temperature and 
then transferred using dichloromethane to a 250 mL separatory funnel.  The solution was diluted 
with 15 mL of dichloromethane and rinsed 1x 15 mL aqueous NH4Cl (sat.). The organic layer 
was collected and dried over MgSO4, filtered and concentrated in vacuo. The crude reaction 
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mixture was purified using flash column chromatography (in general, gradient 25-30% 
EtOAc/hexanes was used).  
General Procedure for the Recrystallization of Silver Triflate:  In a glove box, silver triflate 
(0.5 – 0.8 g) was added to a flame dried, 25 mL pear shaped flask.  The flask was sealed with a 
septum and removed from the glove box.  In darkness, the flask was placed under a nitrogen 
atmosphere followed by the addition of dry benzene (10.0 - 12.0 mL).  Using a heating mantle, 
the slurry was gently heated until all of the silver triflate had completely dissolved (refluxing 
solvent is not necessary; however condensation of solvent may be seen on the upper portion of 
the flask).  Upon dissolution, the entire solution was taken up into a 25 mL syringe and 
immediately passed through a 0.2 μm PVDF ACRODisc into a second flame dried, 25 mL pear 
shaped flask under nitrogen atmosphere (slow transfer can result in precipitates forming within 
the syringe requiring the entire process to be restarted).  The transfer should be done by quickly 
removing the needle from the syringe, attaching the ACRODisc and a 16G needle, and then 
immediately dispelling the liquid into the second, septum sealed flask. The clear solution is then 
allowed to cool to room temperature at which point the silver triflate will begin to precipitate.  If 
precipitation does not occur, the solution can either be briefly cooled using an ice bath, or a 
gentle stream of nitrogen can be passed over the solution until precipitation begins.  Upon 
qualitative completion of precipitation, the benzene was removed via canulation into a separate 
receiving flask.  The silver triflate is then re-dissolved in a minimum amount of benzene (~5.0 – 
8.0 mL) under mild heat.  Upon complete solvation the flask was allowed to cool to room 
temperature.  Upon qualitative completion of precipitation, the benzene was again removed via 
canulation into a separate receiving flask.  This step was repeated once more yielding pure, white 
needles of silver triflate (ACRODisc filtration is only necessary on the first step).  Upon 
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completion of the third recrystallization and canulation the flask was placed under vacuum to 
remove any remaining benzene.  The flask was then covered in aluminum foil and placed in a 
glove box for use in the anti-allylic oxidation reaction.  Preparation of the silver triflate must be 
done immediately prior to the oxidation reaction.  All unused silver triflate (including what is 
lost in the benzene canulations) can be reconstituted and recrystallized again for future reactions. 
NOTE - Structures 7, 8, 12, 16 and 17 were confirmed by NOE experiments. 
 (±)-N-((4R,5R)-4-isopropyl-5-vinyl-4,5-dihydrooxazol-2-yl)-4-nitrobenzenesulfonamide:  
Racemic (±)-N-((2-methylhex-5-en-3-yl)carbamoyl)-4-nitrobenzenesulfonamide 
(102.4 mg, 0.30 mmol) was reacted according to the general procedure.  
Purification by flash chromatography (gradient 25-40% EtOAc/hexanes) provided 
the anti-2-aminooxazoline as a white solid.  Run 1 (75.3 mg, 0.222 mmol, 74% yield [8:1 
C−O:C−N]); run 2 (78.4 mg, 0.231 mmol, 77% yield [8:1 C−O:C−N]). Average: 76% yield, 8:1 
C−O:C−N. 1H NMR (500MHz, CDCl3) δ 8.32 (d, J = 9.0 Hz, 2H), 8.11 (d, J = 8.5 Hz, 2H), 7.66 
(bs, 1H), 5.86 (ddd, J = 17.3, 10.5, 6.8 Hz, 1H), 5.45 (d, J = 17.0 Hz, 1H), 5.39 (d, J = 10.5 Hz, 
1H), 4.83 (t, J = 6.3 Hz, 1H), 3.58 (t, J = 6.0 Hz, 1H), 1.89 (sext., J = 6.7, 1H), 0.99 (d, J = 6.5 
Hz, 3H), 0.96 (d, J = 6.5 Hz, 3H);  13C NMR (125 MHz, CDCl3) δ 161.1, 149.9, 148.0, 133.3, 
127.8, 124.2, 120.6, 82.8, 66.1, 32.0, 18.0, 17.8; IR (film, cm-1): 3217 (br), 3114, 2966, 2935, 
2875, 1631, 1531; HRMS (ESI) m/z calc’d for C14H18N3O5S [M+H]+: 340.0967, found 340.0966.  
 
 (±)-N-((4R,5R)-4-(tert-butyl)-5-vinyl-4,5-dihydrooxazol-2-yl)-4-nitrobenzenesulfonamide:  
Racemic (±)-N-((2,2-dimethylhex-5-en-3-yl)carbamoyl)-4-
nitrobenzenesulfonamide (35.5 mg, 0.10 mmol) was reacted according to the 
general procedure.  Purification by flash chromatography (gradient 25-40% 
ON
NHNs
ON
NHNs
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EtOAc/hexanes) provided the anti-2-aminooxazoline as a white solid. Run 1 (27.4 mg, 0.078 
mmol, 78% [>20:1 C−O:C−N]); run 2 (84.8 mg, 0.240 mmol, 80% [20:1 C−O:C−N]).  Average 
Yield: 79%, >20:1 C−O:C−N. 1H NMR (500MHz, CDCl3) δ 8.33 (d, J = 8.5 Hz, 2H), 8.11 (d, J 
= 8.5 Hz, 2H), 7.65 (bs, 1H), 5.85 (ddd, J = 17.5, 10.3, 6.5 Hz, 1H), 5.44 (d, J = 17.5 Hz, 1H), 
5.37 (d, J = 10.5 Hz,1H), 4.89 (t, J = 5.5 Hz, 1H), 3.50  
(d, J = 5.0 Hz, 1H), 0.94 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 161.2, 149.8, 148.0, 133.7, 
127.8, 124.2, 120.0, 81.0, 69.4, 33.9, 25.0; IR (film, cm-1): 3384, 3307 (br), 3105, 2966, 2873, 
1628, 1529; HRMS (ESI) m/z calc’d for C15H20N3O5S [M+H]+: 354.1124, found 354.1124. 
 
 (±)-N-((4S,5R)-4-isopropyl-4-methyl-5-vinyl-4,5-dihydrooxazol-2-yl)-4-
nitrobenzenesulfonamide:  Racemic (±)-N-((2,3-dimethylhex-5-en-3-
yl)carbamoyl)-4-nitrobenzenesulfonamide (107.0 mg, 0.30 mmol) was reacted 
according to the general procedure with the following modification: 12 μL of 
dimethylacetamide was added in addition to the DCM solvent. The crude 1H NMR shows the 
presence of a minor product that is presumed to be the syn-2-aminooxazoline based on the 
characteristic peaks described at the beginning of this document. Purification by flash 
chromatography (gradient 25-40% EtOAc/hexanes) provided the anti-2-aminooxazoline as a 
white solid. Run 1 (92.6 mg, 0.252 mmol, 84% [>20:1 C−O:C−N], [5.6:1 dr]); run 2 (87.1 mg, 
0.237 mmol, 79% [>20:1 C−O:C−N], [5.6:1 dr]).  Average Yield: 82%, >20:1 C−O:C−N, 
5.6:1 dr. 1H NMR (500MHz, CDCl3) δ 8.32 (d, J = 8.5 Hz, 2H), 8.10 (d, J = 9.0 Hz, 2H), 7.59 
(bs, 1H), 5.79 (ddd, J = 17.0, 10.5, 6.8 Hz, 1H), 5.45 (m, 2H), 4.84 (d, J = 6.5 Hz, 1H), 1.93 (m, 
1H), 1.21 (s, 3H), 0.99 (d, J = 7.0 Hz, 3H), 0.95 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 160.2, 149.9, 148.1, 130.4, 127.8, 124.2, 121.6, 85.8, 66.7, 37.1, 18.8, 17.2, 17.0; IR 
ON
NHNs
Me
H
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(film, cm-1): 3199 (br), 3116, 2978, 1631, 1527; HRMS (ESI) m/z calc’d for C15H20N3O5S 
[M+H]+: 354.1124, found 354.1132. 
 
 (±)-N-((4S,5R)-4-(tert-butyl)-4-methyl-5-vinyl-4,5-dihydrooxazol-2-yl)-4-
nitrobenzenesulfonamide:                   Racemic (±)-4-nitro-N-((2,2,3-
trimethylhex-5-en-3-yl)carbamoyl)benzenesulfonamide (36.9 mg, 0.10 mmol) was 
reacted according to the general procedure with the following modification: 12 μL 
of dimethylacetamide was added in addition to the DCM solvent. Purification by flash 
chromatography (gradient 25-40% EtOAc/hexanes) provided the anti-2-aminooxazoline as a 
white solid. Run 1 (28.7 mg, 0.078 mmol, 78% [19:1 C−O:C−N]); run 2 (29.4 mg, 0.08 mmol, 
80% [19:1 C−O:C−N]).  Average Yield: 79%, 19:1 C−O:C−N. 1H NMR (500MHz, CDCl3) δ 
8.32 (d, J = 8.5 Hz, 2H), 8.10 (d, J = 9.0 Hz, 2H), 7.49 (bs, 1H), 5.80 (m, 1H), 5.47 (d, J = 17 Hz, 
1H), 5.43 (d, J = 10.5 Hz, 1H), 5.03 (d, J = 6.5 Hz, 1H), 1.26 (s, 3H), 0.98 (s, 9H); 13C NMR 
(125 MHz, CDCl3) δ 160.1, 149.8, 148.0, 130.9, 127.6, 124.0, 120.8, 83.5, 68.7, 37.3, 24.8, 18.4; 
IR (film, cm-1): 3199 (br), 2960, 1626, 1529, 1350; HRMS (ESI) m/z calc’d for C16H22N3O5S 
[M+H]+: 368.1280, found 368.1280. 
 
 (+)-N-((4S,5R)-4-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-vinyl-4,5-dihydrooxazol-2-yl)-
4-nitrobenzenesulfonamide: (-)-N-(((2S,3S)-2-((tert-butyldimethylsilyl)oxy)hex-
5-en-3-yl)carbamoyl)-4-nitrobenzenesulfonamide (45.8 mg, 0.10 mmol) was 
reacted according to the general procedure with the following slight modifications: 
12 μL of dimethylacetamide was added in addition to the DCM solvent and the reaction was run 
at 40°C instead of the original 45°C. Purification by flash chromatography (gradient 25-40% 
ON
NHNs
OTBS
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EtOAc/hexanes) provided the anti-2-aminooxazoline as a light yellow oil. Run 1 (36.4 mg, 0.080 
mmol, 80% [>20:1 C−O:C−N]); run 2 (35.1 mg, 0.077 mmol, 77% [>20:1 C−O:C−N]).  
Average Yield: 79%, >20:1 C−O:C−N. 1H NMR (500MHz, CDCl3) δ 8.31 (d, J = 9.0 Hz, 2H), 
8.10 (d, J = 9.0 Hz, 2H), 7.69 (bs, 1H), 5.87 (ddd, J = 17.0, 10.5, 6.5 Hz, 1H), 5.45 (d, J = 17.0 
Hz, 1H), 5.40 (d, J = 10.5 Hz, 1H), 4.83 (t, J = 6.3 Hz, 1H), 3.84 (p, J = 6.0 Hz, 1H), 3.67 (t, J = 
5.5 Hz, 1H), 1.17 (d, J = 6.0 Hz, 3H), 0.86 (s, 9H), 0.11 (s, 3H), 0.09 (s, 3H); 13C NMR (125 
MHz, CDCl3) δ 161.2, 149.9, 148.0, 132.9, 127.9, 124.1, 120.7, 81.5, 69.2, 66.0, 25.7, 19.5, 17.9, 
-4.1, -4.8; IR (film, cm-1): 3365 (br), 3107, 2954, 2931, 2858, 1630, 1531; HRMS (ESI) m/z 
calc’d for C19H30N3O6SiS [M+H]+: 456.1625, found 456.1624; [α]D26.0 = +55.2o (c = 0.5, CHCl3). 
 
 (-)-N-((4R,5S)-4-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-vinyl-4,5-dihydrooxazol-2-yl)-
4-nitrobenzenesulfonamide: (-)-N-(((2S,3R)-2-((tert-butyldimethylsilyl)oxy)hex-
5-en-3-yl)carbamoyl)-4-nitrobenzenesulfonamide(-)-N-(((2S,3S)-2-((tert-
butyldimethylsilyl)oxy)hex-5-en-3-yl)carbamoyl)-4-nitrobenzenesulfonamide 
(45.8 mg, 0.10 mmol) was reacted according to the general procedure with the following slight 
modifications: 12 μL of dimethylacetamide was added in addition to the DCM solvent and the 
reaction was run at 40°C instead of the original 45°C. Purification by flash chromatography 
(gradient 25-40% EtOAc/hexanes) provided the anti-2-aminooxazoline as a light yellow oil. Run 
1 (28.2 mg, 0.062 mmol, 62% [15:1 C−O:C−N]); run 2 (29.6 mg, 0.065 mmol, 65% [13:1 
C−O:C−N]).  Average Yield: 60%, 14:1 C−O:C−N. 1H NMR (500MHz, CDCl3) δ 8.31 (bs, 
1H), 8.30 (d, J = 9.0 Hz, 2H), 8.09 (d, J = 9.0 Hz, 2H), 5.84 (ddd, J = 17.0, 10.8, 6.5 Hz, 1H), 
5.43 (d, J = 17.5 Hz, 1H), 5.35 (d, J = 10.5 Hz, 1H), 5.18 (t, J = 6.0 Hz, 1H), 4.03 (m, 1H), 3.69 
(m, 1H), 1.11 (d, J = 6.5 Hz, 3H), 0.77 (s, 9H), 0.07 (s, 3H), 0.01 (s, 3H); 13C NMR (125 MHz, 
ON
NHNs
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CDCl3) δ 161.1, 149.8, 148.0, 133.7, 128.2, 124.0, 119.8, 81.2, 67.6, 65.5, 25.7, 19.7, 17.8, -4.3, 
-4.7; IR (film, cm-1): 3307 (br), 3265, 3168, 3107, 2954, 2931, 2887, 2858, 1637, 1531; HRMS 
(ESI) m/z calc’d for C19H30N3O6SiS [M+H]+: 456.1625, found 456.1624; [α]D25.6 = -12.4o (c = 0.4, 
CHCl3). 
 
 (-)-N-((4S,5R)-4-((S)-1,2-bis(benzyloxy)ethyl)-5-vinyl-4,5-dihydrooxazol-2-yl)-4-
nitrobenzenesulfonamide: (-)-N-(((2S,3S)-1,2-bis(benzyloxy)hex-5-en-3-
yl)carbamoyl)-4-nitrobenzenesulfonamide (53.9 mg, 0.1 mmol) was reacted 
according to the general procedure with the following slight modifications: 12 
μL of dimethylacetamide was added in addition to the DCM solvent and the reaction was run at 
40°C instead of the original 45°C. Purification by flash chromatography (gradient 25-40% 
EtOAc/hexanes) provided the anti-2-aminooxazoline as a light yellow oil. Run 1 (37.8 mg, 0.070 
mmol, 70% [17:1 C−O:C−N]); run 2 (35.6 mg, 0.066 mmol, 66% [>20:1 C−O:C−N]).  Average 
Yield: 65%, 19:1 C−O:C−N. 1H NMR (500MHz, CDCl3) δ 8.19 (d, J = 9.0 Hz, 2H), 7.99 (d, J 
= 9.0 Hz, 2H), 7.67 (bs, 1H), 7.20-7.39 (m, 10H), 5.82 (ddd, J = 17.0, 10.5, 6.0 Hz, 1H), 5.35 (d, 
J = 17.0 Hz, 1H), 5.30 (d, J = 10.5 Hz, 1H), 5.11 (t, J = 5.8 Hz, 1H), 4.66 (d, J = 11.5 Hz, 1H), 
4.53 (m, 2H), 4.46 (d, J = 12.0 Hz, 1H), 3.95 (m, 1H), 3.63-3.67 (m, 2H), 3.54-3.58 (m, 1H); 13C 
NMR (125 MHz, CDCl3) δ 161.4, 149.7, 147.9, 137.0, 137.0, 133.1, 128.8, 128.8, 128.4, 128.3, 
128.2, 127.8, 127.6, 124.0, 119.5, 81.5, 74.0, 72.7, 68.3, 62.3; IR (film, cm-1): 3365 (br), 3105, 
3064, 3032, 2927, 2860, 1626, 1529; HRMS (ESI) m/z calc’d for C27H28N3O7S [M+H]+: 
538.1648, found 538.1648; [α]D26.9 = -6.7o (c = 1.4, CHCl3). 
 
ON
NHNs
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 (±)-N-((4R,5R)-4-(4-methoxybenzyl)-4-methyl-5-vinyl-4,5-dihydrooxazol-2-yl)-4-
nitrobenzenesulfonamide: Racemic (±)-N-((1-(4-methoxyphenyl)-2-
methylpent-4-en-2-yl)carbamoyl)-4-nitrobenzenesulfonamide (43.3 mg, 
0.10 mmol) was reacted according to the general procedure with the 
following modification: 12 μL of dimethylacetamide was added in addition to the DCM solvent. 
The crude 1H NMR shows the presence of 4 products that were assigned based on the 
characteristic peaks described at the beginning of this document. The characteristic ddd vinylic 
proton of the oxazolines were at ~5.75 ppm (anti) and ~6.0 ppm (syn); the allylic proton of the 
imidazolidinones was at ~4.55 ppm (anti) and ~4.5 ppm respectively (syn). Purification by flash 
chromatography (gradient 25-40% EtOAc/hexanes) provided the anti-2-aminooxazoline as a 
white solid in approximately 80% purity. Run 1 (25.0 mg, 0.058 mmol, 58% [9.7:1 C−O:C−N], 
[4:1 dr]); run 2 (27.6 mg, 0.064 mmol, 64% [10:1 C−O:C−N], [4:1 dr]).  Average Yield: 61%, 
10:1 C−O:C−N, 4:1 dr. 1H NMR (500MHz, CDCl3) δ 8.32 (d, J = 8.5 Hz, 2H), 8.10 (d, J = 9.0 
Hz, 2H), 7.43 (bs, 1H), 7.10 (d, J = 8.5 Hz, 2H), 6.88 (d, J = 8.5 Hz, 2H), 5.77 (m, 1H), 5.48 (d, 
J = 11.5 Hz, 1H), 5.45 (d, J = 5.0 Hz, 1H), 4.85 (d, J = 7.0 Hz, 1H), 3.81 (s, 3H), 2.87 (dd, J = 
17.0, 14.0 Hz, 2H), 1.23 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 160.1, 159.2, 149.7, 147.8, 
131.2, 129.3, 127.7, 125.9, 123.9, 121.6, 114.3, 86.7, 64.2, 55.3, 45.0, 22.0; IR (film, cm-1): 3365, 
3170 (br), 2954, 1631, 1529, 1349; HRMS (ESI) m/z calc’d for C20H22N3O6S [M+H]+: 432.1229, 
found 432.1230. 
 
 (-)-N-((4S,5S)-4-((S)-1-(2-fluorophenyl)propan-2-yl)-5-vinyl-4,5-dihydrooxazol-2-yl)-4-
nitrobenzenesulfonamide: (+)-N-(((2R,3S)-1-(2-fluorophenyl)-2-
methylhex-5-en-3-yl)carbamoyl)-4-nitrobenzenesulfonamide (43.6 mg, 0.1 
ON
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mmol) was reacted according to the general procedure with the following slight modifications: 
12 μL of dimethylacetamide was added in addition to the DCM solvent and the reaction was run 
at 40°C instead of the original 45°C. Purification by flash chromatography (gradient 25-40% 
EtOAc/hexanes) provided the anti-2-aminooxazoline as a light yellow oil. Run 1 (31.2 mg, 0.072 
mmol, 72% [14:1 C−O:C−N]); run 2 (30.8 mg, 0.071 mmol, 71% [11:1 C−O:C−N]).  Average 
Yield: 67%, 13:1 C−O:C−N. 1H NMR (500MHz, CDCl3) δ 8.32 (d, J = 9.0 Hz, 2H), 8.10 (d, J 
= 9.0 Hz, 2H), 7.73 (bs, 1H), 7.23-7.28 (m, 1H), 7.05-7.14 (m, 3H), 5.85 (ddd, J = 17.0, 10.5, 6.5 
Hz, 1H), 5.47 (d, J = 17.0 Hz, 1H), 5.40 (d, J = 10.5 Hz, 1H), 4.92 (ap t, J = 6.0 Hz, 1H), 3.68 (t, 
J = 6.0 Hz, 1H), 2.75 (dd, J = 14.0, 5.0 Hz, 1H), 2.54 (dd, J = 13.5, 8.5 Hz, 1H), 2.12 (m, 1H), 
0.92 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 161.2 (d, J = 242.8 Hz), 161.1, 149.9, 
147.9, 133.0, 131.6 (d, J = 4.5 Hz), 128.9 (d, J = 8.3 Hz), 127.9, 125.1 (d, J = 15.5 Hz), 124.5, 
124.2, 120.8, 115.8 (d, J = 21.9 Hz), 82.3, 64.4, 37.9, 32.2, 14.8; IR (film, cm-1): 3334 (br), 3105, 
2968, 2933, 1628, 1529; HRMS (ESI) m/z calc’d for C20H21N3O5SF [M+H]+: 434.1186, found 
434.1193; [α]D24.9 = -59.4o (c = 1.1, CHCl3). 
 
 
Diversification of a representative 2-aminooxazoline product: 
 
 (±)-(4R,5S)-4-(tert-butyl)-4-methyl-2-((4-nitrophenyl)sulfonamido)-4,5-dihydrooxazole-5-
carboxylic acid: (±)-N-((4S,5R)-4-(tert-butyl)-4-methyl-5-vinyl-4,5-
dihydrooxazol-2-yl)-4-nitrobenzenesulfonamide (110.1 mg, 0.3 mmol, 1 
ON
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equiv.) was dissolved in 2.7 mL MeCN, 2.7 mL CCl4 and 3.8 mL H2O in a 25 mL round bottom 
flask. NaIO4 (282.3 mg, 1.32 mmol, 4.4 equiv.) was then added in one portion, followed by the 
addition of RuCl3.xH2O (11 mg). After stirring at room temperature for 8h, the reaction mixture 
was diluted with 1M HCl (20 mL) and methylene chloride (15 mL) and extracted with methylene 
chloride (4 x 15 mL). The combined organic layers were dried with MgSO4, filtered and 
concentrated. Purification by flash chromatography (99% EtOAc/1% AcOH) provided the 
carboxylic acid product as a light purple solid (99 mg, 86% yield). 1H NMR (500MHz, CD3CN) 
δ 8.31 (m, 2H), 8.07 (m, 2H), 7.57 (bs, 1H), 5.04 (s, 1H), 1.30 (s, 3H), 0.88 (s, 9H); 13C NMR 
(125 MHz, CD3OD) δ 169.8, 161.2, 151.2, 149.6, 129.4, 124.9, 82.9, 69.4, 39.3, 24.6, 18.0; 
HRMS (ESI) m/z calc’d for C15H20N3O7S [M+H]+: 386.1022, found 386.1021. 
 
(±)-(2R,3S)-3-amino-2-hydroxy-3,4,4-trimethylpentanoic acid: (±)-(4R,5S)-4-(tert-butyl)-4-
methyl-2-((4-nitrophenyl)sulfonamido)-4,5-dihydrooxazole-5-carboxylic acid 
(9 mg, 0.025 mmol)  was added to a 1:1 mixture of conc. H2SO4 and D2O 
(H2O can also be used; D2O was used for crude NMR spectroscopy purposes). The reaction 
mixture was stirred at 130°C for 5h. After cooling to room temperature, the reaction mixture was 
transferred to a separatory funnel using 15 mL H2O and 10 mL Et2O. The organic layer was 
washed with H2O (3x). The combined aqueous layers were concentrated in vacuo at 60°C; H2O 
was added three times to remove residual H2SO4. The solid residue was dissolved in a minimal 
amount of water and passed through a DOWEX column (50W X8-400, 200-400 mesh, H+), first 
eluting with water and then with 1M NH4OH to collect the desired (±)-(2R,3S)-3-amino-2-
hydroxy-3,4,4-trimethylpentanoic acid in 80% yield. 1H NMR (500MHz, D2O) δ 4.19 (s, 1H), 
OHH2N
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1.30 (s, 3H), 1.09 (s, 9H); 13C NMR (125 MHz, D2O) δ 178.3, 73.6, 62.9, 36.2, 25.4, 17.6; 
HRMS (ESI) m/z calc’d for C8H18NO3 [M+H]+: 176.1287, found 176.1295. 
 
Scope of the Allylic Diamination Reaction 
General Procedure for the Anti Selective Allylic Diamination Reaction: A 1 dram 
borosilicate vial containing a Teflon stir bar was flame dried, sealed with a Teflon lined cap and 
taken inside a glove box. The homoallylic N-nosyl urea starting material (0.3 mmol, 1 equiv.), 
benzoquinone (0.315 mmol, 1.05 equiv.), Pd(OAc)2 (0.03 mmol, 0.1 equiv.) and B(C6F5)3 (0.03 
mmol, 0.1 equiv.) were added to the 1 dram vial in the glove box, in the order specified. The vial 
was securely sealed with the Teflon lined cap and taken out of the glove box. Tetrahydrofuran 
(1.66M) was quickly added to the 1 dram vial outside of the glove box, under a flow of argon gas. 
The vial was then sealed and stirred in an aluminum block at 45 °C for 72 hours. The solution 
was allowed to cool to room temperature and the crude reaction mixture was directly purified 
using flash column chromatography (in general, gradient 25-30% EtOAc/hexanes was used).  
(±)-(4R,5R)-  4-isopropyl-1-((4-nitrophenyl)sulfonyl)-5-vinylimidazolidin-2-one: 
Racemic (±)-N-((2-methylhex-5-en-3-yl)carbamoyl)-4-nitrobenzenesulfonamide 
(102.4 mg, 0.30 mmol) was reacted according to the general procedure.  
Purification by flash column chromatography (gradient 25-30% EtOAc/hexanes) 
provided the anti- imidazolidinone as a solid. Run 1 (63.1 mg, 0.186 mmol, 62% yield [>20:1 
dr]); run 2 (61.8 mg, 0.182 mmol, 61% yield [>20:1 dr]). Average: 62% yield, >20:1 dr 
(anti:syn). 1H NMR (500 MHz, CDCl3) δ 8.35 (d, J = 9.0 Hz, 2H), 8.24 (d, J = 9.0 Hz, 2H), 5.76 
(ddd, J = 17.0, 10.0, 8.3 Hz, 1H), 5.43 (d, J = 17.0 Hz, 1H), 5.31 (d, J = 10.0 Hz, 1H), 5.16 (m, 
1H); 4.63 (dd, J  = 8.3, 2.3 Hz, 1H); 3.11 (dd, J = 5.5, 2.3 Hz, 1H); 1.79 (m, 1H); 0.94 (ap t, J = 
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6.8 Hz, 6H);  13C NMR (125 MHz, CDCl3) δ 154.2, 150.6, 145.0, 135.1, 129.9, 124.1, 119.5, 
62.6, 61.8, 32.7, 17.8, 17.2; IR (film, cm-1): 3253 (br), 3109, 2964, 1734, 1531; HRMS (ESI) m/z 
calc'd for C14H18N3O5S [M+H]+ : 340.0967, found 340.0965.      
 
(±)-(4R,5R)-4-ethyl-1-((4-nitrophenyl)sulfonyl)-5-vinylimidazolidin-2-one: Racemic (±)-N-
(hex-5-en-3-ylcarbamoyl)-4-nitrobenzenesulfonamide (Run 1: 49.1 mg, 0.15 
mmol; Run 2: 98.2 mg, 0.3 mmol) was reacted according to the general procedure.  
Purification by flash column chromatography (gradient 25-30% EtOAc/hexanes) 
provided the anti- imidazolidinone as a solid. Run 1 (isolated ~90% pure, ~26 mg, 0.083 mmol, 
55% yield [10:1 dr]); run 2 (52 mg, 0.162 mmol, 54% yield [10:1 dr]). Average: 55% yield, 
10:1 dr (anti:syn). 1H NMR (500 MHz, CDCl3) δ 8.35 (d, J = 9.0 Hz, 2H), 8.24 (d, J = 9.0 Hz, 
2H), 5.77 (m, 1H), 5.44 (d, J = 17.0 Hz, 1H), 5.33 (d, J = 10.0 Hz, 1H), 5.06 (m, 1H); 4.51 (dd, J  
= 8, 2.5 Hz, 1H); 3.26 (m, 1H); 1.70 – 1.55 (m, 2H); 0.96 (ap t, J = 7.5 Hz, 6H); 13C NMR (125 
MHz, CDCl3) δ 154.2, 150.5, 144.7, 134.3, 129.7, 123.9, 119.7, 64.7, 57.6, 28.1, 9.1; IR (film, 
cm-1): 3255 (br), 3108, 2968, 1738, 1531, 1352; HRMS (ESI) m/z calc'd for C13H16N3O5S 
[M+H]+ : 326.0811, found 326.0819. 
 
(±)-(4R,5R)-4-isobutyl-1-((4-nitrophenyl)sulfonyl)-5-vinylimidazolidin-2-one: Racemic (±) 
N-((6-methylhept-1-en-4-yl)carbamoyl)-4-nitrobenzenesulfonamide (106.6 mg, 
0.30 mmol) was reacted according to the general procedure. The reaction was 
stopped at 24h. Purification by flash chromatography (gradient 25-30% 
EtOAc/hexanes) provided the anti- imidazolidinone as a solid. Run 1 (60 mg, 0.171 mmol, 57% 
[7.1:1 dr]); run 2 (68.2 mg, 0.192 mmol, 64% [6.7:1 dr]).  Average Yield: 61%, 7:1 dr 
HN NNs
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(anti:syn). 1H NMR (500 MHz, CDCl3) δ 8.35 (m, 2H), 8.23 (m, 2H), 5.77 (ddd, J = 17.0, 10.0, 
8.5 Hz, 1H), 5.43 (d, J = 17.0 Hz, 1H), 5.33 (d, J = 10.0 Hz, 1H), 5.02 (bs, 1H), 4.45 (dd, J = 8.5, 
2.8 Hz, 1H), 3.38 (m, 1H), 1.64 (m, 1H),1.43-1.52 (m, 2H), 0.94 (d, J = 6.5 Hz, 3H), 0.92 (d, J = 
7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 154.5, 150.6, 144.7, 134.4, 129.8, 124.0, 119.9, 65.6, 
54.7, 44.1, 24.5, 23.0, 21.9; IR (film, cm-1): 3219 (br), 3109, 2956, 2872, 1738, 1529; HRMS 
(ESI) m/z calc'd for C15H20N3O5S [M+H]+ : 354.1124, found 354.1127.  
 
(±)-(4R,5R)-4-(tert-butyl)-1-((4-nitrophenyl)sulfonyl)-5-vinylimidazolidin-2-one: Racemic 
(±)-N-((2,2-dimethylhex-5-en-3-yl)carbamoyl)-4-nitrobenzenesulfonamide (106.6 
mg, 0.30 mmol) was reacted according to the general procedure.  Purification by 
flash chromatography (gradient 25-30% EtOAc/hexanes) provided the anti- 
imidazolidinone as a solid, isolated ~90% pure. Run 1 (67.6 mg, 0.191 mmol, 64% [>20:1 dr]); 
run 2 (66.8 mg, 0.189 mmol, 63% [>20:1 dr]).  Average Yield: 64%, >20:1 dr (anti:syn). 1H 
NMR (500 MHz, CDCl3) δ 8.34 (m, 2H), 8.24 (m, 2H), 5.75 (ddd, J = 17.8, 9.3, 8.5 Hz, 1H), 
5.41 (d, J = 17.0 Hz, 1H), 5.30 (d, J = 10.5 Hz, 1H), 5.26 (bs, 1H), 4.71 (dd, J = 8.0, 2.0 Hz, 1H), 
3.01 (dd, J = 2.3, 1.3 1H), 0.91 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 154.4, 150.6, 145.0, 
135.5, 129.9, 124.0, 119.1, 65.2, 60.7, 34.8, 24.6; IR (film, cm-1): 3369, 3292, 3246, 2964, 2870, 
1762, 1734, 1531; HRMS (ESI) m/z calc'd for C15H20N3O5S [M+H]+ : 354.1124, found 354.1125.  
 
(±)-(4R,5R)-4-isopropyl-4-methyl-1-((4-nitrophenyl)sulfonyl)-5-vinylimidazolidin-2-one: 
Racemic (S)-N-((2,3-dimethylhex-5-en-3-yl)carbamoyl)-4-
nitrobenzenesulfonamide (53.5 mg, 0.15 mmol) was reacted according to the 
general procedure. The crude 1H NMR shows a minor amount of the 
NNsHN
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corresponding anti-2-aminooxazoline product. Purification by flash chromatography (gradient 
25-30% EtOAc/hexanes) provided the anti- imidazolidinone as a solid. Run 1 (40.0 mg, 0.113 
mmol, 75% [>20:1 dr], [10:1 C−O:C−N]); run 2 (40.1 mg, 0.113 mmol, 76% [>20:1 dr], [10:1 
C−O:C−N]).  Average Yield: 76%, >20:1 dr (anti:syn), 10:1 C−O:C−N. 1H NMR (500 MHz, 
CDCl3) δ 8.34 (m, 2H), 8.24 (m, 2H), 5.63 (ddd, J = 17.0, 10.0, 9.0 Hz, 1H), 5.41 (d, J = 17.0 Hz, 
1H), 5.37 (d, J = 10.0 Hz, 1H), 4.87 (bs, 1H), 4.65 (d, J = 9.0 Hz, 1H), 1.88 (m, 1H), 1.04 (s, 3H), 
0.97 (d, J = 7.0 Hz, 3H), 0.96 (d, J = 6.5 Hz, 3H); 13C NMR (125 MHz, CDCl3)  δ 153.3, 150.6, 
145.1, 132.5, 129.9, 124.0, 121.0, 66.6, 61.3, 37.4, 18.6, 17.3, 16.5; IR (film, cm-1): 3217 (br), 
3118, 2968, 1732, 1533; HRMS (ESI) m/z calc'd for C15H20N3O5S [M+H]+ : 354.1124, found 
354.1119.  
 
 (±)-(4R,5R)-4-(tert-butyl)-4-methyl-1-((4-nitrophenyl)sulfonyl)-5-vinylimidazolidin-2-one: 
Racemic (±)-4-nitro-N-((2,2,3-trimethylhex-5-en-3-
yl)carbamoyl)benzenesulfonamide (36.9 mg, 0.1 mmol) was reacted according 
to the general procedure. The crude 1H NMR shows a minor amount of the 
corresponding anti-2-aminooxazoline product. Purification by flash chromatography (gradient 
20-30% EtOAc/hexanes) provided the anti- imidazolidinone as a solid. Run 1 (34.2 mg, 0.093 
mmol, 93% [>20:1 dr], [10:1 C−O:C−N]); run 2 (34.5 mg, 0.094 mmol, 94% [>20:1 dr], [10:1 
C−O:C−N]).  Average Yield: 94%, >20:1 dr (anti:syn), 10:1 C−O:C−N. 1H NMR (500 MHz, 
CDCl3) δ 8.33 (m, 2H), 8.24 (m, 2H), 5.63 (m, 1H), 5.39 (d, J = 16.5 Hz, 1H), 5.37 (d, J = 9.5 
Hz, 1H), 5.18 (bs, 1H), 4.83 (d, J = 8.5 Hz, 1H), 1.11 (s, 3H), 0.98 (s, 9H); 13C NMR (125 MHz, 
CDCl3)  δ 153.1, 150.4, 145.2, 133.1, 129.7, 123.9, 120.5, 64.4, 62.8, 38.9, 24.3, 19.4; IR (film, 
NNsHN
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cm-1): 3296 (br), 3089, 2973, 1731, 1531, 1350; HRMS (CI+) m/z calc'd for C16H22N3O5S 
[M+H]+ : 368.12801, found 368.1272.  
 
(-)-(4S,5R)-4-((S)-1,2-bis(benzyloxy)ethyl)-1-((4-nitrophenyl)sulfonyl)-5-vinylimidazolidin-
2-one: Optically pure (-)-N-(((2S,3S)-1,2-bis(benzyloxy)hex-5-en-3-
yl)carbamoyl)-4-nitrobenzenesulfonamide (53.9 mg, 0.1 mmol) was reacted 
according to the general procedure.  Purification by flash chromatography 
(gradient 25-30% EtOAc/hexanes) provided the anti- imidazolidinone as a solid. Run 1 (28.0 mg, 
0.052 mmol, 52% [>20:1 dr]); run 2 (26.9 mg, 0.050 mmol, 50% [>20:1 dr]).  Average Yield: 
51%, >20:1 dr (anti:syn). 1H NMR (500 MHz, CDCl3) δ 8.19 (m, 2H), 8.11 (m, 2H), 7.22-7.38 
(m, 10H), 5.80 (ddd, J = 17.0, 10.0, 7.3 Hz, 1H), 5.39 (d, J = 17.5 Hz, 1H), 5.29 (d, J = 10.5 Hz, 
1H), 4.97 (bs, 1H), 4.88 (dd, J = 7.5, 1.5 Hz, 1H), 4.61 (d, J = 12.0 Hz, 1H), 4.51 (ap. q, J = 11.8 
Hz, 2H), 4.42 (d, J = 12.0 Hz, 1H), 3.62-3.56 (m, 2H), 3.54 (ddd, J = 6.0, 2.0, 1.5 Hz, 1H), 3.44 
(m, 1H); 13C NMR (125 MHz, CDCl3)  δ 154.1, 150.5, 144.8, 137.3, 137.2, 135.0, 129.8, 128.8, 
128.8, 128.4, 128.3, 128.0, 128.0, 123.9, 119.1, 77.7, 73.8, 72.4, 67.3, 61.1, 57.4; IR (film, cm-1): 
3280 (br), 3111, 2868, 1736, 1531; HRMS (ESI) m/z calc'd for C27H28N3O7S [M+H]+ : 538.1648, 
found 538.1650. [α]D26.8 = -40.3o (c = 0.17, CHCl3). 
 
(-)-(4R,5S)-4-((S)-1,2-bis(benzyloxy)ethyl)-1-((4-nitrophenyl)sulfonyl)-5-vinylimidazolidin-
2-one: Optically pure (-)-N-(((2S,3R)-1,2-bis(benzyloxy)hex-5-en-3-
yl)carbamoyl)-4-nitrobenzenesulfonamide (53.9 mg, 0.1 mmol) was reacted 
according to the general procedure.  Purification by flash chromatography 
(gradient 25-30% EtOAc/hexanes) provided the anti- imidazolidinone as a solid. Run 1 (22.0 mg, 
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0.041 mmol, 41% [>20:1 dr]); run 2 (23.1 mg, 0.043 mmol, 43% [>20:1 dr]).  Average Yield: 
42%, >20:1 dr (anti:syn). 1H NMR (500 MHz, CDCl3) δ 8.17 (m, 2H), 8.13 (m, 2H), 7.37-7.23 
(m, 10H), 5.81 (ddd, J = 17.0, 10.0, 8.0 Hz, 1H), 5.32 (bs, 1H), 5.27 (d, J = 10.0 Hz, 1H), 5.26 (d, 
J = 16.5 Hz, 1H), 4.65 (d, J = 12.0 Hz, 1H), 4.63-4.61 (m, 1H), 4.50 (s, 2H), 4.42 (d, J = 11.5 Hz, 
1H), 3.66 (dd, J = 10.5, 4.5 Hz, 1H), 3.55 (dd, J = 10.5, 3.5 Hz, 1H), 3.50 (dd, J = 3.8, 3.5 Hz, 
1H), 3.44 (dd, J = 7.5, 4.3 Hz, 1H); 13C NMR (125 MHz, CDCl3)  δ 154.3, 150.5, 144.7, 137.2, 
137.1, 135.0, 129.6, 128.8, 128.8, 128.4, 128.3, 128.1, 128.0, 124.0, 119.5, 76.6, 73.8, 72.0, 68.2, 
62.2, 58.3; IR (film, cm-1): 3316 (br), 2922, 2854, 1738, 1531; HRMS (ESI) m/z calc'd for 
C27H28N3O7S [M+H]+ : 538.1648, found 538.1644. [α]D24 = -3.1o (c = 0.05, CHCl3). 
 
(±)-(4R,5R)-4-(4-methoxybenzyl)-1-((4-nitrophenyl)sulfonyl)-5-vinylimidazolidin-2-one: 
Racemic (±)-N-((1-(4-methoxyphenyl)pent-4-en-2-yl)carbamoyl)-4-
nitrobenzenesulfonamide (41.9 mg, 0.10 mmol) was reacted according 
to the general procedure.  Purification by flash chromatography 
(gradient 25-30% EtOAc/hexanes) provided the anti- imidazolidinone as a solid. Run 1 (20.9 mg, 
0.050 mmol, 50% [12:1 dr]); run 2 (20.0 mg, 0.048 mmol, 48% [12:1 dr]).  Average Yield: 49%, 
12:1 dr (anti:syn). 1H NMR (500 MHz, CDCl3) δ 8.33 (d,  J = 9.0 Hz, 2H), 8.16 (d, J = 9.5 Hz, 
2H), 7.06 (d, J = 9.0 Hz, 2H), 6.84 (d, J = 8.5 Hz, 2H), 5.77 (ddd, J = 17.0, 10.0, 8.5 Hz, 1H), 
5.38 (d, J = 17.0 Hz, 1H), 5.31 (d, J = 10.0 Hz, 1H), 5.07 (bs, 1H), 4.56 (dd, J = 8.5, 2.5 Hz, 1H), 
3.79 (s, 3H), 3.51 (m, 1H), 2.87 (dd, J = 14.0, 5.3 Hz, 1H), 2.72 (dd, J = 13.8, 8.5 Hz, 1H); 13C 
NMR (125 MHz, CDCl3)  δ 159.1, 153.7, 150.7, 144.7, 134.4, 130.4, 129.9, 127.1, 124.1, 119.9, 
114.6, 64.4, 57.6, 55.4, 40.2; IR (film, cm-1): 3339 (br), 2929, 1738, 1531; HRMS (ESI) m/z 
calc'd for C19H20N3O6S [M+H]+ : 418.1073, found 418.1072. 
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 Diversification of a representative imidazolidinone product: 
 
 
 
 
 
 
 
(±)-(4R,5S)-5-isobutyl-3-((4-nitrophenyl)sulfonyl)-2-oxoimidazolidine-4-carboxylic acid: 
(±)-(4S,5S)-4-(tert-butyl)-4-methyl-1-((4-nitrophenyl)sulfonyl)-5-
vinylimidazolidin-2-one (22 mg, 0.062 mmol, 1 equiv.) was dissolved in 695 
mL MeCN, 695 mL CCl4 and 1.06 mL H2O in a 1 dram vial. RuCl3.xH2O (7.5 
mg) was then added and the vial was cooled to 0°C in an ice bath. H5IO6 (84.8mg, 0.372 mmol, 6 
equiv.) was added in one portion and the reaction mixture was stirred at room temperature until 
completed by TLC. The reaction mixture was diluted with 1M KHSO4 (3 mL) and extracted with 
ethyl acetate (4x5 mL). The combined organic layers were dried with Na2SO4, filtered and 
concentrated. Purification by flash chromatography (gradient 30% EtOAc/69% Hexanes/1% 
AcOH – 80% EtOAc/19% Hexanes/1% AcOH) provided the corresponding carboxylic acid as 
very pale yellow solid (17.9 mg, 0.0484 mmol, 78% yield). 1H NMR (500 MHz, CDCl3) δ 8.36 
(m, 2H), 8.24 (m, 2H), 6.08 (bs, 1H), 4.54 (d, J = 3.5 Hz, 1H), 3.72 (m, 1H), 1.68 (m, 1H), 1.50 
– 1.39 (m, 2H), 0.89 (at, J = 7.0 Hz, 6H); 13C NMR (125 MHz, CDCl3) δ 170.9, 154.0, 151.9, 
145.0, 130.8, 125.0, 62.9, 52.9, 46.1, 24.8, 22.8, 22.1; IR (film, cm-1): 3342, 3113, 2960, 2873, 
1741, 1533, 1351, 1174; HRMS (ESI) m/z calc’d for C14H18N3O7 [M+H]+: 372.0865, found 
372.0862. 
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(±)-(4R,5S)-5-isobutyl-2-oxoimidazolidine-4-carboxylic acid:  
(±)-(4R,5S)-5-isobutyl-3-((4-nitrophenyl)sulfonyl)-2-oxoimidazolidine-4-
carboxylic acid (17.9 mg, 0.0484 mmol, 1 equiv.) was then dissolved in DMF 
(160 mL) in a flame dried 1 dram vial. K2CO3 (16.7 mg, 0.121 mmol, 2.5 
equiv.) was added and the reaction vial was cooled to 0°C in an ice bath. PhSH (8.9 mL, 0.087 
mmol, 1.8 equiv.) was then added dropwise. The reaction mixture was stirred at 0°C for 15 
minutes and then at 45°C for 24h, after which water (2mL) and ethyl acetate (2mL) were added. 
The water layer was concentrated in vacuo and passed through a DEAE – Cellulose column 
(Anion Exchanger, Fast Flow, Fibrous Form) using 10 mL H2O (the column is equilibrated with 
~15-20 mL H2O before product purification). The free urea is obtained as an off white solid (8.4 
mg, 99% yield). 1H NMR in D2O shows the presence of an unknown peak at 1.8 ppm that could 
not be removed by additional work ups or additional DEAE columns. The residue was taken 
forward as was after the first DEAE colum. 
 
(±)-(2R,3S)-2,3-diamino-5-methylhexanoic acid: (±)-(4R,5S)-5-isobutyl-2-oxoimidazolidine-4-
carboxylic acid (8.4 mg, 0.045 mmol) was dissolved in 150mL of 
concentrated HCl and the reaction mixture was stirred at 100°C for 3h. After 
cooling down to room temperature, the reaction mixture was concentrated in vacuo and then 
passed through a DOWEX column (50W X8-400, 200-400 mesh, H+), first eluting with water 
and then with 3M NH4OH to collect the desired diamine (6.4 mg, 90% yield). 1H NMR (500MHz, 
D2O) δ 3.38 (m, 1H), 3.30 (m, 1H), 1.59 (m, 1H), 1.33 – 1.30 (m, 2H); 0.83 (d, J = 6.0 Hz, 3H); 
0.80 (d, J = 6.5 Hz, 3H); 13C NMR (125 MHz, CD3CN) δ 175.2, 56.3, 50.6, 38.0, 23.9, 22.5, 
20.7; HRMS (ESI) m/z calc’d for C7H17N2O2 [M+H]+: 161.1290, found 161.1293.  
NH2H2N
Me COOH
tBu H
NHHN
Me COOH
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Determination of Stereochemical Stability 
 
 
 
 
 
 
(+)-(S)-benzyl(2-methylhex-5-en-3-yl)carbamate: The allylic amine hydrochloride salt was 
synthesized according to the procedure described by Ellman and coworkers.4 
The amine salt (1 equiv.) was dissolved in THF (0.2M) and the reaction flask 
was cooled to 0 °C. DIPEA (4 equiv.) was added via syringe and the reaction mixture was stirred 
at 0 °C for 2-3 minutes. Benzyl chloroformate (1.05 equiv.) was then added dropwise via syringe, 
followed by the immediate formation of a white precipitate. The reaction mixture was stirred at 
0 °C until complete by TLC. A saturated solution of ammonium chloride was added to quench 
the reaction and the aqueous layer was extracted with ethyl ether (3x). The organic layers were 
dried with MgSO4, filtered through a pad of Celite and concentrated in vacuo. The crude reaction 
mixture was purified via column chromatography using 15% EtOAc/Hexanes. The product was 
obtained as a white solid in quantitative yield. 1H NMR (500 MHz, CDCl3) δ 7.30 – 7.38 (m, 5H), 
5.77 (m, 1H), 5.04 - 5.14 (m, 4H), 4.55 and 4.33 (rotomer, m, 0.85H:0.15H), 3.50-3.62 (rotomer, 
m, 1H, peaks overlap), 2.28 (m, 1H), 2.13 (m, 1H), 1.77 (m, 1H), 0.93 (d, J = 7.0 Hz, 3H), 0.89 
(d, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 156.4, 136.8, 134.9, 128.5, 128.0 (br), 117.4, 
66.5, 55.8, 36.9, 31.5, 19.3, 17.8; IR (film, cm-1): 3329, 3068, 3033, 2962, 2873, 1695, 1535; 
HRMS (ESI) m/z calc'd for C15H22NO2 [M+H]+: 248.1651, found 248.1646. [a]D23.9 = +31.5o (c = 
0.25, CHCl3).  
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Racemic standard (±)-benzyl(2-methylhex-5-en-3-yl)carbamate was synthesized 
according to this procedure.  Chrial HPLC (Chiral Technologies Inc. Chiralcel OJ-H column 
(0.46 cm x 25 cm)) was used to determine the enantio-purity of (+)-(S)-benzyl(2-methylhex-5-
en-3-yl)carbamate which was determined to be >99% ee.  
 
 (+)-N-((4R,5R)-4-isopropyl-5-vinyl-4,5-dihydrooxazol-2-yl)-4-nitrobenzenesulfonamide: 
Enantiopure (*)-N-((2-methylhex-5-en-3-yl)carbamoyl)-4-
nitrobenzenesulfonamide was synthesized from the same enantiopure chiral amine 
used in the formation of the above (+)-(S)-benzyl(2-methylhex-5-en-3-
yl)carbamate. (*)-N-((2-methylhex-5-en-3-yl)carbamoyl)-4-nitrobenzenesulfonamide was then 
subjected to the standard 2-aminooxazoline reaction conditions to yield (+)-N-((4R,5R)-4-
isopropyl-5-vinyl-4,5-dihydrooxazol-2-yl)-4-nitrobenzenesulfonamide: [a]D25.7 = +25.8o (c = 0.46, 
CHCl3).  Chiral HPLC (Chiral Technologies Inc. Chiralcel OJ-H column (0.46 cm x 25 cm)) was 
used to determine the enantio-purity to be >99% ee.  This result indicates that the anti- allylic 
C—H oxidation proceeds with no erosion of ee.   
 
(+)-(4R,5R)-4-isopropyl-1-((4-nitrophenyl)sulfonyl)-5-vinylimidazolidin-2-one: (*)-N-((2-
methylhex-5-en-3-yl)carbamoyl)-4-nitrobenzenesulfonamide was subjected to the 
standard anti-imidazolidinone reaction conditions to yield (+)-(4R,5R)-4-
isopropyl-1-((4-nitrophenyl)sulfonyl)-5-vinylimidazolidin-2-one: [α]D27.0 = +66.3o 
(c = 1.0, CHCl3). Chiral HPLC (Chiral Technologies Inc. Chiralcel OJ-H column (0.46 cm x 25 
cm)) was used to determine the enantio-purity to be >99% ee.  This result indicates that the anti- 
allylic amination reaction proceeds with no erosion of ee. 
ON
NHNs
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Stoichiometric Mechanistic Studies 
 
 
 
 
 
 
 
 
Stoichiometric Study with Pd(TFA)2/bis-sulfoxide: 
Part 1: Formation and observation of π-allyl palladium complex (24): A 1 dram vial  (topped 
with a Teflon lined cap) was flame dried and charged with Pd(TFA)2 (66.5 mg, 0.2 mmol, 1 
equiv.), 1,2-bis(phenylsulfinyl)ethane (55.7 mg, 0.2 mmol, 1 equiv.), d8-THF (0.45 mL) and a 
stirbar. The catalyst mixture was allowed to heat at 45 °C for 30 minutes then was allowed to 
cool to room temperature. The solvent was removed by blowing a stream of N2 over the mixture. 
A flame dried ½ dram vial was taken into the glove box and charged with (±)-4-methyl-N-((2-
methylhex-5-len-3-yl)carbamoyl)benzenesulfonamide 23 (62.1 mg, 0.2 mmol, 1 equiv.); the vial 
was taken out of the glove box and nitrobenzene (8.2 mL, 0.08 mmol, 0.4 equiv.) was added. A 
total of 0.3 mL d8-THF (0.15 mL + 0.075 mL + 0.075 mL) was used to transfer the 
substrate/nitrobenzene mixture to the Pd(TFA)2/bis-sulfoxide via glass syringe. The reaction 
mixture was heated to 45 °C for 2 hours then was allowed to cool to room temperature. A 0.075 
mL aliquot was removed and analyzed by 1H NMR. Broad peaks consistent with the formation 
of π-allyl palladium complex 24 were observed; remaining starting material as well as formation 
of (±)-(4R,5S)-4-isopropyl-1-tosyl-5-vinylimidazolidin-2-one 26 were also observed. Due to 
broadness of the π-allyl palladium complex peaks and extensive overlap, accurate yields and 
ratios could not be determined. The mechanistic experiment is continued in Part 2 using the 
crude reaction mixture from Part 1. 
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Part 2: Addition of AgOTf and MeBQ to p-allyl palladium complex and observation of 
preferential allylic C−O bond formation: MeBQ (24.4 mg, 0.2 mmol, 1 equiv.) and freshly 
recrystallized AgOTf (51.4 mg, 0.2 mmol, 1 equiv.) were weighed into a flame dried 1 dram vial 
inside a glove box. The contents of the vial were transferred to the π-allyl palladium complex 24 
mixture from part 1 outside of the glove box, under an Ar shower. The mixture was allowed to 
stir at 45 °C for 3 hours then was allowed to cool to room temperature. A 0.05 mL aliquot was 
removed for 1H NMR analysis; the broad peaks consistent with the π-allyl palladium complex 24 
disappeared. The reaction mixture was then transferred to a separatory funnel using methylene 
chloride and a saturated solution of NH4Cl. The mixture was extracted 3x with methylene 
chloride. The organic layers were combined, dried with MgSO4, filtered through a pad of Celite 
and concentrated in vacuo. The crude reaction mixture was purified using flash column 
chromatography (in general, gradient 25-30% EtOAc/hexanes was used). Run 1 (45% yield 2-
aminooxazoline 25, 14% 26, 20% rsm); run 2 (38% yield 2-aminooxazoline 25, 10% 26, 22% 
rsm). Average yield: 42% 2-aminooxazoline 25, 12% 26, 21% rsm. 
 
(±)-(4R,5R)-4-isopropyl-1-tosyl-5-vinylimidazolidin-2-one: 
1H NMR (500 MHz, CDCl3) δ 7.91 (d, J = 8.5 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 
5.81 (ddd, J = 17.5, 10.1, 7.6 Hz, 1H), 5.40 (d, J = 17.0 Hz, 1H), 5.27 (d, J = 10.0 
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Hz, 1H), 4.82 (bs, 1H), 4.57 (d, J = 7.5 Hz, 1H), 3.05 (m, 1H), 2.42 (s, 3H), 1.72 (m, 1H), 0.91 
(d, J = 7.0 Hz, 3H), 0.89 (d, J = 6.5 Hz, 3H); 13C NMR (125 MHz, CDCl3)  δ 154.4, 144.5, 136.5, 
135.9, 129.3, 128.3, 118.3, 62.3, 61.5, 32.5, 21.6, 17.7, 17.0; IR (film, cm-1): 3325 (br), 2927, 
1730, 1358, 1169. 
 
(±)-N-((4R,5R)-4-isopropyl-5-vinyl-4,5-dihydrooxazol-2-yl)-4-methylbenzenesulfonamide: 
1H NMR (500 MHz, CDCl3) δ 7.81 (d, J = 8.5 Hz, 2H), 7.62 (bs, 1H), 7.27 (d, J = 
8.5 Hz, 2H), 5.86 (ddd, J = 17.5, 10.1, 6.8 Hz, 1H), 5.44 (d, J = 17.5 Hz, 1H), 5.36 
(d, J = 10.5 Hz, 1H), 4.76 (ap t, J = 6.3 Hz, 1H), 3.52 (ap t, J = 6.0 Hz, 1H), 2.40 (s, 
3H), 1.85 (m, 1H), 0.98 (d, J = 7.0 Hz, 3H), 0.95 (d, J = 7 Hz, 3H); 13C NMR (125 MHz, 
CDCl3)  δ 160.7, 142.8, 139.3, 133.5, 129.3, 126.3, 119.9, 82.0, 65.8, 31.9, 21.5, 17.8, 17.7; IR 
(film, cm-1): 3350 (br), 2962, 1626, 1421, 1282. 
 
Catalytic Kinetic Studies 
 
 
Figure S1. Reaction Rate Comparison between the Terminal and the Internal Olefin Starting 
Materials 
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Figure S1: Five 1 dram borosilicate vials containing a Teflon stir bar were flame dried, sealed 
with a Teflon lined cap and taken inside a glove box. The homoallylic N-nosyl urea starting 
material (0.3 mmol, 1 equiv.), benzoquinone (0.315 mmol, 1.05 equiv.), Pd(OAc)2 (0.03 mmol, 
0.1 equiv.) and B(C6F5)3 (0.03 mmol, 0.1 equiv.) were added to each 1 dram vial in the glove box, 
in the order specified. The vials were securely sealed with the Teflon lined cap and taken out of 
the glove box. Nitrobenzene standard (0.12 mmol, 0.4 equiv.) and Tetrahydrofuran-d8 (1.66M) 
were quickly added to each 1 dram vial outside of the glove box, under a flow of argon gas. The 
vials were sealed and placed in an aluminum block at 45 °C. One vial was taken out of the 
aluminum block at each of the following time point: 2h, 5h, 15h, 24h and 72h and its contents 
were diluted with tetrahydofuran-d8. A sample was removed for 1H NMR analysis. The yield was 
determined by integration of the olefinic product peaks relative to the nitrobenzene standard. 
Yields are reported as the average of three runs, with error bars representing standard deviation. 
The same procedure was followed to obtain the kinetic profile of the reaction with the internal 
olefin as the starting material. 
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CHAPTER 2: LINEAR ALLYLIC AMINATION USING OXYGEN (1 ATM) AS THE 
TERMINAL OXIDANT 
 
2.1 Introduction 
 Allyl amines are common moieties in complex natural products and valuable building 
blocks in synthesis.70 Traditionally, nitrogen is installed through oxygenated intermediates 
leading to lengthy synthetic sequences. This could be avoided if the direct installation of nitrogen 
from C−H bonds were possible, an approach that our group has successfully developed using 
Pd(II)/bis-sulfoxide catalysis in combination with a Lewis acid or a base additive.16,17 
The general methods previously used to access linear allylic amines are very nicely 
outlined in detail in a review by Jørgensen,71 therefore I will only briefly touch on the major 
three methodologies for the synthesis of these types of amines, prior to discussing the direct 
allylic C−H amination discovered in our group. Non-metal substitution reactions feature the 
formation of an allylic amine by exchange of a protected nitrogen source with an electrophilic 
allylic functional group such as an alcohol (Figure 2.1, A). Phthalimide protected nitrogen  
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nucleophiles and azides are commonly used with these methods, though there are major concerns 
regarding toxicity, stability and scalability for reactions using azide nucleophiles. The lengthy 
nature of synthesizing allylic amines via this approach is a great disadvantage, especially in 
complex molecule settings. Palladium catalyzed substitution reactions have also been developed 
to synthesize linear allylic amines via allylic carbonates, acetates or phosphates (Figure 2.1, B).72 
In general, the Pd(0) approach suffers from low linear:branched ratios and E:Z selectivities, 
along with the downside of using a pre-oxidized starting material. Finally, direct C−H 
aminations have also been developed, providing a substantial improvement in efficiency by 
directly converting C−H bonds into C−N bonds (Figure 2.1, C). The metal catalyzed nitrene 
insertion reaction is perhaps the most powerful in this class of direct C−H aminations and it 
generally involves the use of hypervalent iminoiodinanes and metals such as iron, ruthenium and 
manganese. Although earlier classes of catalysts were fairly intolerant of double bonds owing to 
high levels of aziridination, newer ligands and nitrogen sources have overcome some of these 
chemoselectivity issues (Figure 2.1, C).73 There are no examples, however, of this method 
providing linear allylic amines; branched allylic amines can in some cases be realized by intra- 
or intermolecular systems.74,75 
 Though a two-step, stoichiometric Pd(II) π-allyl process has been known for some time 
in the literature, rendering it catalytic proved to be a challenge. A major difficulty to solving this 
problem is the electronic demands on the palladium metal center for each individual step in the 
catalytic cycle. For example, the C−H cleavage step requires a highly electrophilic Pd species 
that is stabilized by weakly coordinating ligands, such as sulfoxides or acetone. Alternatively, the 
functionalization step requires a metal with donating, stabilizing ligands to promote 
functionalization (such as phosphines). There is one example of a Pd(II) amination reaction 
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proceeding through a π-allyl intermediate reported by Larock76 and several Pd(0) systems that 
demonstrate the possibility of functionalizing this intermediate. Trost has also shown that a 
palladium allyl species generated from a ring opening of vinyl epoxides in the presence of N-
tosylisocyanate can form oxazolidinones in high yields and good diastereoselectivities.77 With 
these precedents in mind, our group has developed the first catalytic, stereoselective allylic C−H 
amination, in both an intra-20 and intermolecular16,17 fashion (Figure 2.2). Key features of these 
systems include the use of P(II)/bis-sulfoxide catalyst 1 to promote allylic C−H cleavage instead 
of aminopalladation, and renewable, catalytic amounts of acetate base brought in by the catalyst 
that promotes functionalization in the intramolecular system. For the intermolecular reaction, 
functionalization is promoted by the addition of either Lewis acids or catalytic exogenous base. 
 
 
 
 
 
 
 
 
 
 
Our C−H amination reactions are of immediate use to synthetic chemists whose goals are 
to find rapid and convenient routes to intermediates of natural products or drug candidate. On 
scale however, we must address the challenges of relatively high palladium catalyst loadings (10 
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mol%) to Pd(0) methods and the generation of stoichiometric organic waste products from the 
benzoquinone oxidant. Molecular oxygen has been shown to act as terminal oxidant under 
certain reaction conditions,76,78,79 and if our system could be amenable to inclusion of oxygen as 
the terminal oxidant, both challenges discussed above could be addressed (vide infra). To the 
best of our knowledge, no general solution yet exists for inter- or intramolecular C-H amination 
using O2 as the terminal oxidant. Many of the molecular oxygen systems reported so far for 
allylic oxidations suffer from various drawbacks such as elevated temperatures (60-80°C) that 
can negatively affect olefin isomer (E:Z) and/or constitutional isomer (linear:branched) 
selectivity, high pressures of O2 (up to 10 atmospheres), specialized reactors for safe reaction 
setup, and most often the need for solvent quantities of nucleophile.80,81 To circumvent these 
issues we hypothesized that the addition of an effective co-catalyst capable of shuttling electrons 
between catalytic dihydrobenzoquinone (DHBQ) and molecular oxygen under mild conditions 
could be used for our C-H activation reactions and allow us to realize a more ideal allylic 
oxidation reaction. Metal co-catalysis has previously been reported for the reoxidation of DHBQ 
to BQ with O2 for the express purpose of a Pd(0)/Pd(II) catalytic cycle. Interestingly, Backvall et 
al. have shown the oxidation of 1,4-dihydroquinone to p-benzoquinone using a 
Co(II)TPP(5,10,15,20-Tetraphenyl-21H,23H-porphine cobalt(II)) catalyst in the presence of 
molecular oxygen, in the context of a  
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Figure 2.3 Backvall's Diacetoxylation with O2 as the terminal oxidant
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Pd(II) catalyzed diacetoxylation of 1,3-cyclohexadiene (Figure 2.3).82 A literature survey 
revealed that different metal catalysts (Fe, Mn, V) could reoxidize dihydrobenzoquinone to 
benzoquinone in the presence of molecular oxygen,83-86 however, only Co(TPP) was shown to do 
so in the context of a Pd(II)/Pd(0) catalytic cycle.  
The concept of an “oxidation potential relay” system within the context of a Pd(II) 
catalyzed linear C−H activation reaction allows for the use of only catalytic quantities of BQ and 
would lead to a potentially general intermolecular allylic C−H amination reaction using 
molecular oxygen as the terminal oxidant. 
 
 
 
 
 
 
 
 
 
2.2 Results and Discussion 
2.2.1 Reaction Design and Optimization  
 Three aspects of the aerobic intermolecular allylic C−H amination reaction were 
considered critical to the success of this new synthetic method: (1) 5 mol% or less of 
palladium/bis-sulfoxide catalyst 1 needed to be used, (2) the reaction was restricted to only 1 atm 
of oxygen to avoid hazardous reaction setup and (3) a low-cost metal co-catalyst had to be used 
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Figure 2.4 Triple Catalysis Leading to an Aerobic System
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to render the system catalytic in BQ. Additionally, excellent yields and selectivities along with a 
wide substrate scope had to be maintained. Interestingly, our previously published reaction 
conditions with stoichiometric 1,4-p-benzoquinone failed at providing the aminated product 34 
in preparatively useful yields when 5% mol of the Pd/BisSO catalyst 1 is used (Table 2.1, entry 
1). Co(II)Salophen 35 was found to be an optimal metal co-catalyst that aids in the in situ 
formation of catalytic benzoquinone from dihydroquinone and molecular oxygen. Under these 
optimized reaction conditions, allylcyclohexane 33 was converted to	  the desired (E)-linear allylic 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
DHBQ (10 mol%), TBME (1M, 
O2 (1 atm), 45 °C, 72h 34
33 (1 equiv.)
Cocatalyst (2.5 mol%) 
TBAA (6 mol%)
H TsN
O
OMe
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L/B >20:1 
E/Z >20:1
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O
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Co(II)(TPP)
Co(II)(salen)
20%
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74%
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1c
2d
3
4
5
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BQ (2 equiv.)
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O2 (1atm)
O2 (1atm)
O2 (1atm)
NPMoV
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VO(acac)2 36
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-
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7
8
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O2 (1atm)
O2 (1atm)
O2 (1atm)
O2 (1atm)
O2 (1atm)
O2 (1atm)
O2 (1atm)
O2 (1atm)
O2 (1atm)
a Conditions are as listed above unless otherwise noted. b Isolated yield; 
average of 2 runs at 0.4 mmol. c Conditions: 1 equiv. olefin, 6% DIPEA, 2 
equiv. BQ, TBME (0.66M). 72h d 2 equiv. MeOCONHTs, 0.66M TBME. e 
Number in parantheses represents yield at 24h. f 1M THF, 2 equiv. 
MeOCONHTs. g 1 mol% co-catalyst, 1M THF, 2 equiv. MeOCONHTs.
Table 2.1 Optimization of the Aerobic Allylic Amination
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amine product 34 after 72 hours in 79% yield, with excellent E/Z and and linear/branched 
selectivities (Table 2.1, entry 3). Reducing the reaction time to 24 hours led to no significant 
diminishment in yield, while maintaining excellent selectivities (Table 2.1, entry 3). Other 
cobalt(II) sources were also explored, and both Co(TPP) and Co(salen) were capable of 
efficiently reoxidizing dihydroquinone to benzoquinone in situ and giving rise to synthetically 
useful yields of the desired linear allylic amine product (Table 2.1, entries 4 and 5). Inspired by 
previous work by Backvall and coworkers, we investigated various other metals that were shown 
to efficiently catalyze the dihydroquinone reoxidation to benzoquinone in the presence of 
molecular oxygen. A molybdenum-vanadium phosphate complex, iron(II) phthalocyanine and 
manganese(II) salen all failed at providing synthetically useful yields of the desired aminted 
product 34 (Table 2.1, entries 6, 7, 8).  
A survey of the literature revealed one report of a vanadate-catalyzed oxidation of 
dihydroquinones with O2 under very mild conditions (room temperature, 1 atm O2).87 This was 
surprising given vanadium’s central role in biological systems and naturally occurring 
peroxidases and catecholases. Despite this promising report, no vanadium/quinone/O2 oxidation 
system has ever been reported for a palladium-catalyzed process. We therefore questioned if a 
vanadium based system could also potentially allow for an optimized reaction protocol, and thus, 
reaction conditions using V(IV) catalysts were explored further. This would be significant as it 
would represent the first example of a vanadium/quinone/O2 oxidation system in the context of a 
Pd(II)/Pd(0) cycle. After extensive screening of vanadyl complexes, optimized reaction 
conditions using 2.5 mol% of VO(acac)2 gave rise to 77% yield of the desired linear allylic 
amine with excellent E/Z and linear/branched selectivities (Table 2.1, entry 9). Impressively, the 
co-catalyst loading could further be reduced to 1 mol% while maintaining comparable yields and 
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selectivities for the desired product (Table 2.1, entry 10). Inspired by our finding that 
Co(II)salophen was a successful co-catalyst for this reaction, we wondered if a similar outcome 
could be obtained when a vanadyl salophen complex was used instead. However, this complex 
led to poor reactivity, only 20% yield of the desired product (Table 2.1, entry 11). The 
porphyrinato complex did not result in any major improvement in reactivity (Table 2.1, entry 12), 
however, the very cheap vanadyl sulfate gave rise to a comparable yields to the VO(acac)2 (Table 
2.1, entry 13). The metal co-catalyst is required for efficient reactivity: in its absence only 17% 
of the desired product is isolated (Table 2.1, entry 14). 
Because of the low molecular weights of VO(acac)2 and VOSO4, the reactions with 1 
mol% co-catalyst had to be run on much larger scales in order to weigh out an appreciable and 
accurate amount of the vanadium co-catalyst. To be more practical, we decided to continue 
forward and explore the substrate scope while using 2.5 mol% VO(acac)2 complex; however, if 
desired, the 1 mol% co-catalyst reaction conditions can still be utilized in order to successfully 
form the linear allylic amine product.	  
 
2.2.2 Reaction Scope 	   Having optimized around two different systems that allow for the in situ formation of the 
BQ needed for the palladium catalytic cycle to turn over, I next turned to exploring the substrate 
scope using the two metal co-catalysts: Co(II)salophen and VO(acac)2.  As shown in this section, 
we confirm that the newly developed systems possess similar selectivities and functional group 
tolerance to our previously published results, while maintaining or increasing reactivity. As 
shown in Tables 2.2 and 2.3, these reactions proceed with excellent yields and selectivities 
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(>20:1 internal:terminal and >20:1 E:Z) and additionally, fragment-coupling stoichiometries of 
reagents can be used (1 equiv. terminal olefin and 1.5 or 2 equiv. nitrogen nucleophile).  
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Linear aliphatic chains with remote functionality such as protected alcohols are well tolerated, 
leaving the protecting groups intact (Table 2.2, entries 1-5). Protected diols that could lead to 
catalyst deactivation via chelation perform very well and the corresponding products are 
obtained in higher yields than previously reported (Table 2.2, entry 2). Substrates containing silyl 
protected alcohols suffer from lower yields under the VO(acac)2 due to partial desilylation 
induced by the vanadium complex. A glucose-derived substrate reacts very well under these mild 
conditions and the corresponding aminated product undergoes no epimerization at the allylic 
stereocenter (Table 2.2, entry 7). All other contiguous sterocenters present in the molecule 
remain intact as seen by XRD (See the experimental section for more information). This 
illustrates the potential use of the aerobic allylic amination at a late-stage in a complex molecule 
synthesis. Diverse carbonyl functionalities such as amides, masked ketones and esters are also 
very well tolerated, giving rise to linear-(E)-allylic amines in synthetically useful yields (Table 
2.2, entries 6, 8 and 9). Once again, complete stereoretention of adjacent stereocenters is 
observed. 
 Remarkably, the palladium catalyst loading could be decreased further to 2.5 mol% for 
aromatic substrates, while maintaining high yields of the allylic amine products. Both electron 
poor and electron rich aromatic rings are tolerated (Table 2.3, entries 1-5). Additionally, 
reactivity is maintained for highly functionalized aromatic systems with potential for subsequent 
manipulations (Table 2.3, entries 6-8). It should be noted that some aromatic substrates do not 
perform well under the VO(acac)2 conditions; these substrates suffer from low starting material 
conversion (Table 2.3, entries 3 and 5) and not any deleterious side reactions. Silyl protecting 
groups suffer when vanadium is used as the co-catalyst in that the TBS protecting group is lost 
giving rise to the phenol product in 28% yield.  
	   88	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The safrole derived allylic amine (Table 2.3, entry 7) is a direct precursor for a known SSAO 
inhibitor, and was obtained in 95% yield as a single isomer.88 The new aerobic allylic amination 
reaction conditions tolerate a diverse array of functional groups, and heteroaromatic substrates 
(Table 2.3, entry 8), previously reported to lead to catalyst deactivation, are now easily 
functionalized. 
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Sean Reed has previously shown that incorporation of nitrogen via our reported C−H 
amination method can significantly streamline the synthesis of a deoxynegamycin analog (Figure 
2.5, A).17 Compared to a previously reported route that was based on an allylic C−O substitution 
in order to make the same linear aminated intermediate,89 our new route gave rise to almost 
double the overall yield (22% yield), while eliminating 5 steps and 5 functional group 
manipulations from the total synthesis. In order to prove the efficiency of the newly developed 
aerobic reaction conditions, the same linear allylic amine intermediate was now synthesized with 
both reoxidation systems. I was delighted to find that both Co(II)(salophen) and VO(acac)2 gave 
rise to this product in 85% and 83% yield, respectively while using only 5 mol% of the 
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Pd(II)/BisSO catalyst (Figure 2.5, B). This is in stark contrast to the reaction conditions with 
superstoichiometric BQ, which gave rise to only 54% yield of the desired linear allylic amine. 
This improvement led to an overall 35% yield for the deoxynegamycin analog synthesis, almost 
tripling the yield for the original route. 
 
2.2.3 Mechanistic Consideration and the Benzoquinone Effect 
Despite its usefulness as an oxidant, benzoquinone is also known to be a ligand for 
palladium.90 Since the newly developed allylic amination reaction conditions utilize a much 
lower palladium loading than our previously published reports, we wondered if that was a 
consequence of eliminating the stoichiometric benzoquinone from the system. 
 Interestingly, our previously published reaction conditions with stoichiometric 
benzoquinone fail at providing the aminated product in preparatively useful yields when 5% mol  
 
 
 
 
 
 
 
 
-
Co(II)(salophen) 35
Co(II)(salophen) 35
Co(II)(salophen) 35
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BQ (0.1 equiv.), O2 (1atm)
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2,5-DMBQ (1 equiv.)
a Conditions are as listed above unless otherwise noted. b Isolated yield; 
average of 2 runs at 0.4 mmol. c Conditions: 1 equiv. olefin, 6% DIPEA, 2 
equiv. BQ, TBME (0.66M), 72h, no oxygen.
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 of the Pd/BisSO catalyst 1 is used (Table 2.4, entry 1). The catalyst loading must be increased to 
10 mol% in order to obtain good yields of 34.16,17 Our previously published results also indicate 
that certain salen complexes (Cr, Mn) can act as Lewis acid activators, facilitating the 
functionalization of the Pd(π-allyl) intermediate. In order to evaluate the role of Co(salophen) as 
a potential Lewis acid activator, 2.5 mol% Co(salophen) was added to the previously published 
reaction conditions; however, no significant increase in yield was observed (Table 2.4, entry 2). 
Since the optimized allylic amination reaction conditions utilize a much lower palladium loading 
than we previously reported, we wondered if that was a consequence of eliminating the 
stoichiometric benzoquinone, which has the potential to deactivate the Pd catalyst through 
competitive binding. In support of this hypothesis, we have found that when larger amounts of 
BQ are used in place of catalytic DHBQ, the yield of linear allylic amine is considerably lower 
(Table 2.4, entries 4 and 5) and it decreases with increasing amounts of BQ. Notably, when using 
a bulkier quinone such as 2,5-dimethylbenzoquinone (2,5-DMBQ), which should have less of a 
binding affinity for palladium, we observe a significant increase in yield under our previously 
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published reaction conditions (Table 2.4, entry 6). Along with the evidence provided in Table 
2.4, I also investigated the initial rates of reaction in the presence of varying amounts of BQ 
(Figure 2.6). If the palladium catalyst were indeed deactivated by the competitive binding of 
benzoquinone, a change in the overall reaction profile would be observed when	   different	  amounts	  of	  BQ	  were	  used; more specifically, the initial rate of reaction would increase as the 
equivalents of BQ were lowered. This was exactly what I observed when the initial rates of 
reaction with 10% BQ, 50% BQ and 100% BQ were compared under our aerobic conditions 
(Figure 2.6). The initial rate of reaction in the presence of 10% BQ is about 4.5 times higher than 
the initial rate with 50% BQ and almost 9-fold the rate with 100% BQ, further indicating that BQ 
is inhibiting the catalyst’s activity when it is used in higher amounts. 
 
2.2.4 Expanding to an Aerobic Intramolecular Amination 
 Given the broad utility of the newly developed allylic C−H amination reaction in 
synthesizing diverse linear allylic amines, we next sought to evaluate the two different 
reoxidation conditions for other C─H activation reactions previously published using 
stoichiometric BQ. Gratifyingly, intramolecular allylic aminations were readily amenable to 
these reoxidation systems without substantial reoptimization (Tables 2.5 and 2.6).  
 An intramolecular allylic amination leading to 1,2-aminoalcohol precursors was amenable 
to these aerobic reaction conditions but only gave rise to moderate, nonetheless synthetically 
useful yields and diastereoselectivities (Table 2.5). In each case, the anti-oxazolidinone was 
formed as the major product. Initially developed with stoichiometric amounts of oxidant (BQ) by 
Dr. Ken Fraunhoffer in our group, this intramolecular system seems to have a very similar 
substrate scope to what was previously reported. A moderate amount of steric bulk is always 
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needed adjacent to the carbamate tether in order to achieve an acceptable compromise of yield 
and diastereoselectivity (Table 2.5). If the substituent near the tether is either too bulky (tBu) or 
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too small (Et), reactivity plummets. I have synthesized a variety of other possible substrates to be 
subjected to these new oxygen reaction conditions, however, due to steric requirements of this 
intramolecular system, they all failed to give the desired product: substrate conversions are low 
or nonexistent (Figure 2.7). Although I succeeded to explore some of the variables in the new 
aerobic reaction condition with the goal of increasing reactivity and selectivity, more 
optimization needs to be done in order for this system to be comparable or better than previously 
reported.  	   In addition, we sought to determine if our previously reported intramolecular allylic 
amination for the preparation of 1,3-amino alcohol precursors would prove to be competent 
under the aerobic oxidation conditions reported herein. With the help of a very talented first year 
student (Christopher C. Pattillo), we were pleased to find that this intramolecular amination  
 
 
 
 
 
 
 
 
R
O NHNs
O
Bis-SO Liganda (5 mol%)
DCE (1.0M), O2 (1atm)
45oC, 24h R
O NNs
O
Ph
O NNs
O
BnO
O NNs
O
79% yield
 7.7:1 dr
(71%, >20:1 d.r.)c
63% yield
7.6:1 dr
(58%, >20:1 d.r.)c
a BisSO ligand = 1,2-Bis(phenylsulfinyl)ethaneb Reaction run with 10 
mol% of catalyst 1c Isolated yield of major syn product, >20:1 syn:anti
Me
O NNs
O
67% yieldb
7.9:1 d.r.
(59%, >20:1 d.r.)c
O NNs
O
O NNs
O
58% yield 
2.9:1 dr
(43%, >20:1 d.r.)c
1 (5 mol%), 35 (2.5 mol%)
p-nitrobenzoic acid (10 mol%)
DHBQ (10 mol%)
81% yield 
6.9:1 d.r.
 (69%, >20:1 d.r.)c
O NNs
O
70% yield 
7.1:1 d.r.
 (60%, >20:1 d.r.)c
Table 2.6 Intramolecular Amination Leading to 1,3-Aminoalcohol Precursors
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reaction remained efficient under nearly identical conditions to those reported previously. In 
each case, the aerobic amination conditions furnished the syn-oxazinanone products in good 
yield and synthetically useful levels of diastereoselectivity, using only 5 mol% of Pd(II)/BisSO 
catalyst 1 and 2.5 mol% of Co(salophen) co-catalyst 35. For substrates containing internal olefin 
moieties, which could potentially bind to the catalyst and inhibit reactivity, 10 mol% of catalyst 
1 was used. Notably, these new reoxidation conditions resulted in enhanced levels of 
diastereoselectivity in each case as compared to our previously reported results. Additionally, 
this intramolecular C-H amination reaction remains highly selective for terminal olefins, with 
each of the substrates in Table 2.6 providing only the regioisomers shown. Internal olefins and 
acetylenes, as well as benzylic and ethereal C-H bonds, all of which would be labile within a 
nitrene-based reaction manifold, are unreactive under these mild and selective aerobic amination 
conditions. Steric bulk directly adjacent to the carbamate tether is well tolerated, as are protected 
alcohol functionalities. These high levels of chemoselectivity further demonstrate the utility of 
this reaction as an orthogonal approach to similar intramolecular C-H amination reactions 
proceeding via metal-nitrene intermediates; these methods would provide mixtures of C-H 
aminated products in the presence of the variety of activated C-H bonds seen in Table 2.6. 
 
2.3 Conclusions 
In summary, we report an improved and more efficient strategy for the formation of 
linear allylic amines via C─H activation by replacing stoichiometric BQ with molecular oxygen 
as the terminal oxidant with two distinct co-catalytic protocols. In doing so, we have developed 
the first vanadium/ quinone/ O2 oxidation system for a palladium-catalyzed process that proceeds 
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with very low catalyst and co-catalyst loadings. We also demonstrate that our previously 
reported intramolecular C-H amination reactions are competent under these new aerobic 
conditions. Given the generality of the two reoxidation systems presented here, as well as the 
minimization of oxidant waste and toxic byproducts, we anticipate further use of the direct C−H 
allylic amination reaction toward the streamlined synthesis and diversification of complex 
molecules.  
 
2.4 Experimental Data 
General Information: All commercially obtained reagents were used as received: 1,4-
dihydroquinone (DHBQ, Aldrich); White Catalyst (1,2-Bis(phenylsulfinyl)ethanepalladium(II) 
acetate, CAS: 858971-43-4, Aldrich). Tetra n-butylammonium acetate (Aldrich) was stored in a 
glove box under an argon atmosphere and weighed out in a vial in the glove box prior to use. All 
other reagents where purchased from least expensive supplier and used directly unless otherwise 
stated. The cobalt(II) salophen catalyst 35 was prepared using the procedure developed by 
Backvall and coworkers. Solvents: diethyl ether (Et2O), methylene chloride (CH2Cl2), and N, N-
dimethylformamide (DMF) were purified prior to use by passage through a bed of activated 
alumina (Glass Contour, Laguna Beach, California).  All allylic amination reactions were run 
under oxygen balloon atmosphere with no precautions taken to exclude moisture. Thin-layer 
chromatography (TLC) was conducted with E. Merck silica gel 60 F254 precoated plates (0.25 
mm) and visualized with UV, potassium permanganate, and ceric ammonium molybdate staining.  
Flash column chromatography was performed as described by Still et al. using EM reagent silica 
gel 60 (230-400 mesh).  1H NMR spectra were recorded on a Varian Unity 500 (500 MHz) or a 
Varian Unity Inova 500NB spectrometer and are reported in ppm using solvent as an internal 
	   97	  
standard (CDCl3 at 7.26 ppm).  Data reported as: s = singlet, d = doublet, t = triplet, q = quartet, 
m = multiplet, b = broad; coupling constant(s) in Hz; integration, corresponding carbon atom.  
Proton-decoupled 13C- NMR spectra were recorded on a Varian Unity-500 (125 MHz) 
spectrometer and are reported in ppm using solvent as an internal standard (CDCl3 at 77.2 ppm).  
IR spectra were recorded as thin films on NaCl plates on a Mattson Galaxy Series FTIR 5000 
and are reported in frequency of absorption (cm-1).  All optical rotations were determined on a 
Perkin Elmer 341 Polarimeter using the sodium D line (589 nm).  High-resolution mass spectra 
were obtained at the University of Illinois Mass Spectrometry Laboratory. Medium pressure 
liquid chromatography (MPLC) was used in cases with difficult silica chromatography 
separations and consists of a Teledyne ISCO CombiFlash Rf with 12, 24, or 40g RediSep Rf 
Silica columns. Optical rotations were measured using a 1 mL cell with a 100 mm path length on 
a Jasco P-1020 polarimeter. Optical rotations were obtained with a sodium lamp and are reported 
as follows: [α]λT°C (c = g/100 mL, solvent). 
Optimization of the Intermolecular Allylic C−H Amination 
 
Entry 1: The reaction was set up following the procedure described in reference 17. Run 1 (23.9 
mg, 0.068 mmol, 17% yield); run 2 (30.9 mg, 0.088 mmol, 22% yield). Average: 20% yield.  
Entry 2: To a 10 mL round bottom flask containing a PTFE-covered stir bar was added: tetra n-
butyl ammonium acetate (7.2 mg, 0.024 mmol) in a glove box, followed by methyl 
tosylcarbamate nucleophile (183.4 mg, 0.8 mmol), 1,4-dihydroquinone (4.4 mg, 0.04 mmol), 
Co(II)(salophen) 35 (3.7 mg, 0.01 mmol) and catalyst 1 (10 mg, 0.02 mmol). Allylcyclohexane 
(preweighed in a 1/2 dram vial, 49.7 mg, 0.4 mmol) was then added using methyl tert-butyl ether 
(TBME, 0.66M) to rinse the vial. The flask was attached to a cold-water condenser using a PTFE 
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sleeve as a seal, with no additional support of the flask required and Teflon tape was wrapped 
around the joint. The top of the condenser was sealed with a rubber septum, and a balloon of 
oxygen was attached with a needle. The reaction was allowed to stir at 400rpm in a 45°C oil bath 
for 72 hours. Upon completion, the reaction was diluted with dichloromethane and flushed  
 
 
 
 
 
 
 
 
 
 
 
 
through a 3-5 cm silica gel plug with an 80% ethyl acetate/20% hexanes mixture (this plug is 
done to separate the products from the metal catalysts; if this separation is not necessary, then the 
crude reaction mixture can be directly loaded onto a silica gel column). Purification by flash 
DHBQ (10 mol%), TBME (1M, 
O2 (1 atm), 45 °C, 72h 34
33 (1 equiv.)
Cocatalyst (2.5 mol%) 
TBAA (6 mol%)
H TsN
O
OMe
1 (5 mol%)
(1.5 equiv.)
L/B >20:1 
E/Z >20:1
MeO
O
NHTs
Cocatalyst Yield of 34b
-
Co(II)(salophen) 35
Co(II)(salophen) 35
Co(II)(TPP)
Co(II)(salen)
20%
84%
79%(78%)e
60%
74%
Entrya
1c
2d
3
4
5
Oxidant
BQ (2 equiv.)
O2 (1atm)
O2 (1atm)
O2 (1atm)
O2 (1atm)
NPMoV
 Fe(II)Pc
Mn(II)(salen)
VO(acac)2 36
VO(acac)2 36
VO(acac)2 36
VO(Salophen)
VO(TPP)
VOSO4
-
28%
44%
9%
72%
75%
80%
23%
18%
79%
17%
6
7
8
9
10f
11g
12g
13g
14g
15
O2 (1atm)
O2 (1atm)
O2 (1atm)
O2 (1atm)
O2 (1atm)
O2 (1atm)
O2 (1atm)
O2 (1atm)
O2 (1atm)
O2 (1atm)
a Conditions are as listed above unless otherwise noted. b Isolated yield; 
average of 2 runs at 0.4 mmol. c Conditions: 1 equiv. olefin, 6% DIPEA, 2 
equiv. BQ, TBME (0.66M). 72h d 2 equiv. MeOCONHTs, 0.66M TBME. e 
Number in parantheses represents yield at 24h. f 1M THF, 2 equiv. 
MeOCONHTs. g 1 mol% co-catalyst, 1M THF, 2 equiv. MeOCONHTs.
S S PhPh
OO .
Pd(OAc)2
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column chromatography using a gradient of 10-30% EtOAc/hexanes provided pure methyl (E)-
(3-cyclohexylallyl)(tosyl)carbamate. Run 1 (115.3 mg, 0.328 mmol, 82% yield); run 2 (119.5 mg, 
0.340 mmol, 85% yield). Average: 84% yield. 
Entry 3: The reaction was set up following the procedure described for Entry 2 with 1.5 equiv. 
methyl tosylcarbamate nucleophile and 1M TBME. Run 1 (109.6 mg, 0.312 mmol, 78% yield); 
run 2 (112.5 mg, 0.320 mmol, 80% yield). Average: 79% yield. 
Entry 4: The reaction was set up following the procedure described for Entry 2. Co(II)(TPP) 
(6.7 mg, 0.01 mmol) was used as the reoxidation catalyst. Run 1 (84.4 mg, 0.240 mmol, 60% 
yield); run 2 (82.9 mg, 0.236 mmol, 59% yield). Average: 60% yield. 
Entry 5: The reaction was set up following the procedure described for Entry 2. Co(II)(salen) 
(3.3 mg, 0.01 mmol) was used as the reoxidation catalyst. Run 1 (108.2 mg, 0.308 mmol, 77% 
yield); run 2 (99.8 mg, 0.284 mmol, 71% yield). Average: 74% yield. 
Entry 6: The reaction was set up following the procedure described for Entry 2. NPMoV (6.7 
mg, 0.01 mmol) was used as the reoxidation catalyst. Run 1 (40.8 mg, 0.116 mmol, 29% yield); 
run 2 (36.6 mg, 0.104 mmol, 26% yield). Average: 28% yield. 
Entry 7: The reaction was set up following the procedure described for Entry 2. Fe(II)Pc (5.7 
mg, 0.01 mmol) was used as the reoxidation catalyst. Run 1 (60.5 mg, 0.172 mmol, 43% yield); 
run 2 (63.3 mg, 0.180 mmol, 45% yield). Average: 44% yield.  
Entry 8: The reaction was set up following the procedure described for Entry 2. Mn(II)(salen) 
(6.7 mg, 0.01 mmol) was used as the reoxidation catalyst. Run 1 (14.1 mg, 0.04 mmol, 10% 
yield); run 2 (11.2 mg, 0.032 mmol, 8% yield). Average: 9% yield.  
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Entry 9: The reaction was set up following the procedure described for Entry 2. VO(acac)2 (2.7 
mg, 0.01 mmol) was used as the reoxidation catalyst. Run 1 (99.8 mg, 0.284 mmol, 71% yield); 
run 2 (101.2 mg, 0.288 mmol, 72% yield). Average: 72% yield.  
Entry 10: The reaction was set up following the procedure described for Entry 2. VO(acac)2 (2.7 
mg, 0.01 mmol) was used as the reoxidation catalyst, with 2 equivalents of the carbamate 
nucleophile in 1M THF. Run 1 (104 mg, 0.296 mmol, 74% yield); run 2 (105.4 mg, 0.300 mmol, 
75% yield). Average: 75% yield.  
Entry 11: The reaction was set up following the procedure described for Entry 2, but on a 0.8 
mmol scale in order to weigh out an accurate amount of the vanadium co-catalyst. 1 mol% 
VO(acac)2 was used. Run 1 (225 mg, 0.64 mmol, 80% yield); run 2 (222.1 mg, 0.632 mmol, 79% 
yield). Average: 80% yield. 
Entry 12: The reaction was set up following the procedure described for Entry 2. VO(salophen) 
(1.5 mg, 0.004 mmol) was used as the reoxidation catalyst. Run 1 (28.1 mg, 0.08 mmol, 20% 
yield); run 2 (36.6 mg, 0.104 mmol, 26% yield). Average: 23% yield. 
Entry 13: The reaction was set up following the procedure described for Entry 2. VO(TPP) (2.7 
mg, 0.004 mmol) was used as the reoxidation catalyst. Run 1 (23.9 mg, 0.068 mmol, 17% yield); 
run 2 (26.7 mg, 0.076 mmol, 19% yield). Average: 18% yield. 
Entry 14: The reaction was set up following the procedure described for Entry 2 but on a 1.5 
mmol scale in order to measure an accurate amount of the vanadium co-catalyst. VOSO4 (2.4 mg, 
0.015 mmol) was used as the reoxidation catalyst. Run 1 (416.5 mg, 1.185 mmol, 79% yield); 
run 2 (411.2 mg, 1.17 mmol, 78% yield). Average: 79% yield. 
	   101	  
Entry 15: The reaction was set up following the procedure described for Entry 2. No reoxidation 
co-catalyst was added. Run 1 (21.1 mg, 0.060 mmol, 15% yield); run 2 (26.7 mg, 0.076 mmol, 
19% yield). Average: 17% yield. 
Scope of the Linear Allylic Amination Reaction 
General procedure for the Co(II)(salophen) system: To a 10 mL round bottom flask 
containing a PTFE-covered stir bar was added tetra n-butyl ammonium acetate (7.2 mg, 0.024 
mmol, 6 mol%) in a glove box. The following solids were all weighed outside of the glovebox 
and sequentially added to the reaction flask containing TBAA: carbamate nucleophile (137.6 mg, 
0.6 mmol, 1.5 equiv.), DHBQ (4.4 mg, 0.04 mmol, 10 mol%), Co(II)(salophen) (3.7 mg, 0.01 
mmol, 2.5 mol%) and catalyst 1 (5 mg, 0.01 mmol, 2.5 mol% - aromatic substrates or 10 mg, 
0.02 mmol, 5 mol% - aliphatic substrates). (NOTE: Because of the hygroscopic nature of TBAA, 
the reaction flask was not opened until all the other solids were ready to be transferred into the 
flask; in some cases, we have seen lower reactivity when the TBAA is exposed to air for longer 
periods of time). The terminal olefin (0.4 mmol, 1 equiv., preweighed in a ½ dram vial) was 
diluted with 0.1 mL TBME and then added to the reaction flask using TBME for the transfer (0.3 
mL – total of 0.4 mL solvent). The flask was attached to a cold-water condenser using a PTFE 
sleeve as a seal, with no additional support of the flask required and the joint was wrapped in 
teflon tape. The top of the condenser was sealed with a rubber septum, and a balloon of oxygen 
was attached with a needle. The reaction was allowed to stir at 400rpm in a 45°C oil bath for 72 
hours or until completed by TLC. Upon completion, the reaction was diluted with 
dichloromethane and flushed through a 3-5 cm silica gel plug with an 80% ethyl acetate/20% 
hexanes mixture (this plug is done to separate the products from the metal catalysts; if this 
separation is not necessary, then the crude reaction mixture can be directly loaded onto a silica 
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gel column). Purification of the products is done using flash column chromatography - in general, 
with a gradient of 10-30% EtOAc/hexanes. 
 
General procedure for the VO(acac)2 system : To a 10 mL round bottom flask containing a 
PTFE-covered stir bar was added tetra n-butyl ammonium acetate (7.2 mg, 0.024 mmol, 6 mol%) 
in a glove box. The following solids were all weighed outside of the glovebox and sequentially 
added to the reaction flask containing TBAA: carbamate nucleophile (183.6 mg, 0.8 mmol, 2 
equiv.), DHBQ (4.4 mg, 0.04 mmol, 10 mol%), VO(acac)2 (2.7 mg, 0.01 mmol, 2.5 mol%) and 
catalyst 1 (10 mg, 0.02 mmol, 5 mol%). (NOTE: Because of the hygroscopic nature of TBAA, 
the reaction flask was not opened until all the other solids were ready to be transferred into the 
flask; in some cases, we have seen lower reactivity when the TBAA is exposed to air for longer 
periods of time). The terminal olefin (0.4 mmol, 1 equiv., preweighed in a ½ dram vial) was 
diluted with 0.1 mL THF and then added to the reaction flask using THF for the transfer (0.3 mL 
– total of 0.4 mL solvent). The flask was attached to a cold-water condenser using a PTFE sleeve 
as a seal, with no additional support of the flask required and the joint was wrapped in teflon tape. 
The top of the condenser was sealed with a rubber septum, and a balloon of oxygen was attached 
with a needle. The reaction was allowed to stir at 400rpm in a 45°C oil bath for 72 hours or until 
completed by TLC. Upon completion, the reaction was diluted with dichloromethane and flushed 
through a 3-5 cm silica gel plug with an 80% ethyl acetate/20% hexanes mixture (this plug is 
done to separate the products from the metal catalysts; if this separation is not necessary, then the 
crude reaction mixture can be directly loaded onto a silica gel column). Purification of the 
products is done using flash column chromatography - in general, with a gradient of 10-30% 
EtOAc/hexanes. 
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methyl (E)-(3-cyclohexylallyl)(tosyl)carbamate: Spectral data matched previously reported 
data.	   
 
methyl(E)-(5-((tert-butyldiphenylsilyl)oxy)pent-2-en-1-yl)(tosyl)carbamate: 1H NMR (400 
MHz, CDCl3) δ 7.84 (d, J = 8.3 Hz, 2H), 7.71 (d, J = 6.0 Hz, 4H), 
7.67 – 7.35 (m, 6H), 7.25 (d, J = 8.1 Hz, 2H), 5.96 – 5.76 (m, 1H), 
5.75 – 5.52 (m, 1H), 4.44 (d, J = 6.1 Hz, 2H), 3.86 – 3.59 (m, 5H), 2.63 – 2.27 (m, 5H), 1.08 (s, 
9H).  13C NMR (101 MHz, CDCl3) δ 152.84, 144.61, 136.68, 135.71, 134.00, 132.17, 129.79, 
129.40, 128.67, 127.83, 126.62, 63.46, 53.88, 48.72, 35.75, 27.01, 21.77, 19.37. Spectral data 
matched previously reported data. 
 
methyl (R,E)-(6-((tert-butyldiphenylsilyl)oxy)-5-methylhex-2-en-1-yl)(tosyl)carbamate: 
Spectral data matched previously reported data. 
 
methyl(R,E)-(5-((tert-butyldimethylsilyl)oxy)-6-((4-methoxybenzyl)oxy)hex-2-en-1-
yl)(tosyl)carbamate:	   Spectral data matched previously reported 
data. 
methyl (E)-(5-(benzyloxy)pent-2-en-1-yl)(tosyl)carbamate:	  Spectral data matched previously 
reported data. 
 
 (E)-5-((N-(methoxycarbonyl)-4-methylphenyl)sulfonamido)pent-3-en-1-yl benzoate:	  
Spectral data matched previously reported data. 
N
Ts
CO2Me
N
Ts
CO2MeTBDPSO
N
Ts
CO2MeTBDPSO
N
Ts
CO2MePMBO
OTBS
N
Ts
CO2MeBnO
N
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CO2MeBzO
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methyl (R,E)-(5-(methoxy(methyl)amino)-4-methyl-5-oxopent-2-en-1-yl)(tosyl)carbamate:	  
Spectral data matched previously reported data. 
 
 
(2R,3R,4R,5S,6R)-2-(acetoxymethyl)-6-((E)-3-((N-(methoxycarbonyl)-4-
methylphenyl)sulfonamido)prop-1-en-1-yl)tetrahydro-2H-pyran-
3,4,5-triyl triacetate:	  1H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 8.3 
Hz, 4H), 7.36 – 7.24 (m, 5H), 5.99 – 5.90 (m, 4H), 5.26 (t, J = 9.5 
Hz, 2H), 5.02 (ddd, J = 16.9, 13.1, 7.9 Hz, 4H), 4.74 (d, J = 4.9 Hz, 2H), 4.47 (d, J = 3.5 Hz, 4H), 
4.17 (dd, J = 12.3, 4.9 Hz, 2H), 4.04 (dd, J = 12.3, 2.1 Hz, 2H), 3.91 (ddd, J = 9.8, 4.8, 2.2 Hz, 
2H), 3.68 (s, 6H), 2.40 (s, 6H), 2.01 (td, J = 7.6, 3.6 Hz, 26H). 13C NMR (101 MHz, CDCl3) δ 
170.78, 170.14, 169.79, 169.62, 152.63, 144.96, 136.41, 132.36, 129.57, 128.56, 126.26, 72.42, 
70.68, 70.39, 69.68, 69.01, 62.39, 54.07, 48.20, 21.76, 20.81, 20.79, 20.74. 
 
methyl (E)-(3-(1,4-dioxaspiro[4.5]decan-6-yl)allyl)(tosyl)carbamate:	  Spectral data matched 
previously reported data. 
 
 
  
 
tert-butyl (S,E)-3-(((benzyloxy)carbonyl)amino)-6-((N-(methoxycarbonyl)-4-
methylphenyl)sulfonamido)hex-4-enoate:	  Spectral data matched 
previously reported data. 
 
methyl cinnamyl(tosyl)carbamate:	  Spectral data matched previously reported data. 
 
 
NMeO
O
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methyl (E)-(3-(2-methoxyphenyl)allyl)(tosyl)carbamate:	  Spectral data matched previously 
reported data. 
 
 
methyl (E)-(3-(2-((tert-butyldimethylsilyl)oxy)phenyl)allyl)(tosyl)carbamate:	   1H NMR (400 
MHz, CDCl3) δ 7.83 (d, J = 8.4 Hz, 2H), 7.54 – 7.39 (m, 2H), 7.35 – 7.19 
(m, 4H), 6.62 (d, J = 15.9 Hz, 1H), 6.25 (dt, J = 15.8, 6.4 Hz, 1H), 4.61 
(dd, J = 6.4, 1.1 Hz, 2H), 3.73 (s, 3H), 2.43 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 152.81, 
144.86, 136.51, 135.34, 132.92, 131.85, 129.50, 128.65, 128.25, 124.83, 121.95, 54.09, 48.83, 
21.78. IR (neat, cm-1) 3035.4, 2956.4, 2925.5, 28.54.14, 1737.5, 1486.9, 1442.5, 1359.6, 1170.6.   
 
methyl (E)-(3-(4-bromophenyl)allyl)(tosyl)carbamate: 1H NMR (400 MHz, CDCl3) δ 7.83 (d, 
J = 8.4 Hz, 2H), 7.54 – 7.39 (m, 2H), 7.35 – 7.19 (m, 4H), 6.62 (d, J = 
15.9 Hz, 1H), 6.25 (dt, J = 15.8, 6.4 Hz, 1H), 4.61 (dd, J = 6.4, 1.1 Hz, 
2H), 3.73 (s, 3H), 2.43 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 152.81, 144.86, 136.51, 135.34, 
132.92, 131.85, 129.50, 128.65, 128.25, 124.83, 121.95, 54.09, 48.83, 21.78. IR (neat, cm-1) 
3035.4, 2956.4, 2925.5, 28.54.14, 1737.5, 1486.9, 1442.5, 1359.6, 1170.6.	  	   
 
methyl (E)-tosyl(3-(4-(trifluoromethyl)phenyl)allyl)carbamate:	   Spectral data matched 
previously reported data. 1H NMR (499 MHz, Chloroform-d) δ 7.87 
– 7.81 (m, 4H), 7.58 (d, J = 8.1 Hz, 4H), 7.48 (d, J = 8.1 Hz, 4H), 
7.32 – 7.25 (m, 4H), 6.70 (d, J = 15.9 Hz, 2H), 6.36 (dt, J = 15.8, 6.3 Hz, 2H), 4.65 (dd, J = 6.2, 
1.4 Hz, 4H), 3.73 (d, J = 1.1 Hz, 5H), 2.43 (s, 5H), 1.21 (td, J = 6.9, 1.0 Hz, 1H); 13C NMR (125 
N
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MHz, CDCl3) δ 152.75, 144.91, 139.86, 136.45, 132.48, 129.93, 129.67, 129.49, 128.59, 126.84, 
126.82, 125.68, 125.65, 125.62, 125.59, 125.31, 123.15, 77.16, 54.07, 48.68, 21.69. 
 
methyl(E)-2-hydroxy-3-methoxy-5-(3-((N-(methoxycarbonyl)-4-
methylphenyl)sulfonamido)prop-1-en-1-yl)benzoate:	   1H NMR 
(400 MHz, CDCl3) δ 11.03 (s, 1H), 7.81 (d, J = 8.3 Hz, 2H), 
7.41 (s, 1H), 7.32 – 7.21 (m, 2H), 7.06 (d, J = 1.7 Hz, 1H), 6.57 
(d, J = 15.8 Hz, 1H), 6.12 (dt, J = 15.7, 6.4 Hz, 1H), 4.58 (d, J = 6.4 Hz, 2H), 3.97 – 3.87 (m, 6H), 
3.71 (d, J = 0.5 Hz, 3H), 2.38 (d, J = 8.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.78, 152.86, 
152.16, 148.82, 144.83, 136.56, 133.29, 129.74, 129.49, 128.62, 127.36, 126.50, 122.72, 119.97, 
113.98, 112.49, 56.38, 54.08, 52.62, 48.99, 21.75.  
 
methyl (E)-(3-(benzo[d][1,3]dioxol-5-yl)allyl)(tosyl)carbamate:	  Spectral data matched 
previously reported data. 
 
 
tert-butyl (E)-3-(3-((N-(methoxycarbonyl)-4-methylphenyl)sulfonamido)prop-1-en-1-yl)-1H-
indole-1-carboxylate:	  1H NMR (400 MHz, CDCl3) δ 8.18 (d, J = 7.9 
Hz, 1H), 7.85 (d, J = 8.4 Hz, 2H), 7.71 (d, J = 7.7 Hz, 1H), 7.62 (s, 
1H), 7.43 – 7.20 (m, 5H), 6.78 (dd, J = 16.0, 0.5 Hz, 1H), 6.39 – 6.26 (m, 1H), 4.65 (dd, J = 6.5, 
0.9 Hz, 2H), 3.73 (s, 3H), 2.39 (s, 3H), 1.70 (s, 11H). 13C NMR (101 MHz, CDCl3) δ 152.88, 
149.59, 144.71, 136.61, 136.07, 129.47, 128.65, 125.84, 124.85, 124.61, 124.00, 123.07, 120.02, 
117.87, 115.49, 84.08, 54.03, 49.42, 28.31, 21.72. IR (neat, cm-1) 2977.6, 2931.3, 1735.6, 1596.8, 
N
Ts
CO2Me
HO
OMe
O
MeO
N
Ts
CO2MeO
O
N
Ts
CO2Me
BocN
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1554.4, 1452.1.  HRMS (ESI) m/z calculated for C25H28N2O6Na [M + H]+: 507.1556; found: 
507.1567. Spectral data matched previously reported data. 
Starting Material Characterization 
tert-butyl 3-allyl-1H-indole-1-carboxylate 1H NMR (500 MHz, CDCl3) δ 8.39 – 7.91 (m, 1H), 
7.56 – 7.50 (m, 1H), 7.49 – 7.29 (m, 2H), 7.28 – 7.20 (m, 1H), 6.11 – 5.99 (m, 
1H), 5.23 – 5.09 (m, 2H), 3.49 – 3.43 (m, 2H), 1.68 (t, J = 2.8 Hz, 9H). 13C 
NMR (101 MHz, CDCl3) δ 135.95, 130.62, 124.42, 123.01, 122.44, 119.32, 
119.12, 116.32, 115.35, 83.48, 29.65, 28.36. IR (neat, cm-1) 3122.2, 3077.9, 3004.6, 2979.5, 
2931.3, 2931.3, 2904.3, 2934.9, 1727.9, 1641.1, 1610.3, 1596.8.  HRMS (ESI) m/z calculated for 
C16H19NO2Na [M + H]+: 280.1313; found: 280.1320. Spectral data matched previously reported 
data. 
tert-butyl(pent-4-en-1-yloxy)diphenylsilane 1H NMR (500 MHz, 
CDCl3) δ 7.70 (dd, J = 5.1, 2.6 Hz, 4H), 7.50 – 7.06 (m, 6H), 5.89 – 5.50 
(m, 1H), 5.00 (dd, J = 33.5, 13.7 Hz, 2H), 3.71 (t, J = 6.3 Hz, 2H), 2.18 (dd, J = 13.7, 6.8 Hz, 
2H), 1.74 – 1.26 (m, 2H), 1.11 – 0.75 (m, 9H). 13C NMR (126 MHz, CDCl3) δ 138.86, 135.89, 
134.37, 129.83, 127.91, 114.84, 63.59, 32.14, 30.38, 27.19, 19.56. Spectral data matched 
previously reported data. 	  
(2R,3S,4S,5S,6R)-2-(acetoxymethyl)-6-allyltetrahydro-2H-pyran-3,4,5-triyl triacetate 
Supplementary crystallographic data for this compound is yet 
unpublished, .cif file might be available upon request.   
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